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ABSTRACT 
 
Introduction: Miscarriage is the most common complication of pregnancy. It is estimated that 
approximately 1% of women suffer three or more consecutive miscarriages.  
Chromosomal abnormalities are the most common cause of first trimester miscarriage. Maternal 
medical conditions such as uncontrolled diabetes, thyroid disease, thrombophilia’s, infection 
and immunological disorders have all been implicated as a cause for recurrent pregnancy loss 
(RPL). Other important risk factors include advanced maternal age and lifestyle factors such as 
stress, smoking, alcohol intake and body mass index. 
Research conducted at Warwick Medical School recently discovered that RPL is associated 
with stem cell deficiency as well as enhanced cellular senescence and disordered inflammation 
of the endometrium.  
Stem cell recruitment normally occurs in response to menstruation, childbirth, miscarriage and 
curettage of the uterus. The process of stem cell recruitment may be deficient in those with RPL 
but has been shown in animal studies to be enhanced with DPP4 inhibitors.  
Hypothesis:  We hypothesised that DPP4 inhibition with Sitagliptin given prior to conception 
will increase the endometrial mesenchymal stem cell (eMSC) count during menstruation.  
Methods/Design: The SIMPLANT study (Sitagliptin for IMPLANTation) was a double blind 
randomised feasibility study conducted at University Hospital Coventry and Warwickshire.  
The study was aimed at women aged 18 – 42 with 3 or more miscarriages. Participants were 
randomised to one of two groups; an endometrial scratch and 100mg Sitagliptin taken once 
daily for 3 months or an endometrial scratch and placebo taken once daily for 3 months. Group 
allocation was unknown at the time of analysis and so have been labelled as Group 0 and 
Group 1.  
Our primary outcome measure was the eMSC count after 3 months of Sitagliptin versus 3 
months of placebo, measured using a clonogenic assay.  
Results: The results of this feasibility study showed no significant difference in the final eMSC 
count between the two treatment groups. The study was acceptable to participants and very few 
side effects to study medication experienced. 
The study has shown a significant increase in the eMSC count in one treatment group (Group1) 
	 12	
when the baseline eMSC count was compared to the eMSC count after 3 months.  
Conclusion: Our results have shown that the eMSC count after 3 months of treatment of 
Sitagliptin was not significantly different to the eMSC count after 3 months of placebo. 
Significant confounding and limiting factors within this feasibility study design have been 
discussed.  
Results have shown that we may be able to increase the eMSC count in certain patients which 
should in turn improve decidualisation of the endometrium and the environment for implantation; 
however much further work is required before investigating this. 
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1.1 RECURRENT MISCARRIAGE 
	
1.1.1	OVERVIEW	
Miscarriage, defined as the loss of pregnancy before the fetus reaches viability at 24 
weeks gestation, is the most common complication of pregnancy (Rai & Regan, 
2006). As many as 15-25% of clinically diagnosed pregnancies end in miscarriage 
(Lucas et al., 2016b; Rai & Regan, 2006). When combined with pre-clinical losses, 
the true incidence is closer to 50% (Macklon et al., 2002).  Figure 1.0.1 shows how 
a significant proportion of pregnancies end before actually being clinically 
recognised.  
 
FIGURE 1.0.1: Number of Conceptions to Reach Each Stage of Pregnancy.	
  
Diagram Adapted From: (Rai & Regan, 2006).	
	
The number of miscarriages in the UK is estimated to be approximately 200,000 per 
year (Royal College of Obstetricians & Gynaecologists, 2011). Most miscarriages 
are sporadic and occur before 12 weeks’ gestation (Rai & Regan, 2006).  
Recurrent pregnancy loss (RPL) or recurrent miscarriage (RM) is a condition unique 
and distinct to sporadic miscarriages. It is estimated that 5% of women experience 
two consecutive miscarriages and approximately 1 - 2% suffer three or more 
consecutive miscarriages (Ford & Schust, 2009; Stirrat, 1990).  
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The observed frequency of RPL is higher than would be expected by chance alone 
(1% vs 0.4%) suggesting that RPL is a specific type of reproductive failure (Regan, 
1991).  
	
1.2 RECURRENT MISCARRIAGE: DEFINITION  
 
The definition of RPL and when investigations should be instigated has been 
debated.  
The American College of Obstetrics and Gynaecology (ACOG) 2001 and the Dutch 
Society of Obstetrics and Gynaecology (NVOG) 2007 define RPL as 2 consecutive 
pregnancy losses whereas The European Society of Human Reproduction and 
Embryology (ESHRE) 2006 and The Royal College of Obstetricians and 
Gynaecologists (RCOG) 2003 define RPL as 3 or more consecutive miscarriages 
(ACOG, 2001; NVOG, 2007) (ESHRE, 2017). The new EHSRE guideline published 
in November 2017 has recently changed the definition for diagnosis of RPL to 2 or 
more pregnancy losses (ESHRE, 2017). It is thought that this will help with 
facilitating research and providing support to couples earlier. 	
In those without a previous live birth, the risk of a further miscarriage after 2 
miscarriages is 30%. The risk of a miscarriage after 3 losses is 33% (Ford & Schust, 
2009) suggesting that there is a strong reason to look for a cause after 2 
miscarriages.  
	
1.3 KNOWN CAUSES OF MISCARRIAGE  
	
Risk factors such as maternal age and reproductive history have been shown to be 
associated with RPL. Lifestyle factors such as smoking, alcohol, exercise, medical 
factors, genetics, immunological and anatomical causes have all also been linked.  
General practitioners refer their patients to specialist clinics for investigations and 
possible treatment options. 
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Here I will discuss what is known already about conditions associated with RPL. I 
will also assess the evidence for them being causative. A causative factor in 
miscarriage would need to be more prevalent in those with RPL, its presence would 
need to predict miscarriage, and treating the condition would have to prevent 
miscarriage. 
1.3.1	MATERNAL	AGE	
Increasing maternal age and associated ageing oocytes is known to be the most 
common cause of a single miscarriage (Royal College of Obstetricians & 
Gynaecologists, 2011).  
A large prospective study has shown that maternal age is a strong risk factor for 
miscarriage due to an increase in chromosomally abnormal oocytes (Nybo 
Andersen et al., 2000). This population based register linkage study has shown that 
at the age of 42 the risk of miscarriage is more than 50% and reaches 75% in those 
over the age of 45. Regardless of previous miscarriages or parity, high maternal age 
was found to be a significant risk factor for miscarriage (Nybo Andersen et al., 
2000). 
However, the prevalence of chromosomal abnormalities decreases with an 
increasing number of miscarriages and the incidence of euploidic foetal loss 
increases with each additional miscarriage (Ogasawara et al., 2000) implying that 
there are other fundamental factors in addition to age implicated in RPL.  
A cohort study looking at the live birth rate in those with RPL found that the rate of 
live birth within five years of attending the RPL clinic was 67% but also the chance 
of live birth decreased with increasing maternal age (Lund et al., 2012) emphasising 
the role of advanced maternal age in the role of conception, miscarriage and live 
birth.  
Patients need to be carefully counselled about the effect of age on the risk of 
miscarriage so that careful decisions can be made between the couple about further 
attempts to pregnancy. 
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1.3.2	PREVIOUS	REPRODUCTIVE	HISTORY	
The risk of miscarriage in a first pregnancy is 5% and this risk decreases to 4% in 
those who have had a previous successful pregnancy. The risk of miscarriage in 
those who have had a previous miscarriage is 19% (Regan et al., 1989).  
45% of those with RPL have had previous live births showing those with previous 
live births are not precluded from RPL (Rai & Regan, 2006). The risk of further 
miscarriage has been repeatedly shown to increase after each successive 
pregnancy loss, reaching 45% after three consecutive losses (Nybo Andersen et al., 
2000; Regan et al., 1989). 
However, it has also been demonstrated that even after five consecutive 
miscarriages, the likelihood of a live birth is more than 50% (Brigham et al., 1999; 
Rai & Regan, 2006).  
Many studies have found that the number of miscarriages is an important prognostic 
factor for live birth (Quenby & Farquharson, 1993). It is recommended practice to 
obtain a thorough reproductive history from couples who attend a RPL clinic.  
	
1.3.3	SMOKING	AND	ALCOHOL	
There are strong links between cigarette smoking and intrauterine growth restriction, 
placental abruption and stillbirth. Smoking may also be associated with RPL.  
A retrospective study has shown that exposure to tobacco smoke significantly 
increases the risk of RPL and the risk is greater the longer the exposure (Zhang et 
al., 2010).  
Conversely, a case control study in 2003, has shown that those women who 
consume even over 20 cigarettes per day do not have a significantly increased risk 
of miscarriage (Rasch, 2003).  
A cohort study including over 24 000 singleton pregnancies has shown that alcohol 
consumption even at 3-5 units per week increases the risk of first trimester 
miscarriage (Kesmodel et al., 2002). This has also been proven in a case control 
study performed in 2003 (Rasch, 2003).  
A case control study has shown a dose-dependent relationship between 
miscarriage and alcohol. There is an increased risk of miscarriage in those who 
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drink at least once per week compared to those who do not drink at all (Maconochie 
et al., 2007). These studies however have been performed in those with sporadic 
miscarriage rather than RPL.  
Although there is a lack of good quality evidence showing that smoking increases 
the risk of RPL, smoking cessation is recommended to all patients due to the health 
benefits for themselves and also because of the clear increased risk of obstetric 
complications once they become pregnant such as intrauterine growth restriction, 
placental abruption and stillbirth. The same applies for alcohol consumption which is 
associated with foetal alcohol syndrome. We also know that alcohol and smoking 
consumption can affect semen quality and so this lifestyle advice should be given to 
both the patient and the partner.  
	
1.3.4	OBESITY	
A systematic review has shown a higher prevalence of RPL in women with a BMI 
>30 compared with those with a BMI<30 (0.4% vs. 0.1%; OR 2.51; 95% CI 1.03–
12.01) (Boots & Stephenson, 2011; Coomarasamy et al., 2015). 
The frequency of euploidic miscarriage among obese women is higher than those 
with a normal BMI (58% vs 37% respectively) (Zhang et al., 2010) which suggests 
that obesity is an independent risk factor for miscarriage. 
On the converse, being underweight with a BMI <18.5 has been found to be 
significantly associated with first trimester miscarriage (Maconochie et al., 2007). 
However, this has not been consistently proven. There are other studies which have 
not found an increased risk of RPL in those who are underweight (Lo et al., 2012). 
We know that weight loss improves fertility rates and can reduce the risk of obstetric 
complications such as gestational diabetes and therefore patients in RPL clinics 
should be advised on a healthy lifestyle to help achieve a healthy BMI.  
 
1.3.5	INFECTION	
The overall prevalence of chronic endometritis from endometrial biopsies performed 
on women with RPL has been shown to be 9% (McQueen et al., 2014). The 
prevalence of chronic endometritis in RPL patients detected at hysteroscopy has 
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been reported to be 58% (Cicinelli et al., 2014). The effect of treatment and 
subsequent live birth rate is yet to be tested in a randomised controlled trial (Boots 
et al., 2014).  
	  
1.3.6	GENETICS	
Chromosomal anomalies are known to be the most common reason for a sporadic 
miscarriage. The prevalence of chromosomal abnormalities in a single miscarriage 
has been shown to be slightly higher but still comparable to the prevalence in a 
subsequent miscarriage after RPL (45% vs 39%) (van den Berg et al., 2012).  
It is possible to analyse foetal tissue for genetic abnormalities using fluorescence in 
situ hybridisation (FISH) or array-based comparative genomic hybridisation (array 
CGH) which is more accurate than FISH. This can provide a reason to the couple 
for their pregnancy loss.  
In a study of nearly 800 couples with RPL, 3.5% were found to have a chromosomal 
abnormality (Flynn et al., 2014). More than 50% of these abnormalities were 
balanced reciprocal translocations. In the same study however, they did also 
reassuringly find a 64% cumulative live birth rate in patients with RPL.  
It has also been shown that the risk of future miscarriage is dependent on the nature 
of the parental karyotype abnormality. There appears to be increased miscarriage in 
those with reciprocal translocations rather than Robertsonian translocations or other 
types of abnormalities (Sugiura-Ogasawara et al., 2004).  
Parental karyotyping can provide couples with a possible cause for fetal 
chromosomal abnormalities and may help them decide if they want to continue 
trying to conceive or chose prenatal testing or preimplantation genetic diagnosis 
with in vitro fertilisation (IVF). 
It must be noted that even if a parental karyotype abnormality is found, the 
cumulative live birth rate has still been shown to be good despite a higher risk of 
another miscarriage (Flynn et al., 2014).  
Couples with chromosomal anomalies on fetal testing or parental karyotyping 
should be offered genetic counselling.  
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Pre-implantation genetic screening (PGS) or pre-implantation genetic diagnosis 
(PGD) can be considered where chromosomal anomalies are thought to be the 
cause of RPL. This involves IVF with screening for or diagnosing chromosomal 
anomalies prior to embryo transfer.  
PGD may be of particular interest to those couples at high risk of transmitting 
genetic disorders especially structural chromosomal abnormalities which are found 
in RPL patients. A systematic review on the use of PGD on RPL patients with a 
structural chromosomal abnormality actually showed no improvement in live birth 
rate. However, the studies in this review were not of high quality (Franssen et al., 
2011).  
 
1.3.7	FAMILY	HISTORY	
Studies have proven that sporadic miscarriage and RPL can run in families. RPL is 
more common in first degree relatives when compared to controls (Kolte et al., 
2011). This study and others which have confirmed the same however are open to 
much reporting bias. Couples may only talk of their experience of miscarriage if 
others in the family have experienced the same.  
 
1.3.8	ACQUIRED	THROMBOPHILIA	
Antiphospholipid syndrome (APLS) is widely recognised as a risk factor for 
pregnancy complications such as miscarriage, intrauterine growth restriction, pre-
eclampsia and intrauterine death (Ziakas et al., 2010).  APLS is an acquired 
thrombophilia diagnosed when there is a combination of antiphospholipid antibodies 
with pregnancy complications (two or more pregnancy losses) and/or venous 
thromboembolism (van den Boogaard et al., 2013). Antiphospholipid antibodies 
include lupus anticoagulant, anticardiolipin antibodies and B2 glycoprotein 
antibodies.  
There is a strong association of lupus anticoagulant with late RPL and of 
anticardiolipin antibodies with early RPL (Opatrny et al., 2006). The association with 
B2 glycoprotein is not as strong.  
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There have been many randomised controlled trials (RCT’s) over the years looking 
at treatment of APLS to try and reduce the rate of miscarriage in these patients. 
There is very little data on the use of aspirin alone in patients with APLS. Empson et 
al have concluded that the use of aspirin alone does not help to prevent RPL in 
those with APLS when compared to no treatment (Empson et al., 2005). 
A meta-analysis performed in 2002 showed that aspirin and low molecular weight 
heparin (LMWH) may reduce miscarriage risk in those with APLS by 54% when 
compared to aspirin alone (Empson et al., 2002). However, it was also concluded 
that this meta-analysis was based on only two small trials and one lacked adequate 
allocation concealment.  
The Cochrane review of this meta-analysis (Empson et al., 2005) is the strongest 
analysis of treatment for APLS we have and so, patients with APLS ae currently 
advised to have LMWH and aspirin from the date of a positive pregnancy test and 
this is favoured over no treatment.  
There are some conflicting reports. An RCT including 98 women with RPL showed 
that the live birth rate (LBR) in those randomised to heparin and aspirin was not 
significantly higher than those randomised to aspirin alone (72% vs 78%) 
(Farquharson et al., 2002).  
The meta-analysis by Empson et al in 2005 also examined outcomes of many other 
treatment options such as steroids and intravenous immunoglobulin (IVIG) in 
patients with APLS and RPL. It was found that steroid therapy did not increase LBR 
when used with aspirin or aspirin plus heparin. The safety of any intervention is 
important to assess. Prednisolone was found to significantly increase the risk of 
prematurity and gestational diabetes. The safety of heparin has also been assessed 
with regards to risks of prematurity/fetal growth restriction/risk of haemorrhage/bone 
mineral density and fractures. Empson et al 2005 also concluded from a systematic 
review of three RCT’s that IVIG does not reduce the chance of miscarriage.  
The lack of knowledge on the optimal dose of heparin to maximise benefit and 
minimise harm has also been commented on (Empson et al., 2002; Ziakas et al., 
2010). Anticoagulation may need to be adjusted according to weight and renal 
clearance changes in pregnancy.  
Ziakas et al have questioned whether LMWH is the right choice of anticoagulant to 
result a real benefit in those with APLS (Ziakas et al., 2010). In this meta-analysis, 
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treatment with unfractionated heparin (UFH) plus aspirin proved to be more 
efficacious than aspirin alone in reducing first trimester miscarriages and LMWH 
plus aspirin compared with aspirin alone showed no significant benefit in preventing 
pregnancy loss. These results however could have been due to the small study 
samples. 
APLS in those with RPL is not common (15% of cases). In the presence of APLS 
clinicians often tell the patient that a cause has been found and that treatment is 
available. However, it must be noted that clear evidence on APLS is hindered by 
studies with small sample sizes, lack of laboratory standardisation and differences 
in the clinical picture of those with APLS. Matched case control studies to help 
overcomes the huge differences found between patients with APLS which accounts 
for age, number of miscarriage and autoimmune status are necessary (Ziakas et al., 
2010). 
	
1.3.9	INHERITED	THROMBOPHILIA	
Inherited thrombophilias have been implicated as a cause for RPL. Inherited 
thrombophilias include Factor V Leiden mutation, Prothrombin mutation, Protein C, 
Protein S and antithrombin III deficiency. So far, studies looking at the association 
and treatment of inherited thrombophilia and RPL have been inconsistent.  
Protein C, protein S deficiency and antithrombin III deficiency are less common than 
factor V leiden and prothrombin mutations but more strongly associated with venous 
thromboembolism. Even so, only weak associations have been found. A meta-
analysis found no difference in live birth rate when using LMWH vs no LMWH in 
those with RPL and inherited thrombophilia (Skeith et al., 2016). This meta-analysis 
however had a limited sample size (n = 66) and so definite conclusions could not be 
made.  
The ALIFE-2 trial is currently being conducted to evaluate the effect of LMWH 
versus standard pregnancy surveillance in those with an inherited thrombophilia.  
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1.3.10	IMMUNOLOGICAL	CAUSES	
There are many immunological biomarkers that have been associated with RPL.  
However, to date their ability to predict pregnancy outcome in women with RPL has 
rarely been adequately assessed (ESHRE, 2017).    
Measuring anti-HY antibodies and HLA determination in women with RPL is 
currently not recommended. The association between subsequent pregnancy 
outcome and HLA polymorphisms in couples with RPL has not been sufficiently 
studied. Although there is an association between cytokines such as tumour 
necrosis factor alpha (TNF- a) and RPL (Piosik et al., 2013), no treatment options 
are available and prognosis for subsequent pregnancies is unknown.  
Some studies have shown a significant association between peripheral natural killer 
cells (pNK) and RPL (Karami et al., 2012), but there have also been studies which 
did not find this association (Liang et al., 2012). 
Equally, there is conflicting evidence about uterine natural killer cell (uNK) levels in 
patients with RPL. In 1996 Lachapelle et al found a significantly higher number of  
CD56dimCD16+ NK cells in endometrial biopsies in women with RPL using flow 
cytometry (Lachapelle et al., 1996). Using immunohistochemistry several other 
authors found increased uNK cells (CD56+) in the endometrium of women with RPL 
(Quenby et al., 2005). Furthermore, a study has demonstrated that prednisolone 
treatment significantly reduced the number of uterine NK cells (Quenby et al., 2005). 
A pilot randomised controlled trial of offering prednisolone to women with RPL and a 
high uNK cell density suggested an improvement in pregnancy outcom, however, 
this finding has not been confirmed in a large-scale trial (Tang et al., 2013). 
There is inadequate evidence to suggest that screening and treating immunological 
abnormalities should be introduced into routine clinical practise but further work in 
this area is needed. 
 
1.3.11	ENDOCRINE	FACTORS	
Hypothyroidism is associated with miscarriage, intrauterine growth restriction and. 
The neurocognitive development of the fetus can also be affected if hypothyroidism 
is not treated appropriately. Treatment of hypothyroidism and optimisation of thyroid 
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status prior to conception is recommended especially to reduce these potential 
complications of pregnancy. 
Subclinical hypothyroidism has been detected in over 20% of patients with RPL 
(Lata et al., 2013). There is conflicting evidence as to whether subclinical 
hypothyroidism should be treated to manage RPL. Bernardi et al concluded that 
there was no significant difference in the LBR of those with RPL when comparing 
treatment of those with subclinical hypothyroidism and those without (Bernardi et al., 
2013). The European Thyroid Association Guidelines for the Management of 
Subclinical Hypothyroidism in Pregnancy and Children advises treatment of 
subclinical hypothyroidism detected pre-conception and in pregnancy. So far there 
are no large RCT’s to come to a firm conclusion.  
There is however a clear association between thyroid autoantibodies (anti-
thyroglobulin (TG-Ab), TPO-Ab or anti-TSH receptor autoantibodies) and RPL 
(Ticconi et al., 2011). We await the results of the TABLET trial to advise whether 
treatment of those with thyroid autoimmunity will reduce miscarriage or increase live 
birth.  
Also, looking at subclinical hypothyroidism and thyroid autoantibodies in those with 
RPL, the presence of subclinical hypothyroidism has been found to be significantly 
higher in those with TPO-Ab’s (Lata et al., 2013). For this reason, thyroid screening 
and TPO-antibody testing is recommended in patients with RPL (ESHRE, 2017). 
Progesterone is vital for maintenance of pregnancy and so, progesterone support 
has been studied in the women with RPL. The largest and most recent randomised 
controlled trial showed that progesterone did not lead to a significant increase in 
LBR when compared to placebo (RR1.04, CI 0.94 – 1.15, P 0.45) for those with 
unexplained RPL (Coomarasamy et al., 2015).  
Polycystic ovarian syndrome (PCOS) is known to be associated with subfertility and 
pregnancy complications such as gestational diabetes. A clear association between 
PCOS and RPL is difficult to define due to the multi-factorial nature of the syndrome 
including obesity, hyperinsulinaemia and hyperandrogenism but there have been 
studies showing PCOS being more prevalent in those with RPL when compared to 
parous women (Sagle et al., 1988; Watson et al., 1993).  
Although exposure to metformin in pregnancy is regarded as generally safe, there is 
not enough evidence to recommend its use in those with RPL.  
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Vitamin D deficiency is related to antenatal complications such as intrauterine 
growth restriction, pre-eclampsia and gestational diabetes (Aghajafari et al., 2013). 
It is therefore advisable to consider supplementation in those found to be deficient. 
However, there is little published data to assess the effectiveness of vitamin D in 
improving the chance of live birth. 
Prolactin testing, androgen testing, ovarian reserve testing, luteal phase 
insufficiency testing, luteinising hormone (LH) testing and homocysteine plasma 
levels are not recommended for patients with unexplained RPL due to the paucity of 
evidence associating these and RPL and the absence of any prospective or 
randomised data (ESHRE, 2017). 
	
1.3.12	UTERINE	STRUCTURAL	ANOMALIES	
An association between congenital uterine anomalies and RPL has been reported 
(Saravelos et al., 2008). Arcuate uteri are associated with second trimester losses 
whereas septate uteri are associated with first trimester miscarriages when 
compared to women with a normal uterus (ESHRE, 2017). Other congenital uterine 
anomalies include unicornuate, didelphic and bicornuate uteri.  
Acquired uterine anomalies such as myomas or endometrial polyps have also been 
found to be prevalent in those with RPL but the real clinical significance of this is 
unclear. 
Three-dimensional USS (3-D USS) is now the gold standard and should be offered 
to RPL patients as it allows visualisation of the inside and outside of the uterus and 
gives high definition pictures. 3-D USS should be used wherever possible due to 
higher specificity and sensitivity to two-dimensional (2-D USS). If pelvic ultrasound 
reveals an anomaly then combined hysteroscopy and laparoscopy are useful for 
diagnosis (Saravelos et al., 2008).  
Sonohysterography is also accurate in diagnosing congenital uterine anomalies and 
will provide more information than a hysterosalpingogram or an ultrasound scan as 
saline is used to improve the ultrasound images. This can be uncomfortable for the 
patients but may help to avoid the need for more invasive procedures with more 
risks such as a laparoscopy (ESHRE, 2017).  
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Surgery for congenital uterine anomalies can be considered however surgery may 
be at the cost of an effect on fertility and there have been no adequately powered 
randomised controlled trials to confirm efficacy as recruitment to these trials has 
proven to be not feasible. 
There are no well powered studies on the effect of surgery for fibroids in those with 
RPL. There has been work done to show that subserosal and intramural fibroids are 
unlikely to contribute to RPL but in selected patients treatment of submucous 
fibroids may reduce the risk of miscarriage (Jaslow, 2014). 
Overall there is no conclusive evidence that treatment of endometrial polyps or 
fibroids leads to improved outcomes for those with RPL.  
Intrauterine adhesions from previous uterine surgery are often seen in those with 
RPL and small observational studies have recommended removal of adhesions 
(Jaslow, 2014), but further work is required before confidently recommending 
treatment which may actually predispose to further adhesions.  
 
1.3.13	MALE	FACTOR	
Many studies have shown a link between lifestyle factors such as obesity, smoking 
and alcohol consumption and sperm quality (Anifandis et al., 2014), (Li et al., 2011). 
Medication such as selective serotonin reuptake inhibitors, corticosteroids and 
antibiotics are known to have effects on sperm function (Sharma et al., 2013). The 
effects of these medications are reversible and so it is important to take a detailed 
history from the male.  
We also know that semen from couples with RPL have been shown to have 
reduced viability, morphology and progressive motility (Ruixue et al., 2013). 
Therefore, it is reasonable to address male lifestyle factors when assessing a 
couple with RPL. Advise on a healthy diet, exercise, the intake of antioxidants such 
as Vitamin C and E and minerals such as iron and zinc will help reduce levels of 
reactive oxygen species (ESHRE, 2017). 
Recent studies have looked at male genetic defects such as DNA fragmentation 
and Y chromosome deletions. Robinson et al have performed a meta-analysis of 
studies looking at sperm DNA damage. This showed a significant increase in 
miscarriage rates in patients with high sperm DNA damage when compared to low 
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sperm DNA damage (RR 2.16; 95%CI 1.54 – 3.03) (Robinson et al., 2012). 
However, the best test to detect sperm DNA damage has yet to be determined. 
There have been not been any randomised controlled trials of antioxidants that have 
demonstrated an improved live birth rate. 
DNA damage is aggravated by smoking and obesity and so again, it is important to 
assess male lifestyle factors in RPL clinics. 
 
1.3.14	STRESS	
There are no high quality studies assessing the association between maternal 
stress and risk of miscarriage. It is also difficult to ascertain cause or effect in this 
situation. 
 
1.3.15	UNEXPLAINED	RECURRENT	PREGNANCY	LOSS	
Unfortunately, a cause for RPL is not found for the majority of patients attending the 
RPL clinic. To get an overview of treatment options available for such patients I 
performed a PubMed search of RCT’s and systematic reviews conducted over the 
last ten years evaluating the treatment for preventing miscarriage or improving LBR 
in those with unexplained RPL. This PubMed search was by no means an in-depth 
or comprehensive review of all available evidence but gave me some insight into the 
research conducted within this area.  
The Pubmed search was as follows: 
Search (((fetal loss[Title/Abstract]) OR (((((((recurrent miscarriages[MeSH Terms]) 
OR ((recurrent[Title/Abstract]) AND miscarr*[Title/Abstract]))) OR 
((RECURRENT[Title/Abstract]) AND ((spontaneous abortion[MeSH Terms]) OR 
early pregnancy loss[Title])))) OR (((habitual abortion[MeSH Terms]) OR habitual 
abortion[Title/Abstract]) AND "last 10 years"[PDat] AND Humans[Mesh])) AND "last 
10 years"[PDat] AND Humans[Mesh]))) AND TREAT*[Title]
Comment [Office1]: I	can	confirm	that	my	search	was	fetal	
loss	with	a	space	in	it	–	had	saved	search	criteria.		
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The search revealed two systematic reviews looking into IVIG for unexplained 
primary RPL which concluded that they are of no benefit in this patient group (Ata et 
al., 2011; Hutton et al., 2007). One of these systematic reviews concluded that there 
is a significant increase in LBR in those with secondary RPL (Hutton et al., 2007) 
but this finding was not replicated in 2  RCT’s done more recently (Christiansen et 
al., 2015; Stephenson et al., 2010). 
There has also been report of a higher LBR if IVIG is started pre-conceptually in the 
follicular phase before pregnancy (Hutton et al., 2007) but this conclusion did not 
apply when data from women with 3 or more miscarriages was exclusively analysed 
(Coulam et al., 1995; Stephenson et al., 1998). 
Progesterone is essential to maintain pregnancy (Saccone et al., 2017) and it has 
been suggested that deficiency of the hormone in the luteal phase may be linked to 
miscarriage. However, the PROMISE trial has shown that progesterone does not 
increase LBR when compared to placebo in those with unexplained RPL 
(Coomarasamy et al., 2015). Fortunately, there was no increase in frequency of 
adverse effects with progesterone when compared to placebo. Further work may be 
needed on the type, route and dose of progesterone used. 
Another systematic review looking into progesterone for unexplained RPL by 
Saccone et al (Saccone et al., 2017) included 10 RCT’s and 1586 women which 
actually concluded that progestogens do reduce the risk of RPL (RR 0.72, CI 0.53 – 
0.97) and result in a higher LBR (RR 1.07, CI 1.02 – 1.15). However, this systematic 
review included seven studies which were done before 1990, only eight were double 
blind, more than half of the patients came from one trial and different preparations, 
doses and routes of progesterone were used. Therefore, it was concluded that the 
route or dose that would have a significant effect cannot be commented on. Further 
trials would be needed to address this question.  
The role of anticoagulants have also been tested in the quest to find a combination 
that would successfully treat patients with unexplained RPL. The PubMed search 
revealed RCT’s looking at LMWH + folic acid versus folic acid alone (Shaaban et al., 
2017), LMWH versus placebo (Pasquier & Martin, 2015) and LMWH versus 
multivitamins (Schleussner & Petroff, 2015) which all showed slightly inconsistent 
results. This was likely to be confounded by different outcome measures either 
being ‘take home baby’ rate, live birth rate and ongoing pregnancy at 24/40 
respectively.  
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A systematic review looking at aspirin and/or heparin to treat those with or without 
inherited thrombophilia (de Jong et al., 2014) concluded that anticoagulants for 
unexplained RPL cannot be supported. There was also a similar conclusion in a 
systematic review where there were similar birth rates in the aspirin and placebo 
group (Kaandorp et al., 2009). 
Lymphocyte immunotherapy has been evaluated as a treatment option for 
unexplained RPL based on immunological mechanisms thought to reject the 
‘allograft embryo’ (Cavalcante et al., 2017). A systematic review and meta-analysis 
performed in 2017 supported the efficacy and safety of lymphocyte immunotherapy 
for unexplained RPL (Cavalcante et al., 2017), however, there was not a vigorous 
assessment of the quality research in this meta-analysis 
In 2016 Liu et al conducted a meta-analysis including 18 RCT’s which showed that 
lymphocyte immunisation significantly improved LBR (OR 5.25, CI 4.16 ~6.64). LBR 
was improved whether paternal lymphocytes or unrelated donor lymphocytes were 
used (Liu et al., 2016). Again there was inadequate assessment of trial quality in 
this meta-analysis. When the more vigorous Cochrane meta-analysis was 
undertaken there was no benefit over placebo from leucocyte immunisation in terms 
of improving LBR (Wong et al., 2014) 
Human Chorionic Gonadotrophin (HCG), granulocyte colony stimulating factor 
(GCSF) and luteinising hormone (LH) suppression have all also been evaluated as 
treatment options for unexplained RPL (Cavalcante et al., 2017; Morley et al., 2013; 
Scarpellini & Sbracia, 2009) . None of the randomised, placebo controlled trials from 
this PubMed search demonstrated that these interventions led to an improvement in 
pregnancy outcome.  
Many other smaller studies investigating other treatment options were found in this 
search such as treatment of chronic endometritis, treatment of fibroids and 
treatment of varicoceles which although gave new information to build from, did not 
give any definite treatment strategies to implement.  
A Systematic review looking at Chinese herbal medicine (Yang et al., 2013)also 
concluded that it is not possible to recommend such treatment for unexplained RPL. 
There was however much heterogeneity and bias in the studies included in this 
systematic review. 
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Performing this PubMed search provided me with useful insight into the almost 
infinite quest to find a treatment for unexplained RPL. Overall, Lymphocyte 
immunisation, IVIG, prednisolone, heparin, aspirin, progesterone, intralipid and G-
CSF have all been tested in those with unexplained RPL but there is not enough 
good quality evidence to recommend any of these options in those with unexplained 
RPL. 
 
1.3.16	RECURRENT	MISCARRIAGE:	PSYCHOLOGICAL	MORBIDITY	
Recurrent pregnancy loss is a debilitating disorder, associated with considerable 
psychological morbidity. Miscarriage is associated with feelings of loss and grief and 
these feelings are intensified with each loss.  
A national survey of public perceptions of miscarriage including over 1000 
participants showed that over 40% felt they had done something wrong, nearly 50% 
felt guilty and 28% felt ashamed (Bardos et al., 2015). These emotions then lead to 
low mood and anxiety.  
A third of women attending recurrent pregnancy loss clinics are clinically depressed 
with 20% having high levels of anxiety (Rai & Regan, 2006). A prospective survey 
study has shown that 39% of women suffering RPL meet the criteria for moderate to 
severe post-traumatic stress disorder (PTSD) and 20% meet the criteria for 
moderate – severe anxiety compared to 10% of the general population (Farren et 
al., 2016). PTSD was higher at 3 months after the event compared to 1 month after 
the event. It is important to appreciate that going through miscarriage has an impact 
on the quality of life, relationships and physical health.  
It has been shown that compassionate care, acknowledgement of reproductive 
history and recognition that RPL is a significant life event, will affect an individual’s 
experience in the RPL clinic.(Musters et al., 2013). 
 
1.3.17	THE	RECURRENT	PREGNANCY	LOSS	CLINIC	
This clinic offers specialist investigations, research opportunities and possible 
treatment to those with RPL. Along with specialist medical staff there may also be 
psychologists accessible for the couples. 
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At the RPL clinic at University Hospital Coventry and Warwickshire patients are first 
seen by Professor Quenby. The patients’ reproductive history is established, a 
medical and family history is noted and a plan for investigations are made.  
Patients are aware that despite extensive investigations, often a direct cause is not 
actually found. This is understandably distressing for patients even though 
unexplained RPL has a good prognosis for a future successful pregnancy outcome.  
Patients are offered entrance into research trials which will potentially give them the 
opportunity to try new treatment or at least, support the feeling of helplessness. 
Regardless of treatment plans or entrance into research studies, plans for support 
are made for the subsequent pregnancy. All patients have the contact details for the 
Biomedical Research Unit where research midwives are available for support.  
Patients are able to call once they have a positive pregnancy test and an early 
ultrasound scan is booked for 6 weeks gestation with regular 2 weekly follow up for 
ultrasound scans and supportive care until 12 weeks’ gestation. 
 
1.3.18	WHAT	WE	KNOW	SO	FAR	
Despite many randomised controlled trials having been undertaken in RPL,  the only 
treatment with demonstrated significant efficacy for the prevention of RPL is heparin 
and aspirin for those women with APLS (Empson et al., 2005). APLS occurs in only 
15% women with RPL thus there is no effective treatment for 85% of RPL patients.  
This brings us onto the research being conducted at The University of Warwick into 
reasons behind RPL. This paradigm is based on the fundamental relationship and 
interaction between the conceptus and the endometrium to help achieve a 
successful pregnancy.  
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1.4 THE HUMAN ENDOMETRIUM 
 
The human endometrium is one of the most dynamic human tissues (Du & Taylor, 
2009) undergoing approximately 400 cycles of regeneration in a woman’s lifetime 
(Du et al., 2012; Mutlu et al., 2015). Not only does the endometrium undergo 
monthly shedding, regeneration and differentiation with menstrual cycles but also 
regenerates following childbirth, endometrial resection and in post-menopausal 
women taking hormone replacement therapy (Gargett, 2007). 
The endometrium is made of an upper superficial layer called the functionalis and a 
lower deeper layer called the basalis. The basal layer contains glands and small 
arteries which are embedded in stroma. The stroma is made up of fibroblasts and 
collagen which make up the extracellular matrix providing a structural framework for 
the tissue and is vital for wound healing.  
Implantation in humans has always been largely described as a process where the 
blastocyst firstly adheres to the endometrium and then breaches and invades 
through the luminal epithelium. With this view, the maternal tissues need to tolerate 
the blastocyst. Inadequate invasion can lead to complications such as miscarriage 
and on the converse, if invasion through maternal tissues is excessive then this too 
can lead to unfortunate circumstances such as placenta accreta (Quenby & 
Brosens, 2013).  
Emerging insights into the cyclic changes to the endometrium and the mechanisms 
that govern embryo implantation have provided new ontological dimensions to early 
pregnancy loss. We now know that implantation of the human embryo is much more 
dynamically controlled by the endometrium than previously appreciated (Quenby & 
Brosens, 2013).  
	
1.4.1	IMPLANTATION	AND	DECIDUALISATION		
Successful implantation is believed to be the result of appropriate preparation of the 
endometrium for pregnancy (decidualisation) and also as a result of appropriate 
signalling between the conceptus and the endometrium in that particular cycle 
(Lucas et al., 2016b).  
Decidualisation is a process whereby stromal fibroblasts transform into secretory 
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cells (Macklon & Brosens, 2014). It is a transformative process which involves the 
endometrium passing  through a pro-inflammatory phase through to an anti-
inflammatory phase, all prior to conception, in the mid luteal phase of the menstrual 
cycle (Lucas et al., 2016a).  
Pro-inflammatory signals trigger the expression of genes for endometrial receptivity. 
This is followed by an anti-inflammatory response driven by the secretion of 
progesterone which is essential for the support of an embryo. (Salker et al., 2012). 
Usually these pro-inflammatory and anti-inflammatory waves within a menstrual 
cycle mark a narrow window of implantation. Within this narrow window of 
implantation, the endometrial environment is optimised for the successful 
implantation of the blastocyst (Salker et al., 2012). A narrow window of implantation 
with an appropriately receptive and selective endometrium is vital for meaningful 
implantation.  
Menstrual cycles, monthly endometrial regeneration and an optimised implantation 
window all come together as a method of quality control for any new fertilisation. 
The endometrium is normally able to mount an implantation response tailored to 
each distinct pregnancy. (Brosens et al., 2014). The cumulative birth rate for 
patients with RPL is high which suggests that the embryo-endometrial interface 
actually adapts and changes with each cycle allowing a pregnancy to be finally 
successful. 
Decidualisation is vital for the successful preparation of pregnancy and recent 
studies show that the hallmark for RPL is aberrant decidualisation of the 
endometrium (Salker et al., 2010; Salker et al., 2012).  
In patients with RPL the window of implantation is disordered and prolonged, 
leading to ‘super fertility’ with a high rate of early pregnancy loss due to disabled 
embryo selection (Lucas et al., 2016a).  In this situation, endometrial stromal cells 
do not respond to deciduogenic cues in the post-ovulatory phase of the menstrual 
cycle resulting in a defect in cellular maturation and this leads to abnormal 
decidualisation (Lucas et al., 2016b). Abnormal decidualisation is characterised by a 
prolonged inflammatory response, causing the loss of a selectivity checkpoint, 
rendering the endometrium to be excessively receptive but unable to sustain the 
pregnancy (Gellersen & Brosens, 2014).  
On the opposite side of the spectrum is when the decidualisation process is far too 
excessive. This restrains receptivity and leads to conception delay as seen in 
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subfertility patients. (Macklon & Brosens, 2014).  
The concept of super-fertility is supported by the common theme we see in RPL 
clinics where patients state they are able to get pregnant very easily however,  as 
they have a prolonged and disordered window of implantation they then miscarry 
very early too due to abnormal embryo selection. 40% of patients with RPL can 
achieve a pregnancy within three cycles (Orlando & Coulam, 2014). This is in 
contrast to the subfertility patients who struggle to get pregnant because the 
endometrium is far too selective and not receptive. 
 
 
This is a diagrammatic representation of the spectrum of reproductive difficulties. 
For a successful pregnancy, there needs to be a balance of receptivity and 
selectivity.	
	
1.4.2	EMBRYO	SELECTION	AND	IMPLANTATION	
Human embryos have been shown to be exceptionally diverse. Blastocyst analysis 
has shown that the transfer of mosaic embryos can still lead to a successful 
pregnancy with a healthy euploidic baby at birth (Greco et al., 2015). This finding 
has emphasised the presence of an intrinsic and distinct pre-implantation selection 
process whereby those blastocysts even with mosaicism implant, adapt and result in 
successful outcomes.  
Normally, human endometrial stromal cells (HESC’s) become sensitive to 
embryonic protease signals upon decidualisation and respond to low quality 
embryos by inhibiting secretion of implantation factors such as cytokines and growth 
Recurrent miscarriage
↓ Selectivity 
↑ Receptivity
Subfertility
↑ Selectivity
↓ Receptivity
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factors such as interleukin-1 beta (IL1-b) and heparin-binding EGF-like growth factor 
(Teklenburg et al., 2010).  
HESC’s therefore, serve as biosensors of embryos that have breached the luminal 
epithelium (Brosens et al., 2014; Teklenburg et al., 2010).  
This observation leads to the concept of ‘natural selection’. Appropriately 
decidualised endometrium responds to embryonic signals and either supports 
development of the embryo (positive selection) or leads to pregnancy failure through 
menstruation-like shedding (negative selection) (Brosens et al., 2014; Lucas et al., 
2016b). This process protects maternal resources to invest in a future successful 
pregnancy.  
So, appropriately decidualising HESC’s migrate towards the trophoblast rather than 
the trophoblast invading the endometrium as previously considered (Gellersen et 
al., 2013). The embryo will then implant at receptive sites where HESC’s have 
migrated. HESC’s then encapsulate the conceptus and create a specific 
environment for optimal implantation and development (Quenby & Brosens, 2013). 
This concept of endometrial cell migration and the mutual attraction between the 
embryo and endometrium to select and invest in the best quality embryo has also 
been demonstrated by Weimer et al (Weimar et al., 2012). In vitro studies of fertile 
women have shown decidualising cells normally selectively migrate to high quality 
embryos but not low quality ones but decidualising cells from patients with 
miscarriage were not able to discriminate between embryo quality (Weimar et al., 
2012).  
These concepts demonstrate that in RPL, rather than maternal rejection of the 
embryo there is actually a lack of correct selection so abnormal embryos that should 
be lost with menstruation are allowed to implant. The patient then suffers pain, 
bleeding and pregnancy loss. In addition, normal embryos are more supported and 
are also at risk of miscarriage hence suboptimal selection at implantation increases 
the rate of miscarriage.  
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Figure 1.0.2: Embryo Encapsulation by Decidualising Stroma 
 
 
Figure 1.0.2 taken from (Quenby & Brosens, 2013) shows embryo encapsulation 
rather than invasion of the trophoblast into the decidualising stroma.  
It makes sense that there are several check points and stress tests for an embryo to 
overcome for maternal investment into pregnancy. Intrinsic biomarkers and 
signalling between the embryo and the endometrium lead to self-correction of 
mosaicism and implantation (Lucas et al., 2016a). The syncytiotrophoblast cells 
must secrete enough bHCG to help maintain progesterone secretion from the 
corpus luteum. The next stress test is when the placenta must take over to support 
the pregnancy. If there is a failure of the pregnancy to overcome the burden of any 
of these checkpoints it results in a clinical miscarriage. This does not however 
explain the reason for pregnancy loss prior to implantation (Macklon & Brosens, 
2014).  
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Figure 1.0.3: Embryo Selection at Implantation 
 
	
 
The diagram in figure 1.0.3, taken from (Lucas et al., 2016a) shows the check points 
the embryo must pass to prevent a prolonged commitment into a pregnancy that will 
fail. Initially blastocysts are often mosaic. A combination of embryo self-correction 
and decidualised endometrial cells appropriately screening for embryo quality are 
the first hurdles to overcome followed by sufficient bHCG secretion and then the 
inception of placental perfusion at the placental-endometrial interface. 
 
1.5 STEM CELLS AND THE ENDOMETRIUM  
 
Stem cells are undifferentiated cells, present in most organs, capable of self-
replication and differentiation into multiple cell types (Watt & Hogan, 2000). Their 
unique property of self-renewal and differentiation has generated a lot of interest all 
over the world in their potential use in injured and damaged tissue. 
The first study demonstrating the presence of mesenchymal stem cells (eMSC’s) in 
the endometrium was reported only 12 years ago (Chan et al., 2004). Stem cell 
populations in the endometrium are highly dynamic because of their continuous 
recruitment and activation in response to menstruation, miscarriage, or parturition 
(Gellersen & Brosens, 2014; Macklon & Brosens, 2014).
 
Normally, monthly 
menstrual cycles lead to the activation of endometrial stem/progenitor cells, tissue 
regeneration and maturation of endometrial stromal cells (Lucas et al., 2016b). 
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There are three different types of endometrial stem cells; epithelial progenitor cells, 
endometrial mesenchymal stem cells and endothelial progenitor cells (Gargett & 
Masuda, 2010). Endometrial mesenchymal stem cells are shed during menstruation 
(Gargett & Masuda, 2010). 
Research conducted recently at the University of Warwick has shown that RPL is 
strongly associated with endometrial mesenchymal stem cell deficiency. The 
endometrium in those with RPL lacks plasticity due to stem cell deficiency, 
increased cellular senescence and limited differentiation potential (Lucas et al., 
2016b). Low levels of eMSC’s, cellular senescence, disordered inflammation all 
contribute to abnormal endometrial decidualisation (Lucas et al., 2016b).  
These findings are based on results from clonogenic assays performed on 
endometrial biopsies of patients attending the implantation clinic. These patients 
either have a history of RPL or of recurrent implantation failure. Figure 1.0.4 shows 
that those patients with less than 3 miscarriages (control) have a higher number of 
eMSC’s (assessed by a clonogenic assay) compared to patients with three or more 
miscarriages (RPL).  
 
FIGURE 1.0.4: Stem Cell-Ness of the Endometrium in Those with RPL. 
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Figure 1.0.5 taken from  (Lucas et al., 2016b) shows that the stem cell-ness of the 
endometrium decreases with increasing numbers of miscarriages. 
FIGURE 1.0.5: Number of First Trimester Miscarriages and the Relationship to the eMSC 
Count 
 
 	
(Lucas et al., 2016b) 
 
Endometrial stroma consists of MSC’s, fibroblasts and senescent cells. This stem 
cell deficiency at the endometrium has an impact on the overall composition of the 
endometrial stroma. Accumulation of senescent cells in a stroma deficient in 
clonogenic stem cells results in the release of inflammatory cytokines and 
chemokines (Acosta et al., 2013).  
This environment negatively impacts the plasticity of the endometrium for 
appropriate signalling to occur with between the endometrium and the conceptus.  
Endometrial stem cell deficiency is the foundation for my research project. We 
wanted to develop a treatment for endometrial stem cell deficiency to improve the 
environment for implantation.  
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1.6 MECHANISMS OF STEM CELL RECRUITMENT 
 
Intrinsic inflammatory actions lead to stem cell recruitment. Bone marrow 
mesenchymal stem cells (bmMSCs), and (eMSCs) have been shown to be highly 
proliferative and migratory (Khatun et al., 2017).  
eMSC’s have been shown to reside in the perivascular space of the endometrium 
contributing to monthly regeneration with menstrual cycles (Gargett et al., 2009; 
Gargett & Ye, 2012). These stem cells are unique, highly proliferative, have the 
ability for self-renewal and can differentiate into other cell lineages such as 
osteocytes and chondrocytes. (Gargett et al., 2009). It is thought that endometrial 
stromal fibroblasts (eSFs) which are the most common cell type in the endometrial 
stroma are descendants of eMSC’s. 
Several other studies have shown that eMSCs actually originate from the bone 
marrow and migration of these cells towards the endometrium occurs in response to 
tissue injury (menstruation). Here they differentiate into eMSC’s contributing to 
endometrial regeneration (Taylor, 2004).  
 
1.6.1	CXCL12	AND	CXCR4	PATHWAY	
Cytokines and chemokines released in response to hypoxia that occurs in the 
secretory phase of the menstrual cycle are thought to enhance recruitment of 
bmMSC’s to the endometrium (Hu et al., 2013). bmMSC’s are undifferentiated and 
have been shown to travel to distant organs to contribute to tissue repair (Du & 
Taylor, 2007).  
The first study to report bone marrow derived endometrial stem cells  at the 
endometrium looked at the endometrial biopsies of those who received HLA-
mismatched bone marrow transplants (Taylor, 2004). Donor endometrial cells 
(epithelial and stromal cells) were detected in the biopsy from all bone marrow 
recipients suggesting that bone marrow derived stem cells contribute to endometrial 
regeneration (Taylor, 2004). 
In 2012, Du et al were able to show that when male to female bone marrow 
transplantation was performed in mice, a uterine injury resulted in a 2-fold increase 
in bone marrow derived stem cell recruitment to the endometrium (Du et al., 2012). 
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This effect was independent of whether oestrogen was present or not suggesting 
that these bone marrow stem cells are recruited at times of injury but not with 
monthly cyclic regeneration of the endometrium in mice. 
Bone marrow derived stem cells have also been shown to travel to help the repair 
and regeneration of diabetic skin wounds in mice (Castilla et al., 2012).  
One of the postulated methods of stem cell recruitment from the bone marrow is via 
the CXCL12 and CXCR4 pathway. The CXCL12 (SDF-1) and CXCR4 pathway has 
been shown to be vital for chemo-attraction of bone marrow derived mesenchymal 
stem cells to peripheral tissues (Döring et al., 2014; Wang et al., 2015). It has been 
repeatedly shown that when CXCL12 production is increased at sites of injury in the 
body, for example in bone injury or myocardial injury, stem cell recruitment is 
enhanced allowing wound healing and functional recovery (Liu et al., 2013; Penn et 
al., 2012). This highlights the activation of this pathway in many areas of the body in 
response to injury. 
CXCL12 is also produced by endometrial stromal cells
 
and is the primary 
chemokine that recruits bone marrow derived cells to the uterus. CXCR4 is the 
receptor for CXCL12 expressed on the surface of bmMSC’s to modulate migration 
of stem cells to the endometrium (Sahin Ersoy et al., 2017; Wang et al., 2015). The 
interaction between CXCR4 and CXCL12 is vital for stem cell mobilisation (Sahin 
Ersoy et al., 2017).  
An antagonist to CXCR4 has been shown to block migration of stem cells indicating 
that the CXCR4 receptor is vital for chemoattraction of bone marrow cells to human 
endometrial cells (Wang et al., 2015).  
Also, oestradiol is known to induce the expression of CXCL12 and CXCR4 
indicating that stem cell recruitment would actually increase in response to 
hormonal changes with the menstrual cycle.  
 
1.6.2	REGENERATION	FROM	THE	BASALIS	LAYER	
It has also been postulated that eMSC’s reside in the endometrial basalis and help 
to maintain the regenerative capacity of the endometrium each month. Hormonal 
changes with the ovarian cycle and increase in oestradiol is thought to result in the 
migration of endogenous stem cells to the functional layer of the endometrium to 
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help with regeneration of the endometrium every month (Chan et al., 2004).  
Gargett et al have shown that the human endometrium contains small populations 
of epithelial and stromal stem cells which are clonogenic and are involved in 
monthly regeneration of the glands and stroma. Gargett et al used a label retaining 
cell method to identify stem cells and their locality. This experiment demonstrated 
epithelial and stromal stem cells in mouse endometrium. 
This theory is also supported by a study which showed that although MSC’s from 
the bone marrow help with repair after uterine injury, these specific MSC’s are not 
involved in this cyclic regeneration of the endometrium with menstruation. This was 
demonstrated in mice studies where endometrial repair with bmMSCs occurred with 
or without oestrogen (Du et al., 2012).  
It appears that local signals may be more important in enhancing mobilisation of 
bmMSCs to sites of injury rather than hormonal changes with monthly menstrual 
cycles. 
 
 
1.6.3	OTHER	EVIDENCE	
A recent study by Khatun et al reported an experiment where eMSC’s from 
endometrial biopsies and bmMSC’s from bone marrow aspirates were studied. 
Khatun et al looked at surface marker characteristics, migration potential and 
cytokine profiles between bmMSC’s, eMSCs and eSFs. This study demonstrated 
that eMSC’s are more likely to originate from the bone marrow rather than 
descending from the haematopoietic stem cell lineage because all three cell types 
were negative for haematopoietic cell surface antigens. It has been demonstrated 
that both bmMSCs and eMSCs have similar surface marker profiles with high levels 
of migration towards areas of inflammation.   
Figure 1.0.6 taken from (Khatun et al., 2017) shows the migration of bmMSCs from 
the bone marrow to the endometrium in the proliferative phase of the menstrual 
cycle after signals are received by the bone marrow at a time of menstrual injury to 
the endometrium. Differentiation to eMSC’s and eSF’s then occurs.  
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Figure 1.0.6: Migration of bmMSC’s to the Endometrium 
	
 
  
It has also been shown that bmMSCs are recruited by IL-1b.  This cytokine is highly 
expressed during hypoxia and menstruation and may be a recruiting signal to 
bmMSCs (Rossi et al., 2005). It appears that IL-1b is able to trigger migration of 
bmMSCs and eMSCs to areas of inflammation (Khatun et al., 2017). Interestingly, 
IL-1b also promotes CXCL12 expression (Peng et al., 2006) and as mentioned 
above, CXCL12  produced by endometrial stromal cells
 
is the primary chemokine 
that recruits bone marrow derived cells to the uterus. 
 
1.6.4	INCREASING	STEM	CELL	RECRUITMENT		
Migration of bone marrow derived stem cells to the endometrium is known to be 
enhanced after ischaemic injury (Wolff et al., 2011). The potential of increasing 
mesenchymal stem cells at the endometrium as treatment has been demonstrated 
in both animals and humans.  
Infusion of stem cells into the uterus of women with Asherman’s syndrome has 
shown to increase the endometrial thickness in women undergoing IVF (Nagori et 
al., 2011; Singh et al., 2014). Studies on mice with simulated Asherman’s syndrome 
have shown that after a male bone marrow transplant, there is evidence of Y+ cells 
in the endometrium and also improved conception rates (Alawadhi et al., 2014). 
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The discovery of endometrial mesenchymal stem cell deficiency in those with 
recurrent miscarriage has provided further insight into the cause of abnormal 
decidualisation patterns of the endometrium. Stem cell recruitment can be 
enhanced and this could potentially allow improved decidualisation and an improved 
environment for implantation which in turn could improve pregnancy outcomes.  
 
1.7 DPP4 INHIBITORS  
 
DPP4 inhibitors are new class of medication for glycaemic control in diabetic 
patients. They are well accepted and tolerated by diabetic patients because they are 
taken orally (rather than by an injection) and are safe. They also have advantages 
of not causing weight gain or hypoglycaemia (Ahrén, 2007).  
DPP4 inhibitors are particularly relevant here because inhibition of DPP4 retards the 
degradation of CXCL12 and therefore should increase the recruitment of stem cells 
to sites of injury through enhancement of the CXCL12-CXCR4 axis (Brenner et al., 
2014; Jungraithmayr et al., 2012).   
A mouse model found that DPP4 inhibitors increased stem cell recruitment to the 
lung after an ischemic-reperfusion injury by enhancing the CXCL12-CXCR4 axis 
(Hopman & DiPersio, 2014). 
Furthermore, DPP4 expression has been found to be higher in the endometrium 
from women with RPL compared to control subjects (Lucas et al., 2016b). This is 
demonstrated in figure 1.0.7. This may explain the lack of stem cell recruitment due 
to curtailment of the CXCL12/CXCR4 pathway. This also suggests that DPP4 
inhibition would be beneficial in women with repeated miscarriage.  
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figure 1.0.7: DPP4 Expression at the Endometrium in those with Recurrent 
Miscarriage. 
	
Diagram adapted from (Lucas et al., 2016b) 
 
1.7.1	SAFETY	OF	DPP4	INHIBITORS	
So far, there is good data to suggest that DPP4 inhibitors are not only safe but also 
beneficial. A meta-analysis has shown that DPP4 inhibitors may decrease the risk of 
adverse cardiovascular events which diabetic patients are (Patil et al., 2012).  
The TECOS trial, published in the New England Journal of Medicine in July 2015 
also looked at the most commonly used DPP4 inhibitor; Sitagliptin and 
cardiovascular outcomes (Green et al., 2015). This large randomised double blind 
placebo controlled trial revealed very reassuring data about the safety of Sitagliptin. 
Over 14,000 patients were assigned to either Sitagliptin or placebo. This RCT 
showed that the use of Sitagliptin in diabetic patients, who are already at high 
cardiovascular risk, did not increase the risk of cardiovascular complications. 
Sitagliptin was also not associated with a significant increase in the rate of severe 
hypoglycaemia when compared to placebo.  
There have been case reports of pancreatitis associated with the use of Sitagliptin. 
The incidence is not known but presumed to be very low (Merck & Co, 2015). The 
TECOS trial also showed no significant difference in rates of acute pancreatitis in 
the Sitagliptin and placebo groups.  
Additional effects of DPP4 inhibitors are to improve endothelial function, reduce pro-
oxidative and pro-inflammatory states which are all potentially favourable factors for 
	 50	
pregnancy (Avogaro et al., 2014).  
The Summary of Product Characteristics for Sitagliptin states that it does not cause 
hypoglycaemia when used as monotherapy. There is an increase in the risk of 
hypoglycaemia if used with other diabetic medication. There have been reports of 
severe arthralgia and some reports of hypersensitivity including anaphylaxis and 
exfoliative skin conditions. Adverse reactions occurring in over 5% of patients 
include an upper respiratory tract infection, nasopharyngitis and a headache. The 
safety of Sitagliptin in those under the age of 18 has not yet been established. 
Assessment of renal function is recommended before starting a patient on 
Sitagliptin as dose adjustments are needed for moderate or severe renal disease. 
With regards to drug interactions there is a small increase in the peak drug 
concentration of digoxin. No dose adjustment is necessary but if both digoxin and 
Sitagliptin are being taken, patients should be monitored carefully (Merck & Co, 
2015).  
With regards to safety in pregnancy, animal studies have shown that a dose 12 
times higher than the normal recommended dose did not harm the developing fetus. 
Sitagliptin given to rats and rabbits in the period of organogenesis did not result in 
any teratogenic effects at 20-30 times the recommended maximum dose. At doses 
100 times the recommended dose there was an increase in rib malformations in rat 
studies (Co, 2017).  
Sitagliptin has been deemed as a category B drug for pregnancy by The Food and 
Drug Administration (FDA) Agency of the United States Department of Health and 
Human Services. This means that it should only be used if clearly needed. It is not 
known if Sitagliptin is secreted in breast milk so caution is advised.  
Sitagliptin is the most commonly used DPP4 inhibitor. The recommended dose of 
Sitagliptin is 100mg once daily.  
 
1.8 ENDOMETRIAL BIOPSY/SCRATCH 
 
An endometrial scratch is a procedure commonly offered to patients undergoing IVF 
with an aim to improve pregnancy outcomes.  
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It is thought that an endometrial scratch may help with decidualisation and release 
cytokines and growth factors which are all important for successful 
implantation(Laird et al., 2006; Tiboni et al., 2011). 
A meta-analysis has shown that clinical pregnancy rate in those couples having IVF 
is significantly improved when an endometrial scratch has been performed (El-
Toukhy et al., 2012) . A meta-analysis performed by Potdar et al in 2012 has also 
shown that endometrial injury improves the LBR for those women going through 
IVF(Potdar et al., 2012). This finding needs to be confirmed with a well conducted 
randomised controlled study. Also, the effect of an endometrial scratch on 
pregnancy outcome has not yet been assessed in an RCT for patients with RPL.  
It is important to note that the endometrial scratch in itself may act as an injury 
promoting stem cell recruitment as part of a wound healing response.  
 
1.9 CONCLUSION 
	
A national survey carried out by Bardos et al revealed that 78% of patients want to 
know a cause for their miscarriage even if there is no intervention to prevent it as 
this may affect their psychological response (Bardos et al., 2015). The James Lind 
Alliance; a priority setting partnership between patients and health care 
professionals identified new treatments to prevent miscarriage as the number one 
research priority in this area (Prior et al., 2017). It is vital therefore that we continue 
to undertake discovery science into new causes and potential new treatments for 
miscarriage prevention in patients with RPL. 
In this literature review I have demonstrated the need to improve the uterine, 
endometrial environment for implantation. I have demonstrated that a lack of stem 
cell-ness of the endometrium may contribute to the failure of implantation. I have 
found some evidence to support the hypothesis that DPP4 inhibitors could improve 
endometrial stem cell-ness by increasing eMSC recruitment by enhancing the 
CXCL12/CXCR4 pathway.   
I have therefore designed, set up, managed and performed an early phase 
randomised feasibility study to investigate whether Sitagliptin and an endometrial 
scratch improves the stem cell-ness of the endometrium in those with RPL.  
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CHAPTER	2:	TRIAL	DESIGN	AND	PROTOCOL	
DEVELOPMENT	
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2.1 AIMS AND OBJECTIVES 
 
In my literature review in chapter one I have demonstrated the existence of a 
complex interaction between the endometrium and the blastocyst.  
There is a lack of eMSC’s and an increased expression of DPP4 in the 
endometrium of women with recurrent miscarriage.  
An increase in stem cell recruitment to the endometrium should improve the process 
of decidualisation, optimise the balance of endometrial receptivity and selectivity 
and in turn improve the quality of the endometrium and its ability to support 
implantation and early pregnancy. 
Currently, most treatment options for patients with RPL start once they have had a 
positive pregnancy test. The aim of this study is to develop a pre-conception 
treatment aimed at enhancing the environment for implantation for those with 
recurrent miscarriage.  
We hypothesised that DPP4 inhibition with Sitagliptin given prior to conception will 
increase eMSC recruitment above that of endometrial scratch, via an enhancement 
of the CXCL12-CXCR4 axis during menstruation. The DPP4 inhibitor Sitagliptin is 
cheap, safe and well tolerated by diabetic patients and widely used in the UK.  
We set up a randomised, double blind feasibility study to test the null hypothesis 
that the mean number of colonies of stem cells per 1500 endometrial stromal cells 
for the control group (placebo group) is equal to that of the intervention group 
(Sitagliptin group).  
In this study we have also assessed whether the DPP4 inhibitor Sitagliptin is well 
tolerated by non-diabetic individuals by performing a qualitative analysis of adverse 
events reported in each treatment group (Sitagliptin vs. placebo). We have also 
performed a qualitative analysis of the acceptability of the study design. 
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2.2 TRIAL PLANNING AND DESIGN 
 
The Clinical Trials Toolkit published by the National institute of Health Research 
(NIHR) was used to understand the legal and good practise requirements of setting 
up a Clinical Trial of an Investigational Medicinal Product (CTIMP) (NIHR, 2017).  
This toolkit describes the importance of having a robust trial design to ensure a 
clinically useful trial outcome. It also states the need to have a trial design which is 
conceptually simple and tailored to the patient group.  
 
2.2.1	BASIC	TRIAL	IDEA:		
The foundation of this feasibility study was to assess whether the eMSC increased 
after 3 months of treatment with Sitagliptin when compared with placebo. Our 
primary outcome measure would therefore be a laboratory based one. We planned 
to perform the same clonogenic assay performed in the original research this study 
was based upon.  
We considered other outcome measures such as live birth rate. This could not be 
justified however for many reasons. Primarily, we needed to test the hypothesis that 
DPP4 inhibition with Sitagliptin given prior to conception increases the eMSC count 
above that of an endometrial scratch. Without the laboratory based evidence we 
would not be able to scientifically explain any clinical results found.  
Live birth rate could therefore not be used due to time constraints. The set-up of this 
study was going to take one year and we anticipated that recruitment of all 
participants would take just under one year. The study pathway lasted 3 months for 
each participant and so to then look at pregnancy outcomes once participants had 
finished their journey through the study would take at least another year. 
We therefore focused the primary outcome measure on our hypothesis and decided 
to look at the acceptability of the study design and side effects experienced as part 
of our secondary outcome measures to help assess the feasibility of the study 
design for a larger pragmatic trial if the results were positive.   
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Various arms to this randomised study were considered. Essentially, we could look 
at randomisation to an endometrial biopsy and Sitagliptin for 3 months and 
randomisation to an endometrial biopsy and placebo for 3 months. We also 
considered randomisation to an endometrial biopsy with neither Sitagliptin or 
placebo (i.e. no treatment) or having either Sitaglitpin or placebo for 3 months with 
only one endometrial biopsy at the end of the 3 months and no initial endometrial 
biopsy which could in itself positively or negatively affect the results.  
We felt that having a third arm to the study of not receiving any medication 
(Sitagliptin or placebo) could result in difficulties with recruitment. Patients were 
more likely to accept the study if they had a 50% chance of receiving a treatment 
which may help reduce the risk of miscarriage.  
We also decided that performing an endometrial biopsy on all participants to 
ascertain their baseline eMSC count would also allow us to ascertain how the eMSC 
count changed over the 3-month period in each participant. We do not know what 
defines a high or low eMSC cell count and so the initial endometrial biopsy would be 
particularly important in establishing baseline information and looking into whether 
previous data could be reproduced. 
We felt a 3-month treatment period was a good compromise between allowing 
sufficient time for the eMSC count to increase and a suitable time period for 
participants to be committed to taking part in a clinical trial.  
The flow diagram below represents the basic trial idea. It is important to note that 
there are 3 menstrual cycles within the treatment period where the endometrium 
would be regenerated. 
I presented this basic trial design to the Research, Development and Innovation 
department at UHCW. They were keen to be involved in the development of the 
study design and help gain sponsorship from UHCW. 
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2.2.2	BASIC	FLOW	DIAGRAM	FOR	TRIAL	PATHWAY	
	
	
	
FIGURE 2.0.1: Basic Flow Diagram for the Trial Pathway 
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2.3 SAMPLE SIZE CALCULATIONS 
 
To start this project, I looked at the original data that demonstrated the deficiency of 
stem cells at the endometrium of those with RPL.  
I reviewed the results of clonogenic assays done at the Warwick Clinical Sciences 
Research Laboratory in 2014. There were results for 34 patients who had attended 
the Implantation Clinic, all with different reproductive histories in terms of number of 
miscarriages. The mean number of colonies of stem cells per thousand endometrial 
stromal cells in those without RPL (those with less than 3 miscarriages) was 14 
colonies and the mean number of stem cells per thousand endometrial stromal cells 
in those with RPL (3 or more miscarriages) was 3.4 colonies. 
The patients defined as having less than 3 miscarriages were patients who had 
attended the clinic with a history of less than 3 miscarriages or had a history of 
recurrent implantation failure related to primary or secondary subfertility. Some of 
these patients may have had a previous live birth and some may never have 
achieved a clinical pregnancy. The implications of this are discussed in chapter 10. 
My first task in setting up this trial was to establish an appropriate sample size to 
ensure it had sufficient power to test the null hypothesis. The null hypothesis was 
that the mean number of colonies of stem cells per thousand endometrial stromal 
cells for the placebo group is equal to that of the Sitagliptin group. 
The trial statistician and I used the existing data to formulate accurate power and 
sample size calculations to form the basis of this clinical trial.  
When 4 outlying observations for women without recurrent miscarriages women 
were excluded because they may have been due to experimental error, the mean 
for women with no recurrent miscarriages was 7.0 colonies per thousand cells. 
For the power calculation, we assumed that the mean number of colonies per 1000 
cells would remain 3.4 for the control group and the number of colonies would 
increase to 6 for the intervention group (slightly less than the mean for the normal 
women). Using simulation, the power to detect this difference at 10% significance 
level was 95%.  
We calculated that we would need to have a sample size of 30 participants for the 
study to have 95% power at a 10% significance level. 	
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2.4 ETHICAL CONSIDERATIONS 
	
Participants in this study would need to consent to having 2 endometrial biopsies 
and take oral trial medication every day for 3 months. 
 
2.4.1	ENDOMETRIAL	BIOPSY	
Endometrial biopsies are taken with the Wallach endocell endometrial cell sampler, 
which is a simple and safe manual suction device routinely used to take endometrial 
biopsies in gynaecology clinics.  
Endometrial biopsies take approximately three minutes to perform in an outpatient 
setting however, they are intrusive and cause discomfort. Hence, all women would 
be given verbal and written information regarding the biopsy procedure to ensure 
they were adequately informed of this prior to seeking their consent for this study 
and the biopsy.  
In mitigations of discomfort of the procedure it is possible that the biopsy itself is 
beneficial to future pregnancy outcome. Along with the injury of menstruation it has 
been demonstrated in chapter one that performing an endometrial biopsy initiates a 
wound healing response which may enhance stem cell recruitment to the 
endometrium.   
 
2.4.2	TRIAL	MEDICATION	SAFETY	AND	SIDE	EFFECTS	
Participants in this study would also need to consent to taking study medication 
every day. There was a 50% chance of this being Sitagliptin and a 50% chance of 
this being placebo. There are always ethical considerations to consider with the use 
of placebo but we also had to explore the safety of Sitagliptin for this non-diabetic 
patient cohort. 
Sitagliptin is routinely used by patients with type 2 diabetes who often have multiple 
co-morbidities with a very low incidence of reported side effects. It is used as 
monotherapy or dual therapy in combination with insulin, metformin or 
sulphonylureas. 
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I studied the Summary of Product Characteristics (SPC) for Sitagliptin from the 
electronic Medicines Compendium (EMC) which contains up to date information 
about medicines licensed for use in the U.K. I was able to establish common and 
uncommon side effects, contraindications, interactions with other medication and 
pre-prescribing checks. 
Sitagliptin was developed by Merck & Co (MSD).  The lead pharmacist at UHCW for 
clinical trials requested information from MSD on the safety of Sitagliptin in healthy 
humans and also on the safety of Sitagliptin in pregnancy. These documents were 
reviewed thoroughly by myself, the pharmacy team and the Research and 
Development governance team at UHCW.  
Sitagliptin has a high safety profile. The SPC states that the only common side 
effect (frequency ³ 10%) is a headache. All other known side effects occur less 
frequently. Side effects occurring in approximately 5% include upper respiratory 
tract infections and nasopharyngitis. Up to 5% have been known to suffer with 
osteoarthritis or pain in extremities.  
Side effects for which the frequency is unknown includes hypersensitivity, interstitial 
lung disease, vomiting, acute pancreatitis, angioedema, rash, urticaria, exfoliative 
skin conditions, arthralgia, myalgia, and impaired renal function. These have mainly 
been reported as individual case reports. 
Some adverse reactions are observed mainly in those using a combination of 
Sitagliptin and other diabetic medication together rather than with Sitagliptin 
monotherapy. These include hypoglycaemia, influenza, nausea and vomiting, 
constipation, peripheral oedema and dry mouth.  
 
2.4.3	SAFETY	OF	SITAGLIPTIN	IN	HEALTHY	NON-DIABETIC	INDIVIDUALS	
The various RCT’s looking into the safety of Sitagliptin in healthy patients showed 
that Sitagliptin monotherapy did not lead to hypoglycaemia (Devin et al., 2014; 
Herman et al., 2005; Mistry et al., 2008), ECG changes (Mistry et al., 2008) or 
altered immune function (Price et al., 2013). 
There were reports of transient light headedness and nausea which both resolved 
after stopping the medication. Overall there were no adverse drug events and 
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Sitagliptin was well tolerated at 25/50/100/200/400 mg doses (Bergman et al., 
2007).  
The protocol for the study was peer reviewed by Dr O’Hare who is a consultant 
diabetologist. Dr O’Hare with clinical experience of using Sitagliptin confirmed that 
we would not need to monitor blood glucose levels of participants and confirmed 
safety of the medication in the healthy population.  
 
2.4.4	SAFETY	OF	SITAGLIPTIN	IN	PREGNANCY	
It was expected that participants entering this study would need to avoid pregnancy 
for the duration of the study to allow them to have two endometrial biopsies over 3 
months and also allow time for this pre-conception treatment to take effect. 
I did however have to consider the safety of Sitagliptin use in pregnancy in the event 
of pregnancy occurring in any of the participants while on study medication.  
There is lack of human data on Sitagliptin to currently recommend its safe use in 
pregnancy however there are post marketing reports of exposure during pregnancy 
on the Merck &Co pregnancy register. 
Merck pregnancy registries have prospective and retrospective data collection 
systems aimed at detecting adverse effects of certain drug use in pregnancy. This 
register receives voluntary reports from women or healthcare providers for women 
who have taken Sitagliptin or Sitagliptin and metformin during pregnancy. The 
importance of reporting all outcomes of exposure to Sitagliptin in pregnancy as early 
as possible is emphasised. This facilitates the collection of prospective unbiased 
information. It is important to note that retrospective reports to the company 
pregnancy register will contain bias towards reporting mainly abnormal outcomes.  
The fifth annual cumulative review produced by Merck & Co for Sitagliptin/Sitagliptin 
+metformin contained post marketing pregnancy reports received from reports from 
August 2006 to August 2011. There was a total of 16 complete prospective reports 
which included 14 live births (one set of twins) and three spontaneous miscarriages. 
No congenital anomalies were reported in any of the exposed pregnancies (Merck & 
Co, 2015). 
A pre and postnatal development study performed in rats showed no adverse 
effects with the use of Sitagliptin. Reproduction studies on rats and rabbits given 
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doses 12 times the maximum human dose did not impair fertility or harm the fetus 
(Co, 2017). 
Most case reports on outcomes of fetuses exposed to Sitagliptin are from mothers 
with uncontrolled diabetes despite the use of metformin or insulin. It is difficult to 
ascertain if miscarriage is a result of embryonic abnormality, diabetic embryopathy 
or polytherapy. 
The SPC for Sitagliptin states that ‘there is no adequate data from the use of 
Sitagliptin in pregnant women. Studies in animals have shown reproductive toxicity 
at high doses. Due to lack of human data, Sitagliptin should not be used during 
pregnancy’. 
Overall, there is not enough data in the pregnancy register to allow an analysis of 
pregnancy outcomes by type or by timing of exposure. The SPC does not 
recommend the use of Sitagliptin in pregnancy and this needed to be taken into 
account for the purpose of the study.  
Sitagliptin has been assigned FDA pregnancy category B (Co, 2017). This American 
pregnancy risk category classification (A, B, C, D or X) indicates the potential risk of 
a drug to be teratogenic or harmful if used in pregnancy. FDA category B indicates 
that animal studies have failed to show a risk to the fetus but there are no 
adequately well controlled studies in humans. 
Although there are no adequate and well controlled studies in pregnant women 
there were no teratogenic effects when female rats were administered 20 – 30 times 
the maximum recommended human dose (25mg/kg in rats and 125mg/kg in 
rabbits). Doses approximately 100 times the maximum human dose increased the 
risk of rib malformations in offspring. Because of the high safety margins, these 
findings do not suggest a relative risk for human reproduction.  
When Sitagliptin was administered to rats at a dose 100 times that of maximum 
human exposure from 6 weeks’ gestation to 21 days post-natal there was a 
reduction in body weight in offspring. No functional behavioural toxicity was 
observed in the offspring of the rats.  
In order to reduce the risk to any fetus, a series of measures were put into place to 
minimise the risk of women conceiving on the study medication. We also included 
measures to ensure that if pregnancy did occur, it was detected early and the study 
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medication was discontinued as soon as possible.  Details of the measures put in 
place by the trial management group are in the trial protocol.  
	
2.4.5	INVESTIGATION	MEDICINAL	PRODUCT	AND	PLACEBO	
Once it was deemed safe to give Sitagliptin to healthy non diabetic participants I 
started contacting companies who made placebo’s for the supply of Sitagliptin and 
placebo. We had quotes from three separate companies.  
After close liaison with the trial pharmacist we felt that Sharp Clinical Services were 
best placed and best value for money to manufacture and supply the study 
requirements. 
Sharp clinical services were responsible for the packaging, labelling and transport of 
the study medication to the research study site.  
Sitagliptin is usually issued in a tablet form. To ensure the study was blinded, the 
Sitagliptin tablets were converted to capsule form to make them identical to the 
placebo.  
Sitagliptin was encapsulated because it was substantially cheaper to produce 
placebo in capsule form rather than in tablet form. The encapsulated Sitagliptin then 
had to undergo disintegration testing to ensure it had the same bioavailability and 
shelf life as the original tablet form.  
	
2.5 ELIGIBILITY CRITERIA 
 
The endometrial biopsy and use of Sitagliptin in healthy volunteers had been 
considered as safe and ethical for the purpose of this study.  
I needed to explore other variables to ensure the utmost safety for participants and 
homogeneity of the study. These considerations formed the eligibility criteria for the 
study.  
Factors which would determine the eligibility criteria involved 
1. Menstrual cycle length and duration of treatment 
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We decided that participants would need to have a regular 28-30-day cycle 
for inclusion to the study. With a regular 30-day cycle there would be three 
menstruations and therefore three opportunities for stem cell recruitment to 
occur within the treatment period for each participant. Participants with 
longer cycles would not have the same number of opportunities for stem cell 
recruitment in the treatment period. Participants with a cycle length that is 
consistent would be more homogenous and therefore would minimise 
confounding factors.  
 
2. Safety of Sitagliptin in healthy non diabetic individuals 
The SPC for Sitagliptin was initially reviewed by myself, the pharmacy 
advisor and the hospital (UHCW) research governance manager. A plan was 
made with the trial sponsor (UHCW) for a formal review of the SPC every 
three months for the duration of the study. This would ensure the most up to 
date reference safety information was used and consistent with the protocol 
and participant specific documents. I also set up an email address 
specifically for the trial called simplantstudyoffice@uhcw.nhs.uk and 
received any MHRA drug alerts to trigger extra reviews and updates.  
 
We carefully studied the SPC for Sitagliptin to ensure our inclusion and 
exclusion criteria would only include participants in whom using Sitagliptin 
would be safe. 
 
3. Concomitant Medications 
Plasma monitoring of Digoxin would be required if taking it along with 
Sitagliptin. Sitagliptin appears to alter the hypotensive effects of enalapril. 
For this reason, those patients on digoxin or enalapril were not eligible for 
the study. 
 
4. Renal Function 
The SPC for Sitagliptin states that an assessment of renal function is 
recommended prior to its initiation because dose adjustment is required if 
there is mild, moderate or severe renal impairment. In order to accurately 
assess the true effect of Sitagliptin on the endometrium we needed all 
participants to be on the same dose. Therefore, we decided that all 
participants needed normal renal function in order to be entered to the study.  
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5. Hepatic function 
The SPC states that care should be exercised in the use of Sitagliptin in 
those with severe hepatic impairment. Only patients with normal hepatic 
function were therefore entered to the study. 
 
6. Diabetes 
Sitagliptin should not be used in patients with type one diabetes and dual 
therapy of Sitagliptin and other anti-diabetic medication is known to be 
associated with an increased risk of side effects such as hypoglycaemia 
which would require increased monitoring. Therefore, patients with type 
1one or type two diabetes were not included in the trial.  
 
7. Age  
The safety of Sitagliptin has not been studied in patients under the age of 
18. This was therefore the lower age limit for inclusion to the study. As the 
risk of miscarriage naturally sharply increases after the age of 42 this was 
the upper limit of inclusion to the study. 
 
8. Body mass index (BMI) 
There is no dose adjustment of Sitagliptin required for BMI. BMI has no 
clinically meaningful effect on the pharmacokinetics of Sitagliptin. Therefore, 
we did not need to limit inclusion to the study according to BMI. 
 
9. Breast feeding 
Caution is advised when prescribing Sitagliptin to breastfeeding mothers as 
it is not known if it is secreted in breast milk. Breast feeding patients would 
not be eligible for the study. 
 
10. Safety of Sitagliptin in pregnancy 
We needed to assess the safety of Sitagliptin in pregnancy in case 
pregnancy did occur during the treatment period. We contacted MSD and 
obtained reference safety information. This was studied carefully and has 
been considered in section 2.4 (Ethical Considerations). 
There is too little data in the MSD company register to make a conclusion on 
the potential risk for humans and so Sitagliptin should not be used during 
pregnancy. 
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11. Avoiding pregnancy  
Not only is Sitagliptin not recommended in pregnancy but the start and end 
of this study was marked with an endometrial biopsy. This obviously could 
not be performed if the participant was pregnant. 
 
We decided that we will inform participants at the time of consent, that they 
must not try for a pregnancy in the cycle leading up to the first biopsy or for 
the duration of the study. The consent form required participants to be willing 
not try for a pregnancy and also to use barrier methods of contraception in 
the cycle leading up to the biopsy and for the whole duration of the study. 
Barrier contraception (condoms) were provided to participants at the time of 
consent.  
 
If the couple had unprotected intercourse in the cycle leading up to the 
endometrial biopsy the procedure was cancelled.  
 
After a trial management group (TMG) meeting with the sponsor (UHCW) it 
was decided that there needs to be clear pathways of checking for 
pregnancy through the study. This is detailed in the trial protocol. 
 
2.6 PATIENT SPECIFIC DOCUMENTS 
 
As all these ideas came together, the trial protocol was becoming layered with 
deeper and finer details of the study design. 
As well as developing the protocol I developed a participant information leaflet, a 
consent form, a GP letter, a symptom diary, a participant questionnaire and an 
emergency contact card (appendix 1 – 6 inclusive). 
Local standard operating procedures were used to formulate these documents. 
There was a section specific on the consent form for this study which required 
participants to agree not to try to get pregnant and be willing to use barrier 
contraception for the duration of the study.  
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2.7 PATIENT AND PUBLIC INVOLVEMENT 
 
We gained permission from a patient who had previously been involved in a 
research trial for recurrent miscarriage to appraise the basic trial idea and the 
associated documents.  
Her feedback: 
Hi Dr Tewary, 
     I have had a read through the documents today and found that the patient information document 
was very clear and informative, it explains the trial well and I didn't have any other questions after 
reading this that hadn't already been answered. 
 
The consent form is clear and I personally wouldn't have an issue signing any part of it. 
I think the GP letter was informative and had enough information to keep them informed of the trial, the 
only thing I would add to this is that the patient is not to get pregnant on the trial, only because this 
leaps out at me as an important part of the trial and may be worth advising the GP on. 
 
Hope this helps, anything else I can do to help just let me know 
 
Kind regards 
XXX 
 
As a result of this feedback, the G.P letter was amended to include information 
about avoiding pregnancy for the duration of the study.  
Before the protocol and participant specific documents were submitted to the 
Research Ethics Committee (REC) we discussed the proposed trial idea at our local 
‘Patient Public Involvement Group’ (PPI Group).  
This is an initiative set up with the help of a public engagement fund from the 
University of Warwick Medical School. A meeting is held once every two months 
where patients with a history of RPL or the experience of a clinical trial in pregnant 
are invited to discuss potential upcoming research ideas and their sustainability in 
this target group.  
The meeting for the SIMPLANT study was held in the Clinical Sciences building at 
UHCW and attended by five patients and four members of staff. 
A basic description of research terminology was given to the participants to assist 
them with the understanding of a clinical study. I did a formal presentation on the 
basic study design.  
The attendees explored the practicalities of the study and gave me a lot of insight 
into questions and concerns that patients approached for the study may have. 
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There were no objections from any members to the idea of two endometrial biopsies 
as part of the study or the potential side effects of Sitagliptin. Patients also 
expressed the willingness to accept a 50% chance of receiving a placebo tablet on 
the basis that there would be a 50% chance they would receive a treatment which 
may help to prevent further miscarriages which is not otherwise available.  
There was also constructive feedback on how to improve patient documents to 
improve the quality of information and maximise the impartiality of any information 
given back on the symptom diaries.  
Some of the suggestions included:  
o The group felt that if the symptom diary contained a suggestive list of side 
effects such as a dry cough and headache for participants to tick from, they 
may record symptoms which are not real. They recommended to replace it 
with a free text box to help participants record only those side effects actually 
experienced.  
o The group wanted a simplified explanation of the trial pathway. The 
participant information leaflet was amended to include a step-by-step guide 
on what would be involved as part of the study pathway.  
o Members of the group suggested more information about the timing of the 
biopsy. This was included. 
o Patients suggested providing an emergency contact number in case of any 
untoward side effects, concerns or hospital admissions while taking the trial 
medication. We created an emergency contact card which was the size of a 
bank card so that participants could keep it in their wallet. We made formal 
arrangements with the hospital switchboard for participants to be able to 
contact Professor Quenby or Dr Tewary 24 hours a day 7 days a week. 
 
I wanted to ensure the participant information leaflet was easy to read. 
Members in the PPI group were given the participant information leaflet in 2 
two different formats. One in A4 and one in an A5 folded booklet. The 
members felt that the A5 booklet form was too small and the small font made 
it difficult to read.  
 
I also provided two different designs. One was black and white with the 
characteristics of the local trust policy guidelines whereas the other was 
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divided into coloured sections. The following feedback was given regarding 
the two designs: 
 
White	standard	layout	 Coloured	box	layout	
Difficult	for	dyslexic	to	read	as	
text	jumps		
Short	snippets	of	information	make	it	
easier	to	understand	and	digest	
Can	key	information	be	bullet	
pointed?	Too	much	text	to	digest	
Text	needs	to	be	centred	in	boxes		
Boring		 Better	font		
Too	wordy		 Better	layout		
Bland		 People	want	to	read	the	information		
Not	clear	on	what	trial	is	about	 More	interested	in	the	trial	with	this	
layout	
Summary	box	needs	to	be	same	alignment	as	rest	of	text	
Side	effects	would	be	beneficial	in	box	as	makes	it	easier	to	find	
Ensure	spacing,	underlining	and	text	is	uniformed	and	formatted	the	same	
  
All this feedback was taken on board before the final patient specific 
documents were finalised to be submitted to the NHS national REC. We 
developed a participant information leaflet in line with hospital guidelines but 
also with colour and summary boxes making information easier to digest.  
The PPI groups’ unreserved critique of the documents enabled me to make 
the required changes to address patient concerns and encompass the needs 
of the trial. As a result, when the trial opened for recruitment I was confident 
that the documents were comprehensive to the needs of the participants. 
 
2.8 PEER REVIEW 
 
The NIHR describes the importance of a peer review to assess the design, 
feasibility, acceptability and importance of the topic in question (NIHR, 2017). 
The scientific, methodological and statistical aspects of the trial protocol was 
reviewed by two reviewers: Dr Nigel Simpson (External) and Dr Paul O’Hare 
(Internal) (Appendix 7 and 8). 
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The review from Dr O’Hare confirmed the safety of using Sitagliptin proven in very 
large clinical trials and also complimented the study design. Dr O’Hare also 
confirmed that we will not need to carry out blood sugar monitoring as the absence 
of hypoglycaemia is a major reason for the use of DPP4 inhibitors like Sitagliptin in 
patients with diabetes. His overall conclusion was that this is extremely important 
research which should constitute minimal risks to participants.  
The peer review from Dr Nigel Simpson has also confirmed safety of the trial 
especially with the plans for careful counselling and constant surveillance to prevent 
pregnancy. 
2.9 RANDOMISATION PROCEDURES 
We had to ensure randomisation procedures were carefully thought out and 
controlled. 
Production of a randomisation list, medication allocation, blinding and unblinding 
were discussed repeatedly at the TMG meetings until agreements were made by all. 
A coding convention was developed: 
• Participants would be assigned a screening number once consented to the 
trial – e.g. S001, S002. 
• Participants randomised would be assigned a participant trial ID e.g. R01, 
R02. 
• Pack numbers of the trial drug would be allocated from 1001 to 1120. 
 
Random Allocation Sequence 
It was agreed that Sharp Clinical Services who were manufacturing and supplying 
the trial medication would provide a list of pack numbers and contents to the trial 
statistician.  
e.g. 
Pack	No	 Pack	contents	
2351	 Sitagliptin	(B)	
1498	 Sitagliptin	
5641	 Sitagliptin	
6315	 Placebo	(A)	
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7531	 Placebo	
5975 Placebo 
 
The trial statistician would be unblinded to the treatment allocation and be 
responsible for creating the master randomisation list.  
Each treatment pack would contain one months’ supply of medication. Each 
participant would require three months’ supply of IMP/placebo, therefore three 
unique pack numbers will be assigned to each participant (three placebo packs or 
three treatment packs depending on group allocation).   
We also decided to have a second check of the study office master randomisation 
list to confirm that the three packs allocated to each participant all contained either 
Sitagliptin or placebo.  
A computer-generated blocked randomisation sequence would be used, to create 
the master randomisation list.  
 
Study ID Pack No 
1001 6315, 7531, 5975 
  
2.10 UNBLINDING 
 
We had to consider the need for unblinding a participant. We decided that the trial 
statistician would create the master randomisation list and he would also create two 
sets of opaque code break envelopes containing pack numbers and associated 
contents in that pack. We decided to have a separate envelope for each pack 
number so that unblinding would be specific to the pack number assigned to the 
participant at that time.  
If unblinding became necessary, then the envelope labelled with the current pack 
number that had been assigned to the participant would be opened.  
Both sets of code break envelopes would be delivered to the pharmacy at UHCW to 
confirm that the envelopes were sealed and intact. One set of envelopes would be 
kept in a locked cabinet with the medical team in the Biomedical Research Unit 
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(BRU) for use in-case of emergency unblinding, and the second set was kept in a 
locked cabinet with the Sponsor in the Research and Innovation Office as a backup.  
We created a system for unblinding to be possible 24 hours a day and 7 days a 
week. During office hours (8 am to 4pm) participants or healthcare providers could 
call the research office on 02476 967890 or out of ours by contacting the medical 
team via the main hospital switchboard on 02476964000 (ask for Dr Shreeya 
Tewary or Professor Quenby). The contact details were on the emergency contact 
card to be given to participants once randomised. This process of contacting the 
team out of hours through switchboard was formally approved with the manager at 
the hospital switchboard and tested. The unblinding procedure was tested and 
found to be effective prior to initiation of the trial. 
 
2.11 APPLICATION TO REC, MHRA AND SITE 
ACTIVATION 
 
After detailed discussions at TMG meetings, UHCW confirmed sponsorship and 
issued confirmation of capacity and capability approval.  
I was then able to submit the application on the Integrated Research Application 
System (IRAS). This is an electronic system for permission for research in the U.K 
which meets all regulatory and governance requirements.  
This is an extensive form capturing all the information needed for the REC, HRA 
and MHRA approval and takes away the need to do replicate applications. We 
registered the trial on the European Clinical Trials Database and obtained a 
EudraCT number (2016-001120-54). 
 
Health Regulation Authority (HRA) and Research Ethics Committee (REC) 
Approval 
The role of the HRA is to assess the governance and legal compliance of a 
proposed research project. The role of the REC is to ensure the proposed research 
project maintains safety, dignity and well-being of participants taking part in 
research. 
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After submitting the application via IRAS we were invited for a formal REC meeting.  
This was attended by myself and Professor Quenby. This meeting involved a panel 
of over ten members where the design of the study was discussed in detail.  
We received feedback and recommended changes before a favourable opinion 
could be granted (Appendix 10). The requested changes were mainly to do with the 
participant information leaflet. Changes were made and a written response was 
submitted (Appendix 11). 
Submission to the MHRA was postponed due to delays in receiving the technical 
agreement from Sharp Clinical Services. I made an appointment with a 
representative from the company and expedited the finalisation of the technical 
agreement.  
Once we had this approval from the REC and the technical agreement was 
confirmed between Sharp Clinical Services and the sponsor (UHCW) we were able 
to make an application to the MHRA. We received approval from the MHRA on the 
25th July 2016. 
Once we had permission from the REC, HRA and MHRA, site specific training took 
place with the clinical team, randomisation team and pharmacy team. 
A code break test for unblinding and an ‘out of hours’ emergency call’ test were 
performed. Case report form packs were all printed, prepared and stored in the 
research unit. 
We received the green light for site activation from the sponsor on the 14th 
September 2016. I recruited the first patient on the 15th September 2016. 
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CHAPTER	3:	TRIAL	PROTOCOL	
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This Chapter includes the study protocol which was submitted to the REC, MHRA 
and HRA. 
 
3.1 STUDY SUMMARY 
	
FULL	TITLE	
	
Does the DPP4 Inhibitor (Sitagliptin) Increase 
Endometrial Mesenchymal Stem Cells in Women with 
Recurrent Miscarriage? 
ACRONYM	 SIMPLANT (Sitagliptin for IMPLANTation) 
CLINICAL	PHASE	 Phase II study 
HYPOTHESIS	 DPP4 Inhibitors increase endometrial stem cells, 
assessed by a clonogenic assay in women with RPL 
TRIAL	DESIGN	 Single-centre, double-blind, randomised, parallel-group, 
placebo-controlled trial 
TRIAL	POPULATION	
	
Women, aged 18-42 years, with a history of recurrent 
miscarriage (≥3) for whom a cause has not been 
identified 
PLANNED	SAMPLE	SIZE	 30 patients to have completed study  
TREATMENT	DURATION	 13 weeks 
OUTCOME	MEASURES	 Objectives Outcome measures 
Primary  
 
To determine the effect of 
Sitagliptin on endometrial 
mesenchymal stem cell 
count  
The number of colonies 
per thousand endometrial 
stromal cells after 3 
months of Sitagliptin 
(100mg) vs. 3 months of 
placebo, determined by a 
clonogenic assay 
 
Secondary 
 
To determine how well the 
IMP dosing schedule is 
tolerated by participants 
 
 
 
Qualitative analysis of 
adverse events/serious 
adverse events reported in 
each treatment group 
(Sitagliptin vs. placebo) 
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To determine the 
acceptability of the 
protocol to study 
participants  
 
Qualitative analysis of 
process evaluation 
questionnaire in 
participants receiving IMP 
vs placebo.  
INVESTIGATION	MEDICINAL	
PRODUCT		
	
1:1 randomisation to: 
o Sitagliptin 
o Placebo  
FORMULATION,	DOSE,	
ROUTE	OF	
ADMINISTRATION	
Formulation: Encapsulated tablet containing either 
100mg of active Sitagliptin or placebo 
Route of administration: Oral 
Dose:  
Intervention group (100mg Sitagliptin): once daily 
administration of one tablet containing 100mg of active 
Sitagliptin for 3 months from day 1 post-randomisation 
Control group (placebo): once daily administration of one 
tablet containing placebo, identical in size, colour and 
weight to the active Sitagliptin tablet, for 3 months from 
day 1 post-randomisation  
ISRCTN	number		 67932311	
Duration	of	trial	 15 months from 15/09/2017 
Study	Sponsor	 Research, Development and Innovation 
University Hospital Coventry and Warwickshire 
Study	Funder	 Tommy’s Charity 
	
Keywords:		Sitagliptin,	recurrent	miscarriage,	implantation,	endometrium,	stem	cells,	
ischaemic	injury	
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Observation	 	 	 	
VISIT	 	
	
Miscarriage	
Clinic	visit	
	
	
Baseline	visit		
Ovulatio
n	testing	
at	home	
daily	
from	day	
10	of	
regular	
cycle	
Endometrial	
biopsy	clinic	
visit	
Home	
pregnancy	
test	
4	week	
clinic	
visit	
Home	
pregnancy	
test	
8	week	
clinic	
visit	
Home	
pregnan
cy	test	
Ovulation	
testing	at	
home	
daily	
from	day	
10	of	
regular	
cycle	
12	week	
endomet
rial	
biopsy	
clinic	
visit	
Early	
terminati
on	
visit**	
TIME	
POINT	
Standard	
Care		
	
	
	
Patient	
information	
leaflet	given	
	
	
	 7-10d	post-
ovulation	
	
	
If	not	
positive	to	
ovulation	
test	in	first	
cycle	then	
biopsy	
arranged	1	
week	prior	
to	next	
period	due	
2	weeks	
±3d	post-
biopsy	
4	weeks	
±4	days	
post-
biopsy	
6	weeks	
±3d	post-
biopsy	
8	weeks	
±	4	days	
post-
biopsy	
10	
weeks	
±3d	
post-
biopsy	
	 7-10d	
post-
ovulatio
n	
	
Patient	demographics	 X	 	 	 	 	 	 	 	 	 	 	 	
Standard	care	blood	
tests	
X	 	 	 	 	 	 	 	 	 	 	 	
Eligibility	assessment	 	 X	 	 	 	 	 	 	 	 	 	 	
Informed	consent	 	 X	 	 	 	 	 	 	 	 	 	 	
Medical	history	 	 X	 	 	 	 	 	 	 	 	 	 	
Current	medications	 	 X	 	 	 	 	 	 	 	 	 	 	
Ovulation	testing	 	 	 X	 	 	 	 	 	 	 X	 	 	
Pregnancy	test	in	clinic	 	 	 	 X	 	 X	 	 X	 	 	 X	 	
	 79	
 
Transvaginal	
ultrasound	scan	
	 	 	 X	 	 	 	 	 	 	 X	 	
Endometrial	biopsy	 	 	 	 X	 	 	 	 	 	 	 X	 	
Randomisation	 	 	 	 X	 	 	 	 	 	 	 	 	
IMP	dispensed	 	 	 	 X	 	 X	 	 X	 	 	 	 	
Study	drug	intake	 	 	 	 X	 	 	 	 	 	 	 X	 	
Pregnancy	test	at	
home	
	 	 	 	 X	 	 X	 	 X	 	 	 	
Side	effect	diary	
review	
	 	 	 	 	 X	 	 X	 	 	 	 X	
Study	drug	compliance	
review	
	 	 	 	 	 X	 	 X	 	 	 	 X	
AEs/SAEs	 	 	 	 X	 	 	 	 	 	 	 X	 X	
Process	evaluation	
questionnaire	
	 	 	 	 	 	 	 	 	 	 X	*	 X	
Pregnancy	outcome	
recorded	(via	
appointment	or	
medical	records)	
	 	 	 X	 X	 X	 X	 X	 X	 	 X	 X	
End	of	study		 	 	 	 	 	 	 	 	 	 	 X	 X	
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3.2 STUDY AIMS AND OBJECTIVES 
 
The primary objective of the SIMPLANT study is to test the hypothesis that 
Sitagliptin increases the endometrial mesenchymal stem cell count in those with 
RPL. 
The secondary objectives are to determine how well the IMP dosing schedule is 
tolerated by participants and to determine the acceptability of the study protocol to 
participants. 
 
3.3 OUTCOME MEASURES 
	
3.3.1	PRIMARY	OUTCOME	MEASURE	
o The number of colonies per thousand endometrial stromal cells after three 
months of the IMP determined by a clonogenic assay.  
 
3.3.2	SECONDARY	OUTCOME	MEASURES	
o Review of adverse events and serious adverse events reported by the 
participant or healthcare providers in the duration of the trial.  
o Participant acceptability of the trial determined by a questionnaire filled in 
once each participant has completed the trial. 
 
3.4 STUDY DESIGN 
 
This is a pilot randomised double blind, parallel-group, placebo controlled feasibility 
study carried out at a single Centre; University Hospital Coventry and Warwickshire.  
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3.5 ETHICAL CONSIDERATIONS 
 
Participants approached and recruited to the SIMPLANT study would have been 
fully investigated for all known causes of miscarriage. Some will have tried various 
empirical treatment options such as heparin injections to try and prevent 
miscarriage. This cohort of patients would not have any other treatment options to 
help prevent another miscarriage. We were therefore not withholding any treatment 
when they entered the study.   
We know that performing endometrial biopsies is intrusive and can cause some 
discomfort but many patients approached for this trial would be familiar with the 
concept of an endometrial biopsy. Performing endometrial biopsies are safe and 
generally well tolerated.  
We have established that Sitagliptin is safe for non-diabetic individuals. 
When presented at our PPI group there were no objections to the idea of two 
endometrial biopsies in the space of three months.  
 
3.6 SAMPLE SIZE AND POWER 
 
We calculate that we would need to have a sample size of 30 participants for the 
study to have 95% power at a 10% significance level. 
As participants will be in the study for a total of three months we anticipate a drop-
out rate of more than 10%. Therefore, we aim to recruit 34 participants.  
 
3.7 PARTICIPANT ENTRY 
 
Patients invited to participate in this trial will be identified from the RPL clinic or the 
implantation clinic. There is a RPL clinic every week at UHCW lead by Professor 
Quenby.  There are two implantation clinics every week at UHCW lead by Professor 
	 82	
Quenby and Professor Brosens who will first approach any of the patients who will 
be recruited to this study. 
Patients will be advised that participation is completely voluntary and that their 
choice to participate or not participate will not affect their usual care. 
 
3.8 INCLUSION AND EXCLUSION CRITERIA 
	
3.8.1	INCLUSION	CRITERIA	
o Provision of informed written consent 
o History of RPL 
o Regular menstrual cycle, up to 30 days in length 
o Age 18-42 years at consent  
o Any BMI  
o Willing and able to give consent for the study and endometrial biopsy 
o Ability to fully understand the requirements of the protocol  
o Negative pregnancy test on the day of randomisation 
 
3.8.2	EXCLUSION	CRITERIA	
o Under 18 years of age  
o Type I Diabetes  
o Type II Diabetes – based on medical history 
o Pregnancy  
Tested at multiple points in trial – see schedule of events 
o Breast feeding  
o Known hypersensitivity to Sitagliptin  
o Not taking any medications with potential to react with interventional product  
• Digoxin  
• Enalapril  
o Previous diagnosis of pancreatitis 
o Renal impairment (eGFR<50ml/min or AKI ≥1 as this would require dose 
adjustment of IMP) 
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o Hepatic impairment defined as Alanine Transferase (ALT) > 38 U/L, ALP> 
105U/L Bilirubin (BR ) >20 umol 
o Inclusion in another intervention trial 
o Unwilling to use effective contraception for the duration of the trial (from 
consent) 
o Allergy/sensitivity to excipients of the IMP/placebo 
 
*Note: eGFR will be calculated using the Cockroft Gault Equation: 
eGFR =   (140 – Age) x Weight (Kg) x 1.04 
     Serum Creatine (micromol/L) 
 
These inclusion and exclusion criteria are revised criteria which were approved by 
the REC and MHRA after a substantial amendment was made due to the 
suspension of the trial from 21st October 2016 to 15th December 2016. The trial was 
suspended just over one month after opening for recruitment on the basis of 
concerns with screening and eligibility. Details of the trial suspension and the 
changes which were put in place are detailed in chapter six. 
 
3.9 TRIAL PATHWAY 
	
3.9.1	ENROLMENT	PROCEDURE	
Participants will be given the Patient Information Leaflet (PIL) for the study at their 
initial consultation at the recurrent miscarriage clinic.  
After all known causes for miscarriage are excluded and eligibility criteria is 
confirmed they will be able to consent to the study. We will make sure the patient 
has read and understood the PIL, been given the opportunity to ask questions and 
encouraged to discuss their involvement with their GP family and friends. Consent 
will be taken by the chief investigator or myself using the trial specific consent form 
(Appendix 2). 
If patients refuse to participate with or without a reason, this will be respected. 
Information on any reasons for refusal of participation will be recorded on the trial 
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database. Patients will also be made aware that they are free to withdraw at any 
stage of the study without giving reasons. 
Three copies of consent will be obtained – one for the site file, one for the hospital 
notes and one for the patient to keep.  
Consented participants will be asked to monitor for ovulation with a simple urinary 
ovulation kit (provided by Clear Blue). They will be given a phone number and a trial 
specific email address to contact once ovulation had occurred.  
A biopsy will then be arranged for 7-10 days’ post ovulation.  
Participants must not be pregnant at the time of the biopsy. We will provide barrier 
contraception for participants while they are in the study. Hormonal contraception 
cannot be used whilst in this study as it would alter menstrual cycles and the 
endometrial biopsies. If the couple have had unprotected intercourse since the last 
menstrual cycle the procedure will be cancelled.  
Patients will be asked about any episodes of unprotected intercourse  
o When they call to book the biopsy 
o On the day of the biopsy 
o At each face to face consultation through the trial. 
 
Patients will be asked to do a pregnancy test every two weeks once randomisation 
has taken place. Pregnancy test kits will be provided. They will have been given 
instructions on what to do if the pregnancy test is positive. They will be advised to 
immediately stop taking the trial medication and we will arrange an appointment at 
the trial centre. 
 
3.9.2	ENDOMETRIAL	BIOPSY	
The endometrial biopsy will be taken by one of the co-investigators in the presence 
of a chaperone. Participants will have a transvaginal scan prior to the biopsy.  
The participants will be warned beforehand that the sampler can cause some pelvic 
pain and cramps due to uterine contractions. They will be advised that they can 
take 400mg of Ibuprofen and 1g of Paracetamol prior to their visit. Entonox is 
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available to use when the biopsy is being taken. They will also be told to bring a 
sanitary pad as they may experience some spotting after the procedure. 
If the uterus is acutely anteverted or retroverted a plastic disposable vulcellum may 
be used to help hold the cervix while the biopsy is being taken. 
 
3.9.3	RANDOMISATION	PROCEDURE	
Block randomisation, in a 1:1 ratio of active:placebo will be used to ensure 
balanced recruitment to each arm over the course of the study.  
Randomisation will be done by the Research, Development and Innovation (RD&I) 
randomisation team via a phone call. The clinical research team can request 
randomisation during office hours (Monday – Friday 0930 – 1700).  
The randomisation team and study team will remain blinded to treatment allocation. 
Eligibility and consent will be confirmed and 3 pack numbers will be assigned to the 
participant.  
Sponsor confirmation of randomisation will then be sent to the trial office specific 
email address (simplantstudyoffice@uhcw.nhs.uk) and to pharmacy.  
G.P’s will have been informed in writing (with the patient’s consent) about 
participation in the trial and about the possibility of being on Sitagliptin.  
Participants will also be given an emergency contact card with contact details of the 
trial team in case of any emergency admissions and or unblinding is required. 
 
3.9.4	FOLLOW	UP	
Participants will be reviewed every 4 weeks +/- 4 days after starting treatment. This 
will be by a face to face consultation with a doctor. This visit will include a 
pregnancy test and review of the symptom diary. Continued willingness to 
participate will be confirmed and a prescription for the next months’ supply of 
medication will be completed.  
About a week after the first endometrial biopsy participants will have their expected 
menstrual period. They will attend for the first follow up 4 weeks +/- 4 days after 
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starting the treatment and then the second follow up 4 weeks+/- 4 days after this. 
The final visit is to have a biopsy in the third menstrual cycle.  
During the trial period participants should have three menstrual cycles and 
therefore three opportunities for the eMSC to increase.  
	
3.9.5	FINAL	VISIT	
After the third menstrual cycle participants will start to monitor for ovulation again. 
Once the test is positive they will contact the trial team by a phone call or by 
sending an email to the trial specific email address to arrange their final biopsy 7-10 
days after ovulation.  
The day this biopsy is taken marks the end of the study. Participants will be given a 
questionnaire to fill in after this visit is complete. We will request for the 
questionnaire to be sent back within four weeks of the second biopsy. The aim of 
this questionnaire is to assess the acceptability of the trial.  
Any pregnancy which occurs after the trial period has finished will occur after the 
endometrium has been renewed following menstruation. Participants will then be 
offered standard RPL clinic care which includes fortnightly scans in the first 
trimester and high risk antenatal care as is standard practice. 
 
3.10 MONITORING FOR PREGNANCY 
 
Participants will be carefully monitored for any unplanned pregnancies occurring 
during the trial period. Monitoring points for pregnancy will be every two weeks. A 
urinary pregnancy test will be done on the day of randomisation. We will provide 
participants with urinary pregnancy tests so that they can do another test at home 
two weeks after randomisation. They would then have a pregnancy test at the 
hospital follow up appointment two weeks later. This pattern will follow until the end 
of the study. If the test is positive at any time they will be asked to stop the 
medication and ring the trial-coordinating centre to arrange follow up. 
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3.11 TRIAL MEDICATION 
	
3.11.1	PRESCRIBING	AND	DISPENSING	
A trial specific prescription has been produced and will be completed by one of the 
doctors in the research unit.  
 
Dispensing will be done by the site hospital pharmacy. Participants will be 
dispensed the study drug on a monthly basis according to assigned pack numbers. 
3.11.2	TREATMENT	
Trial Interventions: 
 Arm A – Active treatment: Sitagliptin in capsule form, 100mg orally, once 
daily for up to 13 weeks 
 Arm B – Control: Matching placebo, oral capsule, once daily for up to 13 
weeks 
The placebo is a dummy capsule identical in colour, shape and weight to Sitagliptin. 
Sitagliptin has been converted to capsule form for the purpose of the study. No pre-
medication is required. 
Treatment will be initiated on the day of the initial endometrial biopsy and continued 
up until the day of the second endometrial biopsy due 7-10 days after ovulation of 
the third menstrual cycle within the trial. 
Capsules are to be taken orally with water at approximately the same time each 
day. If a dose is missed a double dose should not to be taken on the same day. 
 
3.11.3	DOSE	AND	ROUTE	OF	ADMINISTRATION	
Evidence on the optimal dose of Sitagliptin shows that 100mg once daily dosing 
gives the best efficacy in terms of glucose control and DPP4 inhibition. The capsule 
will be taken orally with water at the same time each day.  
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3.11.4	DOSE	MODIFICATIONS	FOR	TOXICITY	
There are no dose modifications for toxicity. If there are any significant side effects 
treatment will be stopped and participants will be withdrawn from the study.    
 
3.11.5	SUPPLY	OF	SITAGLIPTIN	AND	PLACEBO	
The trial drug will be supplied by Sharp Clinical Services. Commercially available 
Sitagliptin has been over-encapsulated and matching placebo capsules 
manufactured.  
The manufacture will be done under an MIA (IMP) license following Good 
Manufacturing Practice (GMP) & Medicines for Human Use (Clinical Trials) 
Regulations 2004 as amended. Sharp Clinical Services will assign a qualified 
person (QP) to be responsible for batch release and provide support for product 
complaints/queries for the duration of the study. Details of specific arrangements 
have been documented in a GMP Technical Agreement with the Sponsor. 
The trial medication must be stored at ambient temperature 15-25 degrees Celsius 
and will be supplied to the site at the start of the study.  
The trial drug will be supplied as blinded packs of Sitagliptin/placebo 100mg 
capsules, each containing 32 tablets to last one cycle. Each pack had a unique 4-
digit pack number.  
 
3.11.6	LABELLING	
A label for the trial drug has been designed to ensure traceability and identification 
of the trial, identification of the product and facilitate proper use of the trial 
medication in accordance with Volume 4 of Good Manufacturing Practices, Annex 
13 (Manufacture of IMPs). The label for the Sitagliptin and placebo is identical. 
Sample labels designed by us have been created by Sharp Clinical Services and 
been provided to the MHRA for approval prior to manufacture (Appendix 13).  
 
We have added an additional dispensing label which includes patient specific 
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details to the trial drug as part of standard hospital dispensing practice.  
 
3.11.7	COMPLIANCE	MONITORING,	ACCOUNTABILITY,	RECONCILIATION	AND	
DESTRUCTION	
The dispensing of the trial medication will be recorded in pharmacy on the 
Pharmacy IMP Accountability Log (Appendix 16). 
Within the participant symptom diary there is a compliance-monitoring chart. 
Participants will be asked to fill this in daily and bring in left over capsules at the end 
of the study period. We will ensure that the compliance recorded matches up with 
the number of left over capsules.  
At the end of the patient’s participation in the study any un-used study drug will be 
returned to pharmacy to be counted and destroyed. 
 
At the end of the study any unused IMP will be quarantined pending Sponsor 
approval for destruction.  
	
3.11.8	INTERACTION	WITH	OTHER	DRUGS	
There is a low risk of drug-drug interactions as Sitagliptin is primarily eliminated by 
the kidney with hepatic metabolism playing only a small role in clearance. 
If patients are started on any anti-diabetic drugs, digoxin or enalapril, they should 
be withdrawn from the study.  
 
3.12 DATA COLLECTION AND MANAGEMENT 
 
Every patient given a PIL will be entered onto the screening log (Appendix 14). 
They will have a unique screening number (e.g. S001). Once patients have been 
randomised they will have a unique Randomisation number (e.g. R01).  
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Case report forms will be filled in from the day of consent (Appendix 17). These 
have been formulated to collect all required trial data.  The information will be 
stored on a secure trial database. 
The paper copies will be locked in a secure cabinet in the Biomedical Research 
Unit (BRU) while the trial is running and then saved for 25 years in accordance with 
the UHCW NHS Trust archiving procedures.  
 
3.13 CONFIDENTIALITY 
 
The confidentiality of all participants will be preserved under the Data Protection Act 
1998.  
Participants will all be assigned a ‘randomisation number’ which will be used for the 
case report forms (CRF) and this number will also be used to enter information onto 
the secure password encrypted electronic database provided by MedScieNet, for 
randomisation. There is also specific coding for the endometrial samples. Details of 
this coding can be found in chapter 4.4. 
Consent from participants will have been obtained to use the endometrial sample 
for future research projects. If the patient does not consent to this process the 
sample will be discarded as per UHCW Trust policy on disposal of tissue.   
During the project, the patient can withdraw their consent at any time and the 
sample will be discarded according to Trust policy. 
All data collected as part of the trial will be stored securely in password protected 
files (electronic data) or in locked filing cabinets in secure entry-card protected 
areas (hard copy data). 
All the staff involved in the SIMPLANT study will share the same duty of care to 
prevent any unauthorised disclosure of personal information. No data that could be 
used to identify an individual will be published. 
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3.14 RESEARCH ETHICS COMMITTEE (REC) AND 
MEDCINES HEALTH REGULATORY AUTHORITY 
REVIEW 
 
Approval for the trial protocol and supporting documents will be sought from a 
Research Ethics Committee (REC), the local NHS Trust R&D department and the 
Medicines Health Regulatory Authority (MHRA). 
Substantial amendments that require review by a REC will not be implemented until 
the REC and the local R&D department grants a favourable opinion and all 
correspondence with the REC and R&D department will be retained in the Trial 
Master File (TMF).  
An annual progress report will be submitted to the REC within 30 days of the 
anniversary date on which the favourable opinion was given, and annually until the 
trial is declared ended.  
If the study is ended prematurely, the Chief Investigator will notify the REC, 
including the reasons for the premature termination. Within one year after the end 
of the study, the Chief investigator will submit a final report with the results, 
including any publications/abstracts, to the REC.  
 
3.15 PEER REVIEW 
 
The scientific, methodological and statistical aspects of the trial protocol have been 
reviewed by two reviewers: Dr Nigel Simpson (External) and Dr Paul O’Hare 
(Internal).  
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3.16 PUBLIC AND PATIENT INVOLVEMENT 
 
A participant in a previous miscarriage research study has been consulted on the 
design and conduct of this research study. Patient specific documents have been 
reviewed by our local patient and public involvement group. 
 
3.17 REGULATORY COMPLIANCE 
 
The protocol and trial conduct will comply with the Medicines for Human Use 
(Clinical Trials) Regulations 2004 and any amendments and the trial will not 
commence until a Clinical Trial Authorisation (CTA) has been obtained from the 
MHRA. All correspondence with regulatory bodies will be kept in the Trial Master 
File. 
 
3.18 PROTOCOL COMPLIANCE 
 
Prospective, planned deviations from the protocol are not permitted under the UK 
regulations on clinical trials and will not be used. Should accidental deviations from 
the protocol occur the deviation will be documented and reported to the Chief 
Investigator and Sponsor immediately. Protocol deviations which frequently recur 
will require immediate action and may be classified as a serious breach following 
investigation by the Sponsor.  
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3.19 NOTIFICATION OF SERIOUS BREACHES TO GCP 
AND/OR THE PROTOCOL 
 
A ‘serious breach’ will be defined as a deviation from the protocol that is likely to 
affect the safety or physical or mental integrity of the subjects of the trial or the 
scientific value of the trial. 
The sponsor will be notified immediately of any case where the above definition 
applies during the trial conduct phase and the sponsor will notify the licensing 
authority in writing of any serious breach of the conditions or principles of Good 
Clinical Practice (GCP) in connection with the trial or the trial protocol.  
 
3.20 AUDIT AND INSPECTION 
 
The study will be subject to inspection and audit by the sponsor to ensure 
adherence to GCP. A trial monitoring plan will be developed and agreed by a joint 
Trial Steering Committee (TSC) and a Data Monitoring Committee (DMC) based on 
the risk assessment undertaken by the sponsor prior to commencement of the trial.  
Direct access to the study documents and data will be granted to authorised 
representatives from the sponsor, host institution and the regulatory authorities to 
permit trial-related monitoring, audits and inspections. 
 
3.21 PHARMACOVIGILANCE AND SAFETY MONITORING 
The summary of product characteristics (SPC) for Sitagliptin will be reviewed on a 
formal basis every three months for the duration of the study to ensure the most up 
to date reference safety information was used and consistent with the protocol and 
participant documents. simplantstudyoffice@uhcw.nhs.uk will receive any MHRA 
drug alerts to trigger extra reviews and updates.  
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3.21.1	ADVERSE	EVENTS	
An adverse event (AE) is an unintentional and unfavourable sign or symptom that 
occurs while being in the trial. It may or may not have a causal relationship with the 
medication being taken. When taking the endometrial biopsy pain, bleeding and 
feeling faint straight after the biopsy are expected outcomes and so will not be 
recorded as adverse events or reported. 
	
3.21.2	ADVERSE	REACTIONS	
An adverse reaction (AR) is an unintended sign or symptom judged to have 
‘reasonable causal relationship’ to the IMP. As such, the distinguishing feature 
between an AR and AE is whether there is evidence to suggest there is a causal 
relationship between the event and the IMP. 
The following adverse reactions, which are side effects, thought to be ‘common’ i.e. 
occurring 1/10 – 1/100 people are of special interest in this trial: 
o Nasopharyngitis 
o Upper respiratory tract infections,  
o Osteoarthritis 
o Headache 
 
Aa they are listed as common side effects in the SPC for Sitagliptin they do not 
have to be reported to the regulatory authorities. If the outcome to the side effect is 
serious then a Serious Adverse Event form should be completed (Appendix 18). 
 
Frequency not known/Case reports: 
o Hypersensitivity including anaphylactic responses 
o Interstitial lung disease 
o Acute pancreatitis 
o Angioedema 
o Cutaneous vasculitis 
o Exfoliative skin conditions including Stevens-Johnson syndrome 
o Renal impairment/renal failure 
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The causality behind any AE or AR will be made by the investigator responsible for 
the patients’ care. The assignment of causality will be defined as 
unrelated/unlikely/possible/probable/definitely or not assessable.  
	
3.21.3	SERIOUS	ADVERSE	EVENTS	
Any untoward medical occurrence that at any dose: 
- Results in death 
- Is life-threatening * 
- Requires hospitalisation or prolongation of existing hospitalisation 
- Results in persistent or significant disability or incapacity; or 
- Consists of a congenital abnormality or birth defect 
- Requires medical intervention to prevent one of the above, or is 
otherwise considered medically significant by the investigator. 
 
* Life-threatening refers to an event where the participant was at risk of death at the 
time of the event; not to an event that hypothetically might have caused death if it 
was more severe.  A medical review must be undertaken in deciding whether an 
SAE / SAR is serious in other situations.  Those events that are not immediately 
life-threatening or do not result in death or hospitalisation, but may jeopardise the 
subject or may require intervention to prevent one or more of the other outcomes 
listed, should be considered serious. 
 
A Serious Adverse Reaction (SAR) meets the criteria of being an AR and is serious.  
The SmPC contains the known side effects of Sitagliptin, however there needs to 
be a clinical judgement for expecting an unexpected SAR. 
	
3.21.4	REPORTING	PROCEDURES	
Patients will have direct contact with the trial team by telephone and email to report 
any events themselves. Adverse events will be reviewed and unscheduled clinic 
visits will be arranged if further clinical care is required.  
Should any participant be admitted as an emergency to another department of the 
hospital e.g. Accident and Emergency they will have been informed to give their 
‘SIMPLANT Emergency Contact Card’ to the clinician looking after them. The card 
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provides contact details to get in touch with either Professor Quenby (chief 
investigator) or Dr Tewary (trial co-cordinator). The chief investigator will then 
review the event to determine causality and report if necessary. 
 
3.21.5	REPORTING	AES/ARS	
AEs can be observed directly when they attend for their face to face consultations 
or volunteered by the patient. All non-serious AEs/ARs should be reported to the 
sponsor as soon as possible but no later than one month and then recorded onto 
the trial database. If the outcome to the AE is serious then an SAE form should be 
completed (Appendix 19). 
	
3.21.6	REPORTING	SERIOUS	ADVERSE	EVENTS	
Serious Adverse Events (SAE) should be reported to the sponsor within 24 hours of 
research staff becoming aware of an event. An initial report may be made orally but 
must be followed up promptly by a detailed written report. An SAE form will be 
completed together with relevant supporting documents, including an assessment 
of severity, causality and expectedness, as reviewed by the chief investigator. SAE 
form should be submitted to the sponsor’s office at 
RD&Isponsorship@uhcw.nhs.uk.  
Any change of condition or other follow-up information should be emailed to the 
Sponsor as soon as it is available or at least within 24 hours of the information 
becoming available. Events will be followed up until the event has resolved or a 
final outcome has been reached. The Sponsor will inform the regulatory authorities 
within the required expedited reporting timescales. 
	
3.22 IN EVENT OF PREGNANCY 
 
As shown in the timeline of events there are many checks in place to prevent 
pregnancy. 
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o Patients will sign a consent form to agree to not try to become pregnant 
while in the study and will be supplied with barrier contraception. 
o The biopsy will not be performed if unprotected intercourse has taken place 
in the cycle leading up to visit. 
o Patients will do a pregnancy test every 2 two weeks for the duration of the 
trial.  
o A pregnancy test will be done before each endometrial biopsy 
 
In the event of a positive pregnancy test patients will be asked to stop the 
medication immediately and a trial centre visit will be organised. The Chief 
Investigator will be informed, it will be recorded on the trial database and the patient 
will be withdrawn from the trial.   
 
3.23 UNBLINDING 
 
Participants, investigators, research midwives and nurses will remain blinded to the 
trial drug allocation throughout the duration of the trial.  
Unblinding in the study is not allowed unless there are medical or safety reasons to 
do so. Unblinding will only occur when all participants have had their endometrial 
biopsy 3 months after treatment.  
If there is a serious adverse event, then the management of the patient should be 
started as if the patient is on Sitagliptin. If the event or reaction is thought to be 
related to Sitagliptin then unblinding will be considered. 
Unblinding requests may be made by the chief investigator, the chief investigators 
designee or, in the event of an emergency, the participants health care provider.  
Unblinding can occur 24 hours a day and 7 days a week. During office hours (8 am 
to 4pm) participants or healthcare providers can call the research office on 02476 
967890 or out of ours by contacting the medical team via the main hospital 
switchboard on 02476964000 (ask for Dr Shreeya Tewary or Professor Quenby). 
The contact details are on the emergency contact card given to participants once 
randomised.  
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3.24 EARLY TERMINATION VISIT 
 
A participant will be required to discontinue the drug under the following 
circumstances 
o Participant becomes pregnant or is no longer willing to use reliable 
contraception 
o Participant wishes to withdraw for any reason 
o Presence of any medical condition that may jeopardise the participant’s 
safety e.g. development of type two diabetes 
o Non compliance 
o Determination by the investigator that the discontinuation is in the best 
interest of the participant. 
o Adverse event related 
o Sponsor’s decision 
o Lost to follow up 
 
If there is early discontinuation of the medication the patient will be asked to attend 
for an early termination visit. An end of study form in the CRF pack will be 
completed. 
 
3.25 DATABASE 
 
A database compliant with GCP requirements which will be password protected, 
encrypted and stored on a secure drive to NHS standards will be developed for the 
purpose of this trial.   
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3.26 STATISTICS AND DATA ANALYSIS 
	
3.26.1	PRIMARY	ENDPOINT	
The primary end point is the stem cell assay after 3 months of treatment. This will 
be assessed by doing a clonogenic assay. The number of colonies formed reflects 
the stem cell count.  
For each biopsy, 500 cells will be seeded in 3 separate wells of a colony forming 
unit assay plate. We will look at the number of colonies formed per 500 cells 
seeded for each participant in the study.  
 
3.26.2	STATISTICAL	ANALYSIS	
Data exploration will compare baseline characteristics for the women in the 
intervention group (women randomised to receive Sitagliptin) and the control group 
(women randomised to receive placebo).  
For example, for continuous characteristics such as age, we will report the mean 
and the standard deviation and for count data such as number of previous 
miscarriages, we will report the median and the interquartile range (See template 
table below). 
	
Characteristic	 Intervention	 Control	
Age	(years)	
	 Mean	(SD)	
	 	
Number	of	previous	miscarriages	
	 Median	(IQR	range)	
	 	
	
The primary analysis will compare the number of colonies per 500 cells between 
the Sitagliptin group and the placebo group. We will test the null hypothesis that the 
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mean number of colonies for the control (placebo) group is equal to that of the 
intervention group (Sitagliptin) after three months of treatment.  
We will fit a Poisson regression model, which is appropriate for count data. If the 
baseline characteristics are imbalanced between the control and the intervention 
groups, we will perform secondary analysis in which the Poisson regression model 
will adjust for the baseline characteristics.  
Because this is a pilot study, we will test hypothesis tests at 10% significance level. 
 
3.27 TRIAL CLOSURE 
 
The trial will be stopped early if 
o Requested by Ethics Committee 
o Mandated by the data monitoring committee on safety grounds 
o Decided by the Sponsor  
o Funding for the trial ceases 
 
The REC and MHRA will be informed if the trial is terminated earlier than planned 
	
3.28 DEFINITION OF THE END OF THE TRIAL 
This will be when the last patient has had their second endometrial biopsy.  
Following the discharge of the patient from the trial, patients will go back to 
standard care. This involves being given a contact number to phone to book an 
appointment to the RPL clinic as soon as they are next pregnant. 
 
3.29 TRIAL REGISTRATION 
The trial has been registered on the International Standard Randomised Controlled 
Trial Number registry prior to the start of recruitment (ISRCTN 67932311.   
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CHAPTER	4:	CLONOGENIC	ASSAY	
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This chapter outlines the standard operating procedure developed from which to 
perform the clonogenic assay. These assays were performed in the Warwick 
Medical School Clinical Sciences Research Laboratory based at UHCW.  
Each assay took two weeks to complete and required advanced laboratory 
experience. They were performed by Dr Emma Lucas, Dr Katherine Fishwick and 
Dr Paul Brighton. I followed through the first 14 participants with Dr Lucas to get a 
good understanding of how the assays are performed.  
4.1 AIM 
1. Isolate the endometrial stromal cells from the endometrial biopsy 
2. Plate the endometrial stromal cells for a colony forming unit (CFU) assay. 
• Each colony formed is a marker of stem-ness of the sample. A 
property of the stem cells is to self-replicate and form colonies – 
other types of cells don’t do this. 
	
4.2 IMPORTANT POINTS 
a) Clean the biosafety unit from the back to the front with 70% industrial 
methylated spirit (IMS) 
b) Use a class II cell culture microbiological safety cabernet and aseptic 
techniques to avoid microbiological contamination  
c) Ensure to wear a lab coat and gloves. Gloves need to cover the cuff of the 
lab coat 
	
4.3 MATERIALS AND REAGENTS 
1. 70% industrial methylated spirit (IMS) 
2. 60mm sterile petri dish (untreated) 
3. Falcon tubes – 50ml/15ml/14ml 
4. 20 ml syringe 
5. 0.4 um cell strainer 
6. Filter  
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7. Glass pipettes 
8. Strippette 
9. t25 flask 
10. Scalpel for chopping 
11. Digestion media 
14ml falcon tube, 10ml DMEM/F12(additive free, phenol non red), 
100ul DNAase (10mg/ml), 100ul collagenase 
12. Colony Forming unit (CFU) Assay plates (6 well plate) 
13. 2% DCC (serum containing) = dextra charcoal coated  
DMEM/F12 without phenol red containing 2 % DCC, 2 mM L-glutamine 
and 1X antibiotic-antimycotic mix 
14. 10% DCC (DMEM/F12 containing 10 % dextran-coated charcoal filtered 
FBS (DCC), 2 mM L-glutamine, 1X antibiotic-antimycotic mix, 1 nM estradiol 
(E2) and 2 µg/ ml insulin) 
15. 10% DMEM/T12 
500mls DMEM + 50 mls 10% serum, 5mls L-Glutamine, oestradiol 
(mitogen), insulin  
16. Trypsin-EDTA (0.25 %) 
17. sterile filtered phosphate buffered saline (pbs) 
18. plasma fibronectin (1mg/ml) 
19. Basic fibroblast growth factor (BFGF) (1 microlitre/ml) 
20. microcentrifuge tube 
21. trypan blue 
22. 10% neutral buffered formalin (NBF) 
23. 10% dimethyl sulfoxide (DMSO) 
24. harris haematoxylin 
25. neubauer improved haemocytometer 
26. counting slide 
27. luna cell counter.  
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A sample of CFU images for 5 patients. The three wells on the left represent 
colonies of stem cells in the baseline biopsy and the 3 wells on the right 
demonstrate colonies of stem cells in the final biopsy. 
 
 
	
	
	
	
	
	
	
	
	
	
	
	
R01
R02
R04
R07
R08
R09
R10
R11
R12
R13
R14
R15
R17
R18
R19
R20
R21
R22
R23
R24
R25
R27
R28
R29
R30
R31
R32
R35
First Second First Second
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4.4 PROCEDURE 
	
The endometrial biopsy was obtained using a Wallach Endometrial Cell 
Sampler.  
 
Each participant had two endometrial biopsies; one at the start of the trial 
and one at the end of the trial. These were labelled as ‘biopsy A’ and ‘biopsy 
B’. Patient 1 = R01. The biopsy portion used for stem cell analysis was 
labelled R01A and RO1B. These were analysed together to ensure that the 
paired analysis had minimal errors due to minor alterations in the laboratory 
environment. 
 
The biopsy portion sent to tissue bank could not be labelled with letters. 
These were therefore replaced with numbers 
R 9 
Biopsy A 1 
Biopsy B 2 
  
Therefore, R01a and R01b was labelled as 9001 1 and 9001 2 
       RO2a and R02b was labelled as 9002 1 and 9002 2 
 
The biopsy was divided into 4 portions.  
a. A small piece (0.5 – 1cm long) was snap frozen in liquid nitrogen for 
protein analyses. 
b. A small piece (0.5 – 1cm long) was preserved in RNA later for 
transcriptomic analyses. 
c. Another piece (1-2cm) was fixed in 10% neutral buffered formalin 
(NBF) for histology and immunohistochemistry.  
d. The remainder was placed into 10% DMEM/F12 and processed for 
cell culture. 
 
 
 
 
	 106	
4.4.1	DIGESTION	MEDIA	PREPARATION	
1. A 14ml Falcon tube was used to prepare the digestion medium. 
2. 10mls of DMEM/F12 (without phenol red free/additive free), 100ul DNase I 
and 100ul collagenase Ia were mixed together into the 14ml Falcon tube. 
a. The collagenase breaks down the extracellular matrix between the 
cells. 
b. The DNase removes the DNA which would be released from the 
cells after chopping the sample. Removal of the DNA is necessary to 
prevent the DNA causing apoptosis of other cells. 
 
4.4.2	SAMPLE	CHOPPING	
The biopsy was then transferred from the 10% DMEM/F12 vial into a sterile petri 
dish. The tissue was separated from the liquid portion (DMEM/F12) by pouring the 
liquid portion into the petri dish and pouring the endometrial biopsy into the 
upturned lid of the petri dish.  
1. A pipette was used to remove any remaining fluid or any mucus from the 
biopsy material. 
2. The biopsy was then chopped with a scalpel for 5 minutes determined by a 
countdown timer into a ‘milkshake’ texture. This increases the surface area 
for digestion.  
 
4.4.3	ADDING	DIGESTION	MEDIA	AND	WASHING	
1. A filter was attached to the tip end of a syringe.  
2. The pre-prepared digestion media was put into the barrel of the syringe and 
pushed through the filter directly onto the endometrial sample in the sterile 
petri dish. 
a. The enzymes within the digestion medium break down the 
interaction between the cells in the biopsy to produce a single cell 
suspension. 
3. The contents of the petri dish were washed by collecting the mixed digestion 
medium and endometrial sample into a strippette and adding it to a Falcon 
tube. 
4. The flask was shaken vigorously for 15 seconds and placed in an incubator 
for 1 hour at 37°C, 5% CO2. 
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5. During the hour the sample was shaken vigorously every 20 minutes for 
approximately 15 seconds. 
6. At 1 hour the digestion media was cloudy and no visible pieces of tissue 
remained.  
 
4.4.4	CRYOPRESERVATION	
1. The digested sample was poured through a 40µM cell strainer into a 50ml falcon 
tube. The strainer prevented glandular clumps going into the falcon tube. 
2. The 40µM cell strainer was flipped over and placed onto another falcon tube and 
backwashed into a separate tube with additive free media to collect the glandular 
clumps. 
3. 10 ml of 10% DCC (DMEM/F12 containing 10 % dextran-coated charcoal filtered 
FBS (DCC), 2 mM L-glutamine, 1X antibiotic-antimycotic mix, 1 nM estradiol (E2) 
and 2 µg/ ml insulin) was pipetted through the strainer to wash. 
4. The 40µM cell strainer was flipped over and placed onto another falcon tube and 
backwashed into a separate tube with additive-free media (DMEM/F12 without 
phenol red) to collect the glandular clumps. 
5. The two falcon tubes (one with the glandular layer and one with the stromal layer) 
were centrifuged at 270 x g for 5 minutes to pellet cells.   
6. The media above the pellet of epithelial cells was aspirated. 
7. The glandular pellet clump was then digested for a further 10 minutes in Trypsin-
EDTA (0.25 %) at 37 °C and then washed in 10 ml 10 % DCC. The media above 
the pellet was aspirated again.  
i. The 10%DCC inactivates the trypsin  
8. Epithelial cells were cryopreserved in 10 % DMSO in DCC (2 ml per vial) with the 
stromal compartment split into two or three vials depending on the original biopsy 
size.   
9. After controlled cooling in a Mr Frosty container, samples were transferred to liquid 
nitrogen for longer term storage. 
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4.4.5	COLONY	FORMING	UNIT	(CFU)	ASSAY	
 
1. Prepare CFU plates  
a. Make a solution of PBS and 1microlit/ml fibronectin (amount of 
solution prepared depended on number of biopsies being processed) 
i. E.g. 3 participants = Total of 6 biopsies as each participant 
has 2 biopsies. Therefore, 6 CFU plates would be required 
ii. Each CFU plate has 6 wells. Each well needs 1ml of solution 
therefore 36ml solution needed. 
                                               
b. Pipette 1 ml of solution to each well 
c. Put wells in incubator for 20 mins (37 degrees) 
 
2. Thaw the sample 
a. Cryopreserved stromal cells were thawed for 3 minutes at 37 °C in 
the water bath 
b. The 2ml sample was then transferred immediately into 8 ml pre-
warmed 10 % DCC. 
c. The sample was centrifuged at 270 X g for 5 mins to produce a pellet 
§ The pellet at the bottom of the falcon tube contains 3 layers - 
a buffer, a layer of red blood cells and the stromal cells 
d. The supernatant was aspirated to leave only the pellet at the bottom 
of the falcon tube 
e. The cells were re-suspended in 10ml 10% DCC and cryoprotectant 
f. This solution was also then aspirated media from around sample 
 
3. Count cells 
a. 15microlitres of the stromal cell sample was mixed with 15microlitres 
of trypan blue (put both into a micro-centrifuge tube) 
b. Viable stromal cells were counted on a Neubauer Improved 
haemocytometer 
i. Dead cells stain blue as the dye enters the cells 
ii. Live cells don’t stain and so the dye doesn’t enter the cell 
membrane  
c. 10ul of the cell suspension was added to each groove of a cell 
counting slide (2 grooves) using a p10 pipette 
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d. The Luna Cell Counter was used to count the number of stromal 
cells per ml 
 
 
 
An example of a stromal cell count  
Average cell count from 4 x 16 squares 
 = 13.5 
 = 13.5 x 104 x 2 (to account for trypan blue dilution) = 27 x 104/ml 
  = 270000 cells/ml 
  = 270 cells/ul 
 
If we want a baseline of 500 cells seeded for the CFU analysis, we could now 
calculate how much of the solution is needed to be put on the CFU plate  
 
500 cells = 1.85ul of the solution (=500/270) 
 
We wanted to put 500 cells in 3 wells and so 1500 stromal cells were suspended in 
media with FGF before plating. 
 
4. Suspend sample in media with FGF 
a. 9mls of 10%DCC with FGF were put into a falcon tube 
b. 1500 stromal cells were put into the media (as per calculation above) 
 
5. Plate cells 
a. The solution already lining the CFU plate wells (PBS and FN) was 
aspirated 
b. 3mls of media containing 500 stromal cells was put into each well 
c. Plates were cultured in 5 % CO2 at 37 °C, left undisturbed for 3 days 
after which growth was monitored to ensure colonies arose from 
single cells.   
 
6. Media Change 
a. Media was half-changed at 7 days of culture. 
 
7. Counting Colonies 
a. On day 10 cultures were washed in phosphate buffered saline 
(PBS), fixed in 10 % NBF for 10 minutes at room temperature, 
	 110	
washed extensively in sterile water and then stained with Harris 
Hematoxylin for 4 minutes. 
b. For counting colonies, plates were imaged using a G:Box dark room 
imager and GeneSys software.   
c. Images were analysed in ImageJ by a single operator using the 
cellcounter plugin to count colonies of 50 cells or larger. 
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CHAPTER	5:	TRIAL	MANAGEMENT	
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This chapter outlines the team work involved in the management of this study, the 
risk assessments performed and important information on research governance. 
5.1 ROLES AND RESPONSIBILITES  
	
5.1.1	TRIAL	SPONSOR	
The NIHR toolkit on clinical trials states that The Research Governance Framework 
requires that all health research should have a formal sponsor (NIHR, 2017).  
The sponsor of this trial was University Hospitals Coventry and Warwickshire NHS 
Trust (UHCW). The sponsor was responsible for ensuring the study met all 
regulatory standards and arrangements were in place for initiation, management, 
reporting, monitoring and financing of the trial. 
Within this trial the sponsors were involved in the trial set up and thoroughly 
reviewed the protocol and all patient specific documents before they were sent to 
the REC, HRA and MHRA for approval.  
They ensured that principles of GCP were adhered to and when they felt that there 
was a breach of protocol, the trial was suspended until appropriate measures were 
put into place. 
	
5.1.2	CHIEF	INVESTIGATOR	AND	PRINCIPLE	INVESTIGATOR	
The chief investigator and principle investigator for this trial was Professor Siobhan 
Quenby who is a world renowned professor and has been conducting research in 
RPL for over 20 years. Her guidance was instrumental to the set up and running of 
the trial.  
The protocol was thoroughly reviewed by the chief investigator to ensure the trial 
could run in concordance with how it was set out in the protocol.  
The chief investigator delegated trial related responsibilities to suitably trained staff 
in the research unit. These responsibilities included helping booking appointments, 
being an empathetic and understanding chaperone for the endometrial biopsies, 
collecting medication from pharmacy and helping with follow up visits. All respected 
roles were captured and signed on the delegation log.  
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The chief investigator reviewed the trial master file and ensured all CV’s and 
evidence of appropriate training of all site staff was present in the file.  
All adverse events were reviewed and signed by the chief investigator before they 
were sent to the sponsor. The chief investigator ensured that the trial was run in 
accordance with GCP principles. 
The chief investigator also ensured all source data was complete as an ‘end of 
study sign off’ was completed each time a participant completed their journey in the 
trial.  
 
5.1.3	TRIAL	CO-ORDINATOR	AND	TRIAL	MANAGER	
I was the principle trial co-ordinator and responsible for the daily running of the trial. 
I have been heavily involved in the care of all the participants in the SIMPLANT 
trial. I approached and counselled all patients in the RPL clinic with Professor 
Quenby. 
I followed patients up with phone calls and emails to answer any further questions 
and concerns they may have.  
I have been present to consent all participants and have performed all the 
endometrial biopsies for participants recruited during my time as a research fellow. 
There were just 2 participants randomised by research fellows continuing to work in 
the research unit after I finished my post.  
I have been present for the whole trial journey for most of the participants and rarely 
been away when they have attended for follow up visits. I have therefore 
understood their journey through the trial very well. Also, performing 94% of the 
biopsies myself has also allowed standardisation in the methods used to collect the 
biopsies.  
I have been present for all the trial management group meetings and trial steering 
committee meetings. Working closely with the chief investigator and the trial 
manager on a daily basis, as well as planning and attending these meetings has 
given me a good understanding of how to conduct a clinical trial.  
The day-to-day running of the trial involved co-operation between the research 
team, the laboratory team, the pharmacy team and the trial manager.  Putting in 
	 114	
measures to ensure there were no missing lines in communication and good 
working relations between all those involved helped to improved my team working 
and team leadership skills.  
I was supported by a trial manager; Mrs Katie Bruce who helped with the set-up of 
the study. Her role was taken over by Dr Indrani Manoharan just before the trial 
opened for recruitment. Having a new trial manager just before the trial opened for 
recruitment brought about new challenges but at this point I appreciated the 
importance of having an organised trial master file and an organised system for all 
trial specific documents and correspondence to help make the change of trial 
managers efficient.  
All correspondence to the sponsor was done through the trial manager.  All adverse 
events and a monthly tracker on the status of the trial were reported to the trial 
manager.  
The trial master file was set up and maintained by myself and the trial manager. 
This was stored in the RD & I department on the 4th floor at UHCW. We had a site 
file in the BRU which contained documents needed for the daily running of the trial. 
All the staff in the BRU were involved in the running of the trial. This included 
myself, a lead research midwife for the trial, the clinical trials assistants and the 
secretarial staff. A site initiation visit was done by myself and separately by the trial 
manager for all staff. 
 
5.1.4	TRIAL	PHARMACIST	
We had expert advice during the set up and running of the trial from the trial 
pharmacist; Mr Mojid Khan.  
He was responsible for finalising agreements and quotes from Sharp Clinical 
Services. A visit to the main site of manufacture was made to ensure systems were 
in place to conform with regulatory requirements. He was heavily involved in the 
finalising of the technical agreement between Sharp Clinical Services and the 
sponsor. This technical agreement was necessary to set out roles and 
responsibilities between the sponsor (UHCW) and the manufacturer of IMP (Sharp 
Clinical Services). This agreement contained finer details such as recall 
responsibilities, temperature and storage monitoring. 
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The trial pharmacist was responsible for overseeing the disintegration testing which 
had to be performed when Sitagliptin was converted to capsule form to ensure it 
had the same bioavailability and shelf life as the tablet form.  
I had meetings with the trial pharmacist to confirm capsule size, packaging and 
labelling. The trial manager was responsible for the code break test and also 
making plans for accountability of trial medication and destruction when the trial 
ended. 
The trial pharmacist overlooked the pharmacy team responsible for checking 
prescriptions and issuing the trial medication. 
	
5.2 RISK ASSESSMENT 
 
A risk assessment is deigned to identify potential vulnerabilities in trial design and 
to prepare trial management and monitoring plans to minimise the risks. The risk 
assessment addressed the investigational medicinal product (IMP) risk category 
and devised a clear risk monitoring plan. The risk assessment was submitted to the 
MHRA.  
This trial was categorised as a type A study (i.e. no higher risk than that of standard 
medical care) because 
1. There are no substantial dose modifications made in comparison to the 
licensed indication. 
2. There are no combinations of medication for which interactions are 
suspected. 
3. There is no reason to suspect a different safety profile in the trial 
population. This was supported by the evidence from MSD Ltd provided 
on the use of Sitagliptin in healthy volunteers. 
 
The extensive risk management and risk management strategies were 
signed by the chief investigator, the sponsor, the research governance 
manager and the research pharmacist. 
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5.3 RESEARCH TEAM AND SITE INITIATION VISIT  
 
Before the study was opened for recruitment I carried out a site initiation training 
session for all staff involved in the trial. This was attended by the research unit staff, 
the randomisation team, the pharmacy team, the trial manager, one member from 
the sponsor team and the chief investigator. 
This involved a formal presentation on the scientific basis of the trial and an 
explanation of the patient pathway within the trial. I discussed everybody’s roles 
and responsibilities and ensured there were no concerns. 
I performed the training on two separate occasions so that everyone had an 
opportunity to attend. All those involved in the trial, including the laboratory team 
had GCP certification and had good experience of clinical trials already.  
 
5.4 DATA COLLECTION AND MANAGEMENT 
 
Data management processes are essential to ensure data included in trial reports 
and publications are accurate. A data management plan with clear data entry 
instructions were created by the trial manager. 
I designed the case report forms (CRF) for the trial. Each participant was assigned 
a case report form pack which contained all the paper work for all the hospital visits 
for that participant within the trial (screening, consent, intervention 1 & 
randomisation, follow up visit 1, follow up visit 2 and intervention visit 2) (Appendix 
17 - Sample of screening and consent CRF). 
The CRF packs were reviewed at trial management meetings before submission to 
the sponsor for local approval. The paper case report forms were filled in by myself 
at the participants’ clinic visit. Original CRF’s have been stored in locked filing 
cabinets in the Biomedical Research Unit. A paper copy of each case report pack 
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will be securely saved for 25 years in accordance with the UHCW NHS Trust 
archiving procedures. 
The CRF’s allowed us to capture important information from each hospital visit but 
also included a pregnancy test log as participants had to complete one every two 
weeks. This was entered into an electronic pregnancy test log weekly so that I was 
able to constantly kept up to date with pregnancy test tracking. If there were any 
pregnancy tests that were overdue, I would alert the lead research midwife who 
would ring or email the participants. 
An agreement with MedSciNet was made for development of the electronic trial 
database. The database is compliant with GCP requirements and is password 
protected. Validation testing was conducted by myself and the trial manager. Any 
anomalies were resolved in liaison with the database manufacturer before the start 
of data entry.  
Once a participant had completed their journey in the trial the trial manager was 
emailed. The CRF pack for that patient was photocopied without any identifiable 
data. Data from the CRF was entered onto the electronic database by the trial 
manager. The photocopied version was then scanned and stored onto the 
electronic research drive and the photocopied paper copy stored in the CRF folder 
in the R&D offices at UHCW. 
 
5.5 TRIAL MANAGEMENT GROUP MEETINGS 
 
There were regular trial management meetings (TMG) from the initial set up and 
design of the trial and then quarterly during the running of the trial.  
The TMG team consisted of   
• Chief investigator: Siobhan Quenby 
• Myself: Shreeya Tewary 
• RD+I manager: Becky Chadwick 
• The trial manager: Katie Bruce then Dr Indrani Manoharan 
• A member of the UHCW governance team: Isabella Petrie 
• The trial pharmacist Mojid Khan 
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• The trial statistician Peter Kimani 
 
At the first meeting we discussed the study design and objectives. We also 
discussed timelines, recruitment targets, funding and processes to secure trust 
sponsorship.  
Between the first and second TMG meeting I had to finalise the trial protocol, 
organise peer reviews and the risk assessment from pharmacy and RD&I 
Governance.  
The next meeting was held one month later where sponsorship by UHCW was 
confirmed following a low risk assessment. Funding by Tommy’s charity was also 
confirmed at this meeting.  
Quotes that I had received from various companies to supply the placebo had been 
evaluated by the trial pharmacist and discussed at the trial management meetings. 
After discussion with everybody at the meeting it was decided that Sharp Clinical 
Services would be best to deliver the study requirements.  
We also discussed and confirmed methods of randomisation with the trial 
statistician.  
There were four further TMG meetings before the trial commenced to ensure there 
was no room for error when the trial opened. The agenda for each meeting would 
follow the same pattern which included review of minutes and action points from 
previous meetings, updates on progress & recruitment, pharmacy updates, review 
of any substantial or non-substantial amendments, monitoring plans and safety 
reporting.  
There was an extensive checklist to be completed at the TMG meeting on the 23rd 
August 2016 to ensure there was tight control on all aspects of trial management 
before the trial was officially opened (Appendix 20).  
The trial then opened for recruitment on the 15th September 2016. We have had 
quarterly TMG meetings since to review the progress of the trial.  
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5.6 TRIAL STEERING COMMITTEE (TSC) AND DATA 
MONITORING COMMITTEE(DMC) 
 
As this was a small single centre study with a laboratory rather than a clinical 
outcome, the sponsors agreed that a Joint TSC/DMC would be appointed.  
The members were;  
• Independent chair: Professor Arri Coomarasamy (University of Birmingham),  
• Independent members: A consultant obstetrician, Dr Gupta (Heart of 
England NHS Trust)  
• An independent statistician: Dr Tobias (Spanish Council for Scientific 
Research)  
• The non-independent members were the chief investigator, the trial 
manager, the trial statistician and myself.  
The TSC/DMC charter was developed by the trial manager to be signed by all 
members of the TSC/DMC to commit to join the SIMPLANT TSC/DMC. 
The joint Trial Steering Committee and Data Monitoring Committee (TSC/DMC) 
provided independent overall supervision of the trial, in particular with respect to the 
progress of the trial, adherence to the protocol, participant safety and review of any 
new information, particularly with medication safety.  
At the first TSC/DMC meeting I presented an overview on the scientific basis 
behind the trial. We then discussed the safety data and information on optimal 
dosing of Sitagliptin. We also discussed the validity of the sample size calculations 
with the trial statistician.  
The Trial Steering Committee had reviewed and agreed the final version of the 
Protocol before submission to the REC and MHRA. 
Once the trial had opened for recruitment, telephone conference meetings were 
held at six monthly intervals. The trial manager and myself were responsible for 
producing an update report and circulating this to the TSC/DMC one week ahead of 
the meeting. This would involve up-to-date information on recruitment targets with a 
consort diagram and adverse event reporting.  
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The following diagram shows the flow of information between the TSC/DMC and 
the Trial Management Group (TMG). I would receive an open report from the 
TSC/DMC and a closed report would be shared between the trial statistician and 
the TSC/DMC. 
	
																																																																									Open	&	closed	reports			
	
	
																																		Open	report																																			
	 																						Open	report												Recommendations/Actions		
	
	
	
	
5.7 RESEARCH GOVERNANCE 
 
Appropriate and effective research governance ensures the proposed research 
protects the safety of patients and so monitoring and audit measures are put in 
place for any research trial. 
A formal monitoring plan which was put in place by Isabella Petrie (Research 
Governance Manager). This was approved by the TMG Committee at a meeting 
before the trial opened for recruitment.  
This monitoring plan included 
• Three monthly TMG meetings 
• Six monthly TSC meetings by teleconference 
• A site visit to view set up and team understanding of trial 
• Pharmacovigilance plans to regularly monitor any SAE’s and a list of trigger 
factors which would lead to a monitoring visit (e.g. persistent late reporting 
of AE/SAE’s, concerns with data collection, protocol deviation).  
Trial	Statistician	 Data	monitoring	committee	/	Trial	
Steering	Committee	(DMC/TSC)	
Trial	Management	Group	(TMG)	
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This monitoring plan also details governance procedures which will take place at 
the end of the trial which include: 
• Communication of closure of trial to participants registered but not 
randomised 
• Site visit and closure notification 
• IMP accountability 
• Provisions for archiving. 
We had an internal and external audit of this trial which forms a large part of 
research governance procedures. 
 
5.8 TRIAL SUSPENSION 
 
Despite thorough review of all documents and many TMG meetings to agree and 
finalise how the trial would be managed and run, the trial was suspended on the 
21st October 2016 due to a serious breach of the trial protocol. Details of this trial 
suspension and actions taken to overcome it are detailed in chapter six. 
5.9 TRIAL MONITORING 
	
5.9.1	INTERNAL	MONITORING	
In November 2016 when the trial was actually suspended and applications were 
being made to the REC and MHRA to restart the trial, we had an internal monitoring 
visit from the sponsor.  
This involved a review of all relevant documentation, the trial protocol, CRF’s and 
patient notes. 
In the final report there were some areas of concern, mainly to do with data entry 
which were easily rectified but overall the report commented on good practice. 
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5.9.2	EXTERNAL	MONITORING	
External monitoring forms an integral part of effective Research Governance and 
ensures levels of control are being implemented. 
On the 27th January 2017, just six weeks after the trial had been re-opened we 
were informed of an external audit and monitoring exercise which was going to take 
place on the 8th February 2017 by Trueman Hall Associates Ltd (Appendix 24). 
We were informed that access to all research files and patient hospital notes would 
be necessary and we would need to be available to answer any queries. All 
participant hospital notes and case report forms were made available for review.  
We received feedback on the audit and produced a response to some concerns 
raised. Overall, the concerns raised were actually due to certain information not 
being available on the day of the audit. This was rectified very quickly. There were 
some concerns about the protocol, sample consent form, and participant 
information card in the investigator site file not being signed by all three parties. 
Again, all these issues were addressed. Overall, the sponsor was pleased with the 
outcome of the external audit.  
 
5.10 CODE BREAK TEST 
Along with the code break test which occurred before the trial opened for 
recruitment there was another code break test while the trial was running on the 
19th January 2017. This confirmed the safety and integrity of the systems in place to 
contact the clinical team and also unblind participants if necessary. 
	
5.11 AMENDMENTS 
	
5.11.1	NON	SUBSTANTIAL	AMENDMENTS	
A non-substantial amendment was made soon after the trial opened to provide 
clarification on the contact details on the emergency contact card. Originally the 
contact card had a phone number on it and stated to ask for the SIMPLANT 
research team in case of an emergency. This was thought to be a bit vague with 
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possibilities of confusion between the participant and switchboard. We changed the 
card to state that participants should specifically ask for Dr Tewary or Professor 
Quenby when calling switchboard out of hours in an emergency situation. it was felt 
that this change would facilitate appropriate re-direction of the call by switchboard 
staff. 
Before this non substantial amendment was submitted to the REC it was tested with 
a ‘out of hours’ test call’. We had written confirmation from switchboard that their 
staff had all been made aware of possible calls relating to the trial and where to 
transfer the call. 
 
5.11.2	SUBSTANTIAL	AMENDMENTS	
Two substantial amendments were made when the trial was suspended. These are 
detailed in the chapter six titled ‘Trial Suspension’. 
The third substantial amendment was made in relation to our required sample size. 
It was calculated that 30 participants would be needed for the trial have a power of 
95% at a 10% significance level. To allow for a 10% drop-out rate we had planned 
to recruit 34 participants.  
At the point of 20 participants being randomised we had 4 participants who had 
already been withdrawn. This meant that if there were any further withdrawals we 
would not been our planned sample size of 30 participants by recruiting 34 
participants. 
We therefore made an application for a substantial amendment to our recruitment 
target. Our amendment stated that we would like to randomise up to 40 participants 
as the supply of the study medication would allow for this but would stop 
recruitment once 30 participants have completed the study.  
Also, to allow time to recruit the additional participants we amended the protocol to 
extend the recruitment period from 12 months (ending June 2017) to 18 months 
(ending December 2017). The study was funded for 24 months and therefore the 
existing funding would cover the extended recruitment period. This extended 
recruitment period would not affect the shelf life of the study drug. This amendment 
was approved swiftly by the REC, MHRA and HRA. 
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CHAPTER	6:		TRIAL	SUSPENSION	
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6.1 EVENTS SURROUNDING SUSPENSION 
 
The SIMPLANT study opened for recruitment on the 15th September 2016. We had 
randomised 4 participants within the first month. On the 21st October 2016 the study 
was suspended by the sponsor due to a serious breach of the trial protocol. This 
breach was related to screening and eligibility criteria.  
As described in the protocol, normal renal function was necessary for participants to 
be eligible for the study. This is because the SPC for Sitagliptin states that before 
initiating Sitagliptin at the standard dose of 100mg, normal renal function should be 
confirmed and for patients with an estimated glomerular filtration rate (eGFR) below 
50mL/min the dose of Sitagliptin should be lowered. We needed all participants to 
be on the same dose to look at the true effect of Sitagliptin on the eMSC count.  
Therefore, normal renal function was part of the eligibility criteria so that a standard 
dose of 100mg of Sitagliptin could be safely administered. 
The eligibility criteria on the original proposed protocol stated ‘normal renal and 
hepatic function’. When the initial application with this protocol was made to the 
REC, one of the recommendations was the need to define ‘normal renal and 
hepatic function’.  
The protocol was amended and I had defined normal renal function with the 
reference ranges from the laboratory at UHCW (Urea 2.5 – 7.8mmol/L, Creatinine 
50 -90umol/L, potassium 3.5 – 5.3mmol/L, Sodium 133 -146mmol/L). I had no 
reason to suspect that the young and healthy group of patients who would be 
approached for this study would not have normal renal function and hepatic 
function.  
Some of the above components of a renal or liver function test can however be 
altered by hydration status. For example, a slightly low creatinine or urea level is of 
no clinical significance and actually only expresses normality for this population of 
young fit and healthy women. If a creatinine level is lower than the normal range or 
a bilirubin level is lower than the normal range, this result is actually viewed as 
better than normal. Clinically, these slight deviations from the specific laboratory 
reference ranges would not be viewed as abnormal.  
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Soon after the trial opened for recruitment we realised that the inclusion and 
exclusion criteria were too tight. This issue became apparent when a patient was 
deemed eligible to enter the study as her renal function was better than normal as 
she had a marginally lower urea level than the normal range. This was however 
unacceptable due to the reference ranges in the protocol. At this point I realised 
that clinical judgement had no bearing on defining eligibility of the patient. This only 
came to light when I called the randomisation team on the day of her first 
intervention visit. 
After her endometrial biopsy was performed the randomisation team revealed that 
they would not be happy to perform randomisation as the participant did not actually 
fulfil eligibility criteria. Long discussions between the chief investigator and the trial 
manager left us in a position only to be told to break the news to the participant that 
she had to be withdrawn from the study. 
When explaining the situation to the participant she explained that she had 3 litres 
of water to drink just before her blood test was performed and questioned whether 
this was the reason her blood test was abnormal.  
With this new information we concluded that her blood tests were actually clinically 
invalid and needed to be repeated. We repeated her renal function tests which were 
now within normal range. The randomisation team were called with the new set of 
results and she was successfully randomised. She started medication that day. 
Repeating the blood tests and effectively re-screening the participant to confirm 
eligibility was identified by the sponsor as a serious breach of the protocol. This 
lead to a local formal investigation straight away. 
An investigation of all patients who had been screened for the study took place by 
the sponsor. There were other patients who had been deemed eligible as their renal 
and hepatic function were clinically normal. However, there were certain values 
within the tests which were marginally out of the reference range, in fact their 
results were better than average, however, were not within the range specified in 
the eligibility criteria and so the sponsor deemed this is as persistent non-
compliance with the protocol and was therefore reported as a serious breach of 
protocol. 
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The trial was suspended on the 21st October 2016. The notification of this serious 
breach of the trial protocol was made to the REC and MHRA by the sponsor on the 
24th October 2016.  
The sponsors directed me to  
1. Recall and remove the patient who had been screened twice prior to 
randomisation 
2. Remove patients who had been consented based on their blood test results 
which did not actually meet eligibility criteria.   
These were difficult phone calls to make. Fortunately, the patients were very 
understanding and appreciative of the care they had received so far. They were all 
asked if they would like to participate in any other RPL trials in the future which they 
were all happy for. 
Between the 21st October 2016 and 15th December 2016 I worked hard with the 
chief investigator and sponsors to get the trial open again. We submitted 2 
substantial amendments through the REC and MHRA.  
 
6.2 SUBSTANTIAL AMENDMENT 1 
 
Notification of the suspension which was sent via IRAS to the REC on the 25th 
October 2016. On the 26th October 2016 the REC acknowledged receipt of the 
amendment.  
On the 9th November 2016 the REC gave favourable ethical opinion of the 
suspension amendment and action which had been undertaken as a result of the 
suspension. On the 14th November 2016 the MHRA accepted the amendment and 
the actions that had been put in place. 
It had taken nearly one month to receive acknowledgment from the MHRA of the 
trial suspension. Although they responded within a standard time frame, I realised 
that opening the trial for recruitment again would take a very long time considering 
two separate amendments would have to be sent; firstly proposing changes that 
would be made to the current trial pathway and then secondly to request to restart 
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the trial. I had a meeting with the trial sponsor and after discussion with the MHRA, 
an agreement was made to send the second and third amendment together. 
 
 
6.3 SUBSTANTIAL AMENDMENT 2 +3 
 
I formulated a statement of all the changes that would be put in place to ensure 
safe running of the trial (Appendix 22). 
Issues we had to address were 
• Defining normal renal function 
• Defining normal hepatic function 
I had to change the eligibility criteria on the protocol and the information about 
blood tests on the participant information leaflet. I then also had to amend the 
consent form to ensure it referred to the correct new version of the participant 
information leaflet. 
Changes instigated to renal and hepatic function: 
Renal Function 
Eligibility Criteria on Original Protocol  
• Inclusion Criteria: Adequate renal function defined as Urea 2.5 – 7.8mmol/L, 
Creatinine 50 – 90 umol/L, potassium 3.5 – 5.3mmol/L, sodium 133 – 
146mmol/L. 
• Exclusion Criteria: Renal impairment with eGFR<50mL/min. 
The SPC for Sitagliptin actually uses eGFR (estimated glomerular filtration rate) to 
define renal function which is a calculated result relative to a participants age, 
weight and creatinine level. eGFR would give us a more accurate assessment of 
renal function. The SPC states that if the eGFR is <50mL/min then dose adjustment 
is required and this is why it was originally part of the exclusion criteria.  
In the original protocol, there were participants who had normal renal function and 
this would have been reflected with a normal eGFR however, were rendered 
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ineligible according to the original eligibility criteria because one of the parameters 
of the renal function tests fell out of reference range e.g. urea 2.4mmol/L with 
reference range 2.5 – 7.8mmol/L.  
After discussion at a TMG meeting we decided to use eGFR as a more important 
and accurate way of assessing renal function. This would also take away the 
possibility of the result being altered by the patients’ hydration status. eGFR is 
calculated using the Cockcroft Gault Equation.  
I contacted Dr Paul O’Hare who is a consultant physician and the endocrinology 
advisor for the trial and also Mr Mojid Khan, the clinical trials pharmacist at UHCW 
who agreed that eGFR will be a more accurate way of measuring renal function and 
at the same time will ensure that fit and healthy patients are not rendered ineligible. 
A written report from Dr O’Hare was provided for the application. 
 
Revised Eligibility Criteria on New Protocol 
• Inclusion Criteria: No longer includes renal function – only in exclusion criteria 
• Exclusion Criteria: Renal impairment (eGFR <50mL/min or AKI >1) 
o *Note: eGFR will be calculated using the Cockroft Gault Equation: 
eGFR =   (140 – Age) x Weight (Kg) x 1.04 
     Serum Creatine (micromol/L) 
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Figure 6.0.1: Statement from Dr O’Hare 
	 	 	
 
Hepatic Function 
Eligibility Criteria on Original Protocol version 1.2, 11th May 2016 
Inclusion criteria: Adequate hepatic function defined as total protein 60 – 80g/L, 
Albumin 35 – 50g/L, Bilirubin 4 – 20umol/L, Alkaline Phosphatase (ALP) 35 – 
105U/L, Alanine Transferase (ALT) 5 – 38u/l. 
Exclusion criteria: Liver impairment, defined as any value out of normal range (total 
protein 60 – 80g/L, Albumin 35 – 50g/L, Bilirubin 4 – 20umol/L, Alkaline 
Phosphatase (ALP) 35 – 105U/L, Alanine Transferase (ALT) 5 – 38u/l. 
With this original eligibility criteria, patients with a bilirubin <2 umol/L (range 4 – 
20umol/L) or an ALP of 34 U/L (range 35 – 105 U/L) with otherwise normal blood 
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tests were not eligible for the study. Again, these results are out of the reference 
range but of no clinical significance. They actually tell us that the blood test results 
are better than would be expected and so patients were being unfairly excluded.  
The SPC for Sitagliptin states that Sitagliptin has not been studied in patients with 
severe hepatic impairment and care should be exercised.  
After discussion with Dr Paul O’Hare it was decided that ALT, ALP and bilirubin are 
sufficient markers of hepatic function but values below the lower limit of the 
reference range are clinically insignificant in this situation. 
Revised Eligibility Criteria on New Protocol 
Inclusion criteria: No longer includes hepatic function. 
Exclusion criteria: Liver impairment defined as any value above the normal 
reference range (alt >38U/L, ALP >105U/L, Bilirubin >20umol. 
 
6.4 TRIAL RE-START 
 
Approval for substantial amendment 2.0 & 3.0 was received from the REC on the 
6th December 2016 and from the MHRA on the 7th December 2016 (Appendix 23). 
The sponsor had set out further action points to be completed before the 
suspension could be lifted.  
The chief investigator and I had to read and sign all the local standard operating 
procedures for the running of a clinical trial. 
We had to re-train all staff involved in the study. This included training for the 
randomisation team and pharmacy team as well as a new site initiation visit for the 
clinical research team.  
The principle investigator and co-investigators also had to attend a GCP refresher 
course.  
The trial opened again on the 15th December 2016. 
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6.5 LESSONS LEARNED 
 
The suspension of this trial which lasted two months taught me that a trial protocol 
must be written extremely carefully taking into consideration the safety of 
participants but also ensuring that patients are not unfairly excluded. 
I learnt skills of team working at this difficult time. I had to liaise with the trial 
management team, the sponsor, the REC and MHRA to make changes and prove 
that I could run this trial safely.  
I learnt skills of time management as I ensured all new documents, cover letters, 
statements and peer reviews were ready in good time to send as soon as possible. 
I facilitated discussions with the MHRA to help us to submit amendment 2+3 
together which was a fundamental part of accelerating the process. This is because 
receipt of each amendment takes 32 days to be acknowledged and then decision 
making with a formal response can take a long time. 
I also learnt that a trial protocol is not like a clinical guideline which is essentially 
used as a guide and can be overridden if clinically justified. When I write another 
protocol I would use a very different thought process. 
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CHAPTER	7:	TRIAL	RECRUITMENT		
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7.1 TRIAL PATHWAY 
 
7.1.1	PARTICIPANT	ENTRY	
All the patients invited to participate in this trial were identified from the recurrent 
miscarriage clinic or the implantation clinic at UHCW.  
70 patients were screened and given information on the study at the recurrent 
miscarriage clinic.  
During my time as a clinical research fellow I was present at each of these clinics to 
further counsel patients about the trial once they had seen Professor Quenby or 
Professor Brosens.  
I discussed the scientific basis of the trial with every participant approached for the 
study and explained the requirements of the trial. This visit would typically last an 
hour. Patients would understandably have questions and concerns as it was a big 
commitment for any patient to enter this trial. 
Patients were given the PIL for the trial at this visit and given contact details for the 
research unit. All patients given a PIL were entered onto a screening log (Appendix 
14). 
I had specifically set up an email address for the participants taking part in the trial 
called simplant@uhcw.nhs.uk. This was given to all patients approached for the 
study so that they could send any questions they had about the trial once they had 
left the clinic. 
Patients were advised that participation was completely voluntary and that their 
choice to participate or not participate would not affect their usual care. 
 
7.1.2	PARTICIPANTS	NOT	ELIGIBLE	AFTER	SCREENING	
Five of the seven patients did not meet the eligibility criteria for the trial due to 
abnormal liver function tests or renal function tests.  
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There was one patient who was not eligible as she turned 43 years old before she 
re-attended to the clinic to take part and consent to the trial.  
There was one patient who was on metformin and therefore not eligible as there is 
a risk of hypoglycaemia when Sitagliptin is used with other diabetic medication. 
 
7.1.3	WITHDRAWALS	PRIOR	TO	RANDOMISATION	
There were four participants who consented to take part in the study but were 
withdrawn prior to randomisation. Two of these patients self-withdrew as they 
changed their mind about postponing attempts to pregnancy for three months which 
was a requirement of the trial.  
One of the participants had to be withdrawn because an endometrial biopsy could 
not be obtained despite attempts by myself and the chief investigator. We referred 
her on to have a hysteroscopy by one of the consultants in reproductive medicine.  
The fourth participant was withdrawn at the time of the trial suspension. She had 
been considered eligible to enter the trial by the co-ordination team as her renal and 
liver function tests were clinically normal however one of the parameters in the liver 
function tests was out of range (result: 34U/L, range: 35 – 105 U/L) and therefore 
according to the eligibility criteria of the original protocol she was not actually 
eligible although her results were actually better than the normal range. Details of 
this withdrawal, the trial suspension and the substantial amendment submitted to 
the REC and MHRA and are detailed in chapter 6. 
 
7.1.4	WITHDRAWALS	AFTER	RANDOMISATION	
There were five participants who were withdrawn after randomisation. The first 
participant was withdrawn in concordance with the trial suspension as she was 
considered not actually eligible for the trial on the basis of her renal function test 
(result: urea 2.3 mmol/L, range 2.5 – 7.8mmol/L). Again, her results were better 
than the normal range. Details of the trial suspension and her withdrawal can be 
found in chapter six. 
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There were two participants who became pregnant after randomisation while taking 
trial medication and were therefore withdrawn. Both of these participants conceived 
in the cycle after the initial biopsy in the first month of taking medication. They both 
stopped taking the medication immediately and arranged a follow up visit at the 
research unit as soon as possible. 
Both of these patients have been followed up every three months as per the 
sponsors risk assessment protocol. I am pleased to report that one of them has 
given birth to a healthy baby.  
There was one participant who was withdrawn by the trial co-ordination team. She 
did not attend for her scheduled follow up appointment one month after the biopsy. 
After repeated attempts to email and telephone the participant she was withdrawn 
due to non-compliance with the trial pathway. These follow up appointments were a 
fundamental part of the trial pathway to assess for any side effects to the 
medication, exclude pregnancy and also to issue the next months’ supply of 
medication. We did find out over one month after her follow up was due that she 
had not attended and changed her home and mobile phone number due to 
personal reasons. 
There was one participant who withdrew the day the endometrial biopsy was taken. 
When she received the treatment pack and realised that the medication was in 
capsule form she questioned the presence of gelatine in the capsule. We confirmed 
the ingredients did actually include gelatine and so for religious reasons the 
participant decided to withdraw herself from the study before any medication was 
taken.  
 
7.2 ENROLMENT PROCEDURE 
 
Once patients who had been invited to participate had sufficient time to read the 
information and make a decision about enrolment an appointment was made with 
me at the research unit to confirm eligibility and sign consent forms.   
As this was a Clinical Trial of an Investigational Medicinal Product (CTIMP), 
consent had to be taken by a doctor. I consented all participants for the trial myself.  
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There were 39 participants who consented to take part in the study. Once consent 
forms were signed, participants were given an ovulation kit, barrier contraception 
and contact details to get in touch once ovulation had occurred. It was emphasised 
that they must not have had unprotected intercourse in the cycle leading up to the 
biopsy.  
	
7.3 INTERVENTION VISIT 
 
Consented participants would then email me once they had a positive ovulation 
test. The intervention visit would then be planned for 7-10 days after ovulation, 
during the implantation window, when the endometrium is receptive to the 
implanting embryo.  
The first participant attended for the endometrial biopsy and randomisation on the 
16th September 2016. In total there were 35 participants who attended for the initial 
intervention visit and were randomised. 
This intervention visit had to be arranged at a time to suit the patient, the laboratory 
team, pharmacy team and the randomisation team. Participants were warned 
beforehand that the endometrial biopsy may cause some pelvic pain and cramps 
due to uterine contractions. I advised them to take 400mg of ibuprofen and 1g of 
paracetamol prior to their visit.  
At the intervention visit consent would be confirmed. Then, a pregnancy test would 
be undertaken and it would be confirmed that no unprotected intercourse had 
occurred in the month leading up to the visit.  
The participant would be asked to empty their bladder before a pelvic ultrasound 
scan was performed. Patients with RPL are all familiar with transvaginal scans from 
previous pregnancies. During the pelvic ultrasound I was able to assess the 
endometrial thickness and also the axis of the uterus. The scan provided me with 
the location of the endometrial cavity relative to the cervix so that the biopsy could 
be obtained as quickly and easily as possible to reduce patient discomfort. 
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I would then discuss what to expect from the procedure. I always explained that the 
first part of the procedure was similar to a smear test in that they would be in the 
same position and a speculum would be inserted. The aim of this explanation was 
to help normalise the procedure to help reduce the anxiety associated with having 
this intrusive test performed. 
I would explain that a small catheter would be inserted through the neck of the 
womb into the uterus to take the biopsy and induce a wound healing response and 
that once the catheter was inside the uterus I would count back from 10 to 1 and 
although the procedure may cause some period-like cramps it is quite quick. 
Participants were always informed that the procedure could be stopped at any point 
they felt necessary. Entonox was available to use when the biopsy was being 
taken. 
Taking the endometrial biopsy involved inserting a Cusco’s speculum into the 
vagina to visualise the cervix. The cervix was then cleaned with a cotton tip dipped 
in normal saline. A Wallach Endocell sampler was used to take the biopsy. This is a 
simple manual suction device commonly used in gynaecology clinics used to 
screen for carcinoma, pre-cancerous conditions and menstrual disorders. It is 
mouldable for easy insertion into an acutely anteverted or acutely retroverted 
uterus. No cervical dilatation is required. It provides excellent suction by elastomeric 
seal piston plunger. The sampler is inserted through the cervix into the uterus to 
take the endometrial biopsy.   
A research fellow from the laboratory was always present at the time of taking a 
sample so that there was minimal but consistent time taken in the transport of the 
sample from the participant to its initial processing.  
 
7.4 BIOPSY TRANSPORTATION AND 
CRYOPRESERVATION 
 
A member of the laboratory team present at the time of the biopsy would take the 
biopsy to the clinical sciences research laboratory for immediate preparation and 
cryopreservation.  
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The time the biopsy was taken and the time it was stored for cryopreservation was 
recorded in the laboratory data tracker. 
The average time from collection of the biopsy to cryopreservation was 114.3 
minutes (range 105 – 120 minutes). 
	
7.5 RANDOMISATION 
Once the biopsy was taken and transported to the laboratory for initial processing, 
randomisation was performed.  
This involved a phone call to the randomisation team in RD&I where consent and 
eligibility criteria were checked again before the participant was allocated three 
pack numbers, each containing one months’ supply of medication. These three 
pack numbers were documented on the case report form.  
A prescription for the first pack was completed, signed and sent to pharmacy. In 
pharmacy, the prescription and medication was checked by two pharmacists before 
it was made ready for collection. 
The participant was then given the treatment pack which came as a bottle, along 
with: 
1. A pregnancy test to complete in two weeks at home 
2. A symptom diary 
3. An emergency contact card.  
4. Barrier contraception 
5. A follow up appointment in 4 weeks +/- 4 days 
In total, 35 patients were randomised. Randomised participants would then be 
added onto the recruitment log (Appendix 15). 
I would then send the letter approved by the REC and HRA to the G.P informing 
them of participation in the trial and the possibility of the participant being on 
Sitagliptin.  
 
 
	 140	
7.6 FOLLOW UP VISIT 1 
 
At 4 weeks +/- 4 days the participant would attend for a follow up visit. The 
symptom diary would be collected and reviewed. Any adverse events would be 
reported to the sponsor and a pregnancy test would be completed.   
I would confirm that no new medication had been started, there was no change in 
medical history, there were no concerning adverse events and the participant was 
happy to continue in the trial.  
Safety of continuing in the trial would be confirmed before another prescription for 
the next pack number assigned to the participant would be completed. Medication 
for the following month would be issued.  
Participants would also be given another symptom diary for the next month and 
another pregnancy test to complete in two weeks at home. Further barrier 
contraception would be given to couples. 
The five participant withdrawals after randomisation all occurred within the first 
month of treatment after the baseline endometrial biopsy. Therefore, there were 30 
participants in total who attended the first follow up visit.  
	
7.7 FOLLOW UP VISIT 2 
 
At 4 weeks +/- 4 days, participants would attend for a second follow up visit. Once 
again, the symptom diary would be collected and reviewed, any adverse events 
would be reported to the sponsor, a pregnancy test would be completed and safety 
of continuing in the trial would be confirmed. 
At this 2nd follow up visit, the 3rd month of medication would be issued. A pregnancy 
test would be issued to be completed two weeks later at home.  
This time, participants would also be issued an ovulation kit to plan for the second 
endometrial biopsy to mark the end of the trial. 
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Participants would email me directly at simplant@uhcw.nhs.uk once their ovulation 
test was positive and a second endometrial biopsy was arranged for 7-10 days 
later, again after liaising with the laboratory team for availability. 
 
7.8 INTERVENTION VISIT 2 
In total, there were 30 participants who attended for the final visit of the trial 
pathway. This visit marked the end of the trial period.  
Symptom diaries were reviewed and any left-over medication was collected and 
sent to pharmacy for accountability and destruction.  
The procedure of this visit was exactly the same as the first intervention visit where 
patients would have a pregnancy test before proceeding to a pelvic ultrasound scan 
and endometrial biopsy. 
Participants were given a questionnaire to fill in about their experience of being in a 
clinical trial. 
Follow up after the second biopsy was part of standard clinical care. Patients who 
become pregnant after having been seen in the recurrent miscarriage clinic or 
implantation clinic routinely get regular early pregnancy scans from six weeks’ 
gestation. 
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CHAPTER	8:	STATISTICAL	ANALYSIS	PLAN	
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8.1 STATISTICAL ANALYSIS PLAN 
8.1.1	CONSORT	DIAGRAM	
We summarised the patient pathway using a consort diagram adapted from the 
consort-statement.org. The consort diagram can be found at the start of the results 
chapter. 
The whole study team and myself were blinded to treatment allocation when results 
were analysed.  
All participants in one treatment arm were labelled as Group 0 and all participants in 
the other treatment arm were labelled as Group 1. This is also reflected in the 
consort diagram at the start of the results chapter. 
8.1.2	CLONOGENIC	ASSAY	
When performing the clonogenic assays we performed the stem cell count for each 
participant in 3 wells to ensure there is uniformity across the sample and results 
were replicable.  
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The table below shows an example of results for two participants.  
• RX has a count of 8, 6, 6 colonies in each well per 500 endometrial stromal 
cells in the baseline biopsy and a count of 8, 5, 15 colonies per 500 
endometrial stromal cells in the final biopsy 
 
RXx has a count of 8, 5, 3 colonies in each well per 500 endometrial stromal 
cells in the baseline biopsy and a count of 8, 5, 15 colonies per 500 
endometrial stromal cells in the final biopsy.	
 
RID 
 Well 1a 
500 cells 
 Well 2a 
500 cells 
 Well 3a 
500cells 
sumA/ 
1500cells 
well 1b 
500 
cells 
well 2b 
500 
cells 
well 3b 
500 
cells 
SumB/ 
1500 cells 
RX 8 6 6 20 8 5 15 28 
RXx 8 5 3 16 3 6 4 13 
 
 
We decided to take the sum of the colonies in all 3 wells to get a colony count per 
1500 endometrial stromal cells rather than an overage of all three wells so that we 
were able to include all results obtained. It is biologically plausible that one well 
from the same sample could contain a different number of clonogenic cells to 
another and so, at a meeting with the investigators and the statistician it was 
decided not to exclude outliers.  
Exclusion of outlying assay results when the assay is done in triplicate is standard 
laboratory practise when there is a large sample size as the variability can be 
explained by laboratory error.    
Therefore, through the results chapter, the endometrial mesenchymal stem cell 
count (eMSC count) is a calculated as a count of the colonies of stem cells grown 
per 1500 endometrial stromal cells. 
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8.1.3	PATIENT	DEMOGRAPHICS	
Continuous and ordinal characteristics were summarised using the mean, median, 
standard deviation (sd), interquartile range (IQR) and range. Categorical 
characteristics were summarised using the count and equivalent percentage.  
Demographic data compared between treatment groups included 
• Age 
• Baseline eMSC count 
• Number of previous miscarriages 
• Body Mass Index 
• Surgical Management of Miscarriage in the past (ERPC) 
All characteristics between the two treatment groups were compared using the 
Mann Whitney U test. 
Any statistically significant difference between the two treatment groups was 
accounted for in the secondary data analysis when fitting the adjusted Poisson 
Regression Model. 
As discussed in chapter one, Asherman’s syndrome and/or intrauterine adhesions 
from repeated evacuation of retained products of conception (ERPC) has been 
linked to RPL. I wanted to ensure there was no difference in the number of ERPC’s 
performed between the two treatment groups.  
 
8.1.4	eMSC	COUNTS	
Our primary outcome measure as outlined in the trial protocol was the eMSC count 
after three months of Sitagliptin versus three months of placebo determined by a 
clonogenic assay.  We fitted a Poisson model to compare the eMSC counts in the 
two treatment groups at three months. The only predictor in the model was the 
intervention group allocation. 
Although we have 30 participants who successfully completed the study we have 
29 complete clonogenic assays from the set of initial (baseline) endometrial 
biopsies. This is because we have one sample which could not be analysed due to 
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heavy yeast contamination which prevent the stem cell growth hand colony 
formation.  
Also, we have 29 results in the set of 30 final endometrial biopsies. Again, there is 
one sample with heavy yeast contamination and so stem cell colonies could not be 
counted.	
 
8.2 PRIMARY OUTCOME MEASURE 
 
Our primary end point as outlined in the trial protocol was the eMSC count after 3 
months of Sitagliptin versus 3 months of placebo assessed by a clonogenic assay.  
 
8.3 SECONDARY OUTCOME MEASURES 
 
We have used a Fisher’s Exact Test to assess the significance of difference in 
reports of adverse events between the two groups.  
The questionnaire results have been expressed as ratios and comments received 
by participants have been reviewed to evaluate any concerns with tolerability of the 
study medication and also the acceptability of the study. 
8.4 OTHER DATA ANALYSIS 
We were also interested in evaluating the increase in the eMSC count from the 
baseline biopsy to the final biopsy between the two groups and so we needed a 
model which allowed for this.  
Although there was not a significant difference in the baseline eMSC count between 
group 0 and group 1, the mean baseline count for group 0 was higher than group 1 
and so we wanted to fit a model that adjusts for this as well.  
Also, there were some participants whose eMSC count changed from one colony in 
the first (baseline) biopsy to three colonies in the final biopsy. This is a higher 
relative rise than for those whose count changed from 20 in the first (baseline) 
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biopsy to 28 in the final biopsy. 
The Poisson regression model analysed the baseline eMSC and the final eMSC as 
the dependent variable, and age, intervention group, time (baseline/final biopsy) 
and an interaction term for each group and time.  
The interaction term was included to allow for the different gradients between the 
baseline and final biopsy in each group and also to allow for the possibility of 
different magnitudes of difference in the eMSC count between each group firstly at 
the baseline biopsy and then at the final biopsy. 
To adjust for the fact that a woman’s baseline and final biopsy are likely to be 
corrected, we included a random effects term; a random effects Poisson regression 
model. 
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CHAPTER	9:	RESULTS	
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9.1 CONSORT DIAGRAM 
In the 30 participants who completed the trial, despite five withdrawals, there was 
equal randomisation among the two groups with 15 participants randomly allocated 
to Group 0 and 15 participants randomly allocated to Group 1. 
Figure 9.0.1: Trial Consort Diagram 
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9.2 RECRUITMENT  
	
Figure 9.0.2: Monthly Recruitment Chart 
	
	
	
	
FIGURE 9.0.3: Cumulative Recruitment Chart 
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The cumulative chart in figure 9.0.3 shows a steady rate of recruitment over 12 
months. The monthly recruitment chart in figure 9.0.2 highlights the decrease in 
recruitment during November and December due to the trial suspension. There 
were no participants randomised in May but screening and consent occurred which 
is then reflected in improved recruitment from June to August 2017. 
9.3 PATIENT DEMOGRAPHICS 
Table	9.0.1	summarises	the	age,	baseline	eMSC	count,	number	of	first	trimester	
miscarriages,	BMI	and	number	of	ERPC’s	between	group	0	and	group	1.		
TABLE 9.0.1: Table of Patient Demographics 
	
Characteristic  
 
All women  
(n=30), n(%) 
Group 0 
(n=15), n(%) 
Group 1 
(n=15), n(%) 
P-
value† 
Age, Years 
Mean (Sd) 
Median (IQR) 
Range 
 
32.90 (4.47) 
33.00 (29.75 – 37.00) 
24 - 40 
 
31.30 (4.0) 
32 (28.0- 34.0) 
24 - 37 
 
34.5 (4.4) 
36 (31.0 – 38.0) 
26 - 40 
 
0.037 
 
Baseline eMSC 
count µ 
Mean (Sd) 
Median (IQR) 
Range 
 
 
20.34 
9.00 (6.0-28.0) 
1 - 77 
 
 
26.64 (26.56) 
15.50 (6.0 – 52.0) 
2 - 78 
 
 
14.47 (19.19) 
8.00 (4.0 –11.0) 
1 - 74 
 
 
 
0.252 
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Number of T1 
miscarriages 
 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
Total 
 
 
 
 
1 (3) 
3 (10) 
5 (17) 
6 (20) 
2 (7) 
5 (17) 
1 (3) 
2 (7) 
1 (3) 
0 (0) 
2 (7) 
1 (3) 
1 (3) 
30 
 
 
 
 
0 (0) 
2 (13.3) 
3 (20) 
3 (20) 
2 (13.3) 
2 (13.3) 
0 (0) 
1 (6.7) 
0 (0) 
0 (0) 
1 (0) 
0 (0) 
1 (6.7) 
15 
 
 
 
 
1 (6.7) 
1 (6.7) 
2 (13.3) 
3 (20.0) 
0 (0) 
3 (20) 
1 (6.7) 
1 (6.7) 
1 (6.7) 
0 (0) 
1 (6.7) 
1 (6.7) 
0 (0) 
15 
 
 
 
 
 
 
0.595 
BMI kg/m2 
Mean (Sd) 
Median (IQR) 
Range 
 
26.94 
25.20 (23.72 – 28.88) 
19.5 – 38.4 
 
26.55 (4.76) 
25.6 (23.20 – 28.20) 
21.1 – 38.4 
 
27.33 
27. 40 (23.90 -30.50) 
19.5 – 35.7 
 
 
0.412 
 
Number of 
ERPC’s 
 
0 
1 
2 
3 
4 
5 
 
 
 
14 (47) 
2 (7) 
7 (23) 
3 (10) 
2 (7) 
2 (7) 
 
 
 
7 (46.7) 
2 (13.3) 
4 (26.7) 
2 (13.3) 
0 (0) 
0 (0) 
 
 
 
7 (46.7) 
0 (0) 
3 (20.0) 
1(6.7) 
2 (13.3) 
2 (13.3) 
 
 
 
 
 
 
0.436 
† The p-value compares groups 0 and 1 using the Mann Whitney U test. 
µ eMSC count in Group 0 (n = 14), eMSC count in Group 1(n = 15) 
	
We can see that overall participants in Group 1 seemed generally older than group 
0. The mean age in group 0 was 31.3 and the mean age in group 1 was 34.5. The 
difference in age between the two groups was statistically significant (p = 0.037). 
Our calculations showed a statistically significant difference in the age of 
participants between Group 0 and Group 1 and therefore this needed to be 
adjusted for in our analyses.  
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The difference in the baseline eMSC count was not statistically significant (p=0.252) 
between the two groups and therefore these results show that both groups were 
balanced in terms of the baseline eMSC count.  
The mean number of first trimester miscarriages among the whole patient cohort 
was 6.5 miscarriages (sd=3.16, range 2 – 12). There were five participants who had 
suffered over 10 first trimester miscarriages.  
In group 0 there was one participant who suffered 14 first trimester miscarriages. In 
group 1 there was one participant who suffered 13 first trimester miscarriages. 
In group 0, 40% of participants suffered six or more miscarriages. In group 1, 54% 
of participants suffered 6 or more miscarriages. 
The difference in the number of miscarriages between the two groups was not 
significant (p=0.595), which means that both the control (placebo) and intervention 
(Sitagliptin) groups were balanced for the number of first trimester miscarriages.  
The overall mean BMI in the whole patient cohort was 26.9kg/m2 which is 
considered overweight by international standards of BMI calculation. 
The mean BMI for group 0 was 26.55 (range 21.1 – 38.4) and the mean BMI for 
group 1 was 27.33 (range 19.5 – 35.7). The difference in the BMI values between 
the two groups is not statistically significant (p=0.412). This tells us that although 
the patient cohort was generally in the overweight category, the mean BMI was 
overall balanced between the two groups. 
There was a non-significant difference (p=0.436) in the number of ERPC’s 
performed in both group 0 and group 1. 	
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9.4 DISTRIBUTION OF MISCARRIAGES IN EACH GROUP 
	
Figure 9.0.4 below complements table 9.0.1 to show the number of women and the 
number of miscarriages they suffered between each treatment group. 
FIGURE 9.0.4: Distribution of T1 Miscarriages in Each Treatment Group 
	
	
FIGURE 9.0.5: Distribution of T1 Miscarriage in Each Treatment Group 
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9.5 RELATIONSHIP BETWEEN PATIENT 
DEMOGRAPHICS AND INITIAL EMSC COUNT 
	
9.5.1	AGE	AND	eMSC	COUNT	
The scatter graph in figure 9.0.6 shows that there was no relationship between age 
and the initial eMSC count over the whole participant cohort. 
FIGURE 9.0.6: Scatter Graph of the Relationship between Age and Initial eMSC Count 
	
	
9.5.2	BMI	AND	eMSC	COUNT	
The scatter graph in figure 9.0.7 shows that there was no relationship between BMI 
and the initial eMSC count over the whole participant cohort. 
FIGURE 9.0.7: Scatter Graph Showing the Relationship Between BMI and Initial eMSC 
Count 
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9.5.3	NUMBER	OF	T1	MISCARRIAGES	AND	eMSC	COUNT	
The scatter graph in figure 9.0.8 shows that there is no relationship between the 
baseline eMSC count and the number of T1 miscarriages.  
Figure 9.0.8: Scatter Graph Showing the Relationship Between T1 Miscarriages and eMSC 
Count 
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9.6 THE EMSC COUNT PROFILES 
 
Figure 9.0.9: eMSC Count Profile in Each Treatment Group 
	
	
 
	
Figure 9.0.9 show the profiles of eMSC counts between the initial baseline biopsy 
(Biopsy 1) and the final biopsy (Biopsy 2) for each participant in the two groups.  
The beginning of each coloured line represents the baseline initial eMSC count and 
the end point of the line represents the final eMSC count for each participant 
separately. 
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9.7 PRIMARY ANALYSIS (UNADJUSTED ANALYSIS) 
Table 9.0.2: Estimated Mean eMSC Count At Final Biopsy Between The Two Treatment 
Groups 
Group Estimated mean 
eMSC count at 
final biopsy   
(month 3) 
Difference P=Value 
0 3.30 0.0026 0.971 
1 3.30 
 
Table 9.0.2 shows the mean count at the final biopsy for each group using a 
Poisson regression model which takes into account that the data is not normally 
distributed.  
This analysis does not account for variables such as the mean age difference in the 
two groups and does not tell us the change in eMSC count compared to the 
baseline biopsy, which is relative.  
Using a Poisson model that compares the final eMSC count between groups 0 and 
1, the mean eMSC count for Group 0 is 3.30 and the mean for Group 1 is 3.30 
(rounded to 2 decimal places).   
The difference in the mean count at the final biopsy between the two groups (mean 
of group 1 – mean group 0) is 0.0026 (95% CI -0.1376 to 0.1427). This difference is 
not statistically significant (p=0.971).  
 
 
 
 
 
 
 
	 159	
9.8 SECONDARY ANALYSIS (ADJUSTED ANALYSIS) 
Table 9.0.3 gives an estimate of the difference in mean eMSC at baseline between 
the two groups (Row 1) and an estimate of the difference in the mean eMSC at the 
final biopsy between the two groups (Row 2).  It also gives an estimate of the 
difference in the mean eMSC between the final biopsy and the baseline biopsy in 
each treatment group separately (Row 3 and Row 4).  
TABLE 9.0.3: Adjusted Analysis of eMSC Counts Between Baseline and Final Biopsy and 
Between Both Treatment Groups 
Row Effect Difference  
Estimate (95% 
CI) 
P-value 
1 Month 1 (Baseline biopsy) 
Group 1- Group 0 
-0.72 (-1.52, 0.0870) 0.071 
2 Month 3 (Final biopsy) 
Group 1 – Group 0 
-0.17 (-0.9709, 
0.6239) 
0.660 
3 Group 0 
Month 3 – Month 1 
0.06(-0.0775, 
0.2051) 
0.3750 
4 Group 1 
Month 3 – Month 1 
0.61 (0.4375, 0.7761) <0.001 
 
Row 1 gives an estimate of the difference in the mean eMSC count between groups 
0 and 1 at baseline. The difference is -0.72 (Group 1 – Group 0) (95% CI -1.52, 
0.09), which is almost one extra colony of stem cells in group 0 at baseline than 
group 1. Participants in Group 0 were also on average older than Group 1. Although 
the difference is not statistically significant the p-value is small (p=0.071) and the 
confidence interval varies from -1.52 to 0.08 suggesting a tread towards a 
difference. These results reflect the profiles in figure 9.0.9 where the groups did not 
seem well balanced at the baseline biopsy. 
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9.8.1	PRIMARY	OUTCOME	MEASURE	
Row 2 gives an estimate of the difference in mean eMSC count between groups 0 
and 1 at the final biopsy (month three). This is effectively our primary outcome 
measure; the stem cell count after three months.  
The difference between the two groups is - 0.17 (Group 1 – Group 0) which is small 
and not statistically significant (p=0.660).  
The results reflect the profiles in Figure 9.0.9, where the eMSC count at 3 months 
for the two groups overall seemed similar.  
The unadjusted analysis revealed the mean difference in the eMSC count between 
the two groups at the final biopsy to be 0.0026 (p=0.971). The adjusted and 
unadjusted analyses were different as we adjusted for the difference in age and the 
baseline eMSC count between the two groups.  
 
9.8.2	OTHER	RESULTS	
Although there was no significant difference in the eMSC count after three months 
between Group 0 and Group 1 there are some other interesting results. 
We looked at the difference in the eMSC count between the initial and final biopsy 
between the two treatment groups.  
Row 3 of Table 9.0.3 gives an estimate of the difference in the mean eMSC count 
between the baseline and final biopsy in group 0. The difference is 0.06 (month 3 – 
month 1) which is very small and not statistically significant (p=0.370).  
These results again are reflected in the profiles in 9.0.10 where it can be seen that 
there were only very few participants in this group who appeared to have a large 
change in the eMSC count between the baseline and final biopsy. 
Row 4 gives an estimate of the difference in the mean eMSC count between the 
final and baseline biopsy in group 1. The difference is 0.61 (month 3 – month 1) 
which is 10 times higher than the change in group 0.  The difference in group 1 is 
highly statistically significant (p = <0.001) and the confidence interval is narrow.  
This significant result for participants in group 1 may indicate a therapeutic target. 
This difference of nearly one colony per 1500 cells is biological significant. This is 
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because each colony contains in the region of 100-1000 cells that have originated 
from one cell in just the 10 days of the assay. If this is viewed in the context of the 
whole endometrium with millions of cells, one extra stem cell colony with the ability 
to reproduce exponentially and rapidly per 1500 cells would translate to thousands 
of additional colonies each able to make thousands more cells. Hence one extra 
stem cell-forming colony per 1500 cells could make a large biological difference to 
endometrial regeneration.  
Figure 9.0.10: Graphical Representation Of Adjusted Secondary Analysis 
(Expected profiles for women of 33 years (median age in the whole cohort) in 
groups 0 and 1)	
 
	
 
The graph in figure 9.0.10 represents the information in the table of results from the 
adjusted secondary analysis.  
The final eMSC count in group 0 and group 1 was not significantly different. The 
null hypothesis is therefore correct. 
eM
SC
 c
ou
nt
Biopsy 1 Biopsy 2
0
0.
25
0.
5
0.
75
1
1.
25
1.
5
1.
75
2
2.
25
2.
5
2.
75
3
Expected counts for woman of 33 years in group 0
Expected counts for woman of 33 years in group 1
	 162	
Other observations were that there is a higher baseline mean count in group 0 than 
group 1, Group 0 did not have a statistically significant increase in the eMSC count 
between the baseline and the final biopsy and Group 1 had a statistically significant 
increase in the eMSC count between the baseline and final biopsy.  
	
9.9 SECONDARY OUTCOME MEASURES 
	
9.9.1	ADVERSE	EVENTS	AND	SIDE	EFFECTS	
Table 9.0.4: Adverse Effects and Side Effects in Each Treatment Group 
Adverse	event/Side	Effect	 Group	0	
n=	15	
Events	(participants,	%)	
Group	1	
n	=	15	
Events	(participants,%)	
Headache	 26	events	(7	participants,	47%)	 7	(	3	participants,	20%)	
Dizziness	 0	 1	
Nausea	 0	 0	
Thirst	 0	 1	
Myalgia	 1	 1	
Diarrhoea	 2	(2	participants)	 0	
Dry	mouth	 1	 1	
Rash	 2	(1	participant)	 0	
Chills	 1	 1	
Night	sweats	 0	 1	
Mouth	ulcers	 2	(1	participant)	 0	
Nose	bleed	 1	 0	
UTI	 0	 1	
 
Reported adverse reactions related to Sitagliptin which occur in >5% of patients 
include symptoms of an upper respiratory tract infection, nasopharyngitis and 
headache.  In our study there were 7 participants (47%) who suffered with at least 
one headache in the three-month period in Group 0 and 3 participants (20%) in 
Group 1 who suffered with at least one headache in the three-month period. 
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Using the Fisher’s Exact Test, the difference in participants experiencing 
headaches between the two groups is not significant (p = 0.245).  
All other adverse events occurred in a maximum of one participant in one group. 
There was one participant who suffered with diarrhoea once and mouth ulcers on 
twice.  
 
9.10 QUESTIONNAIRE 
	
9.10.1	STUDY	ACCEPTABILITY	
We received 29 questionnaires of the 30 participants who completed the study 
(97% return rate).  
Participants did not always answer all parts of the questionnaire and so 
percentages in table 9.0.5 are displayed in a ratio of how many responses we 
received for each question. 
We assessed acceptability of the study with the following questions:  
1. I found taking part in this study a worthwhile experience 
2. Given the choice, I would like to continue taking part in this study 
3. I would recommend taking part in the study to others 
4. I found taking part in the study supportive to my care 
5. I would be open to taking part in other research studies 
The aim of these questions was to assess if participants had a positive experience 
and would recommend this to family and friends. If participants had a positive 
experience they are more likely to continue, recommend it to others and be open to 
taking part in other research studies.  
Participants were asked to use a scale to answer the questions 
• 5 = Strongly agree 
• 4 = Agree 
• 3 = Neither agree/disagree 
• 2 = Disagree 
• 1 = Strongly disagree	
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The overall results of the questionnaire are displayed in Table 9.0.5 
Table 9.0.5: Questionnaire Results 
 Strongly 
Agree 
n (%) 
Agree 
 
n (%) 
Neither 
Agree or 
Disagree 
n (%) 
Disagree 
n (%) 
Strongly 
Disagree 
n (%) 
I found taking part in this study 
a worthwhile experience 
26 (93) 2 (7) 0 (0) 0 (0) 0 (0) 
Given the choice, I would like 
to continue taking part in this 
study 
22 (79) 3 (11) 1 (4) 2 (7) 0 
I would recommend taking part 
in the study to others 
27 (93) 
 
2 (7) 
 
0 (0) 0 (0) 0 (0) 
I found taking part in the study 
supportive to my care 
27 (93) 
 
2 (7) 0 (0) 0 (0) 0 (0) 
I would be open to taking part 
in other research studies 
21 (72) 5 (17) 2 (7) 1 (3) 
 
0 (0) 
 
26 of 28 participants found taking part in the study worthwhile and 27 of 29 
participants would recommend the study to others and felt well supported.  
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9.10.2	STUDY	MEDICATION	ACCEPTABILITY		
There were three questions on the questionnaire related to study medication. The 
results of these are displayed in table 9.0.6 
Table 9.0.6: Study Medication Acceptability 	
 Strongly 
Agree 
n(%) 
Agree 
 
n(%) 
Neither 
Agree or 
Disagree 
n(%) 
Disagree 
n(%) 
Strongly 
Disagree 
n(%) 
Medication was easy to take 25 (86) 3 (10) 0 (0) 0 (0) 1 (3) 
Side effects of the medication 
were easy to manage 
22 (81) 2 (7) 2 (7) 1 (4) 0 (0) 
 
Table 9.0.7: Study Medication Acceptability and Compliance 
 Often Sometimes Rarely 
n(%) 
Never 
n(%) 
I forgot to take the study medication 0 0 5 (18) 23 (82) 
 
96% of participants strongly agreed or agreed that the medication was easy to take 
and 88% either strongly agreed or agreed that the side effects were easy to 
manage.  
Even though we do not have responses from two participants we can see that at 
least 23 of the 30 participants never forgot to take the study medication. 
 
9.10.3	ACCEPTABILITY	OF	PARTICIPANT	INFORMATION	LEAFLET	
All the 29 participants who returned the questionnaire reported that the participant 
information leaflet described the study clearly. There were no extra comments in 
the free space regarding the information leaflet.  
 
9.10.4	CARE	RECEIVED	BY	RESEARCH	TEAM	
We asked participants if they felt the hospital visits within the study supportive to 
their care and if they were able to contact the research team when needed. 28 of 
the 29 participants found the hospital follow up visits supportive to their care and 
were able to contact the research team easily. 
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28 of the 29 participants reported no problems with booking their appointments for 
the biopsy visits or the follow up visits. One participant had trouble booking her 
second biopsy appointment due to work commitments, living very far away and also 
having a narrow window of when the appointment could be made (7-10 days post 
ovulation). 
 
9.10.5	IMPROVING	CARE	
As part of the questionnaire we asked participants if they felt any part of their 
journey could have been improved.  
• There were six participants who answered ‘no’ to this question with no other 
comments. All other comments are listed here: 
• No the team were amazing in every way 
• No, been really helpful and friendly 
• None whatsoever! 
• No it was explained well to me and I was supported throughout 
• More local clinics 
• Was very well organised 
• Not having to attend for the monthly visits or doing it over the phone, but I 
understand the necessity. 
• It would have been good to see the same midwife/nurse each time. 
• None - although it would be good to receive updates on the research in an 
email post completion of my involvement in the study. 
• All the staff were lovely and very supportive. I quite enjoyed the experience. 
• Everyone was really fantastic! 
• Fantastic service 
• No! Husband just said dedicated parking 
• No - felt very looked after	
We also gave free space for participants to leave any other comments. The 
comments we received were: 
• Could not thank the team enough for all the care and support. It's been so 
exciting to be part of this trial. Made even better by Dr. Tewary and Angela 
Polanco, they have been amazing. 
• The first time I have felt cared for within the NHS is with your staff - A* 
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• Dr Tewary was very accommodating. Very lovely team & always friendly. 
• I felt supported every step of the way. Contacting the doctor was easy with 
both phone numbers and email addresses. All my questions and worries 
were answered and reassured. 
• It was very helpful to be able to email staff rather than phone because of my 
work. 
• Thank you for the opportunity and looking after us! 
• I found everyone very helpful and supportive, thank you 
• The team are amazing and very supportive 
• The whole team were very supportive & friendly - making the whole 
experience so much easier. 
• Everyone we have dealt with have been incredible! Thank you 
• Everyone involved were so supportive and empathetic 
• Fantastic supportive care 
• Staff were incredibly supportive and took time to talk things through with me 
• The team and Shreeya were flexible for our visits from West Wales 
• The team and staff have been very supportive and professional. Thank you. 
• Parking is a problem at the hospital, meaning participation took longer than 
anticipated and I had to leave plenty of time in advance to get to the hospital 
to park the car in order not to be late to the appointment. 
• Everyone made me feel very relaxed every time I came to my appointments. 
• Thank you for your support throughout. 
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CHAPTER	10:		DISCUSSION	
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10.1 RECURRENT MISCARRIAGE 
 
Miscarriage is the most common complication of pregnancy. RPL is considered a 
distinct  and unique disorder affecting 1-5% of couples (Ford & Schust, 2009).  
Chapter one gives some insight into the difficulties we face giving couples with RPL 
a real cause and a prevention strategy. And ultimately, after dealing with the 
emotional, psychological and physical morbidity of a miscarriage, an explanation is 
most important to couples to help them move forward.  
Risk factors such as maternal age, obesity, smoking and reproductive history have 
been shown to be associated with RPL (ESHRE, 2017). We spend time in clinic 
counselling couples about weight loss, reducing smoking and alcohol consumption 
which is which very important to reduce risks to health in general but also to reduce 
the risk of obstetric complications. There have not been any well conducted trials 
demonstrating that these health care interventions prevent miscarriage as these 
trials would incur ethical and feasibility problems. 
Medical co-morbidities such as endocrine, haematological, cardiovascular and 
immunological disorders have all been associated with RPL. In line with pre-
pregnancy counselling, thyroid disorders, diabetic and hypertensive management 
are optimised to improve pregnancy outcomes, one of which is miscarriage.  
Despite many randomised controlled trials looking into causes and treatment of 
RPL, the only treatment with demonstrated significant efficacy for the prevention of 
RPL is heparin and aspirin for those women with APLS (Empson et al., 2005). 
Others are categorised as ‘unexplained RPL’. Understandably, this is generally not 
acceptable to them and so most couples are willing to consider research projects in 
the hope that experimental treatment may help them. 
There is emerging evidence that the human endometrium plays an important role in 
determining the success of implantation. There have already been huge advances 
in the research into this paradigm.  
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10.2 THE ENDOMETRIUM AND RECURRENT 
MISCARRIAGE 
 
The human endometrium is one of the most unique and dynamic tissues in the 
body (Du & Taylor, 2009). It is able to prepare for potential pregnancy, is shed and 
then regenerates every month in response to hormonal signalling and does so 
approximately 400 times in a woman’s lifetime (Mutlu et al., 2015). 
Decidualisation of the endometrium is vital for successful pregnancy (Salker et al., 
2010). When the endometrium has been appropriately decidualised it responds to 
embryonic signals and leads to positive or negative selection of the embryo. There 
is parallel but mutual signalling between endometrium and the embryo where 
selectivity and receptivity of the endometrium is defined. Decidualisation is known 
to be dysfunctional in those with RPL. Low levels of endometrial mesenchymal 
stem cells, cellular senescence and disordered inflammation all contribute to 
abnormal decidualisation (Lucas et al., 2016b). Abnormal decidualisation results in 
the loss of a selectivity checkpoint, resulting in the endometrium being excessively 
permissive to implantation but unable to sustain the pregnancy (Gellersen & 
Brosens, 2014; Macklon & Brosens, 2014).  For patients, this means the exposure 
to repeated miscarriage which comes with significant psychological, emotional and 
physical morbidity.  Endometrial mesenchymal stem cell deficiency contributing to 
abnormal decidualisation was the focus point of this research project. 
There have already been huge advances in research into endometrial 
mesenchymal stem cells, their origin and their therapeutic use in the last 10 years. 
Du et al have demonstrated that ischaemia/reperfusion injuries in the uterus 
promote bone marrow derived stem cells to migrate to that area of injury (Du et al., 
2012). There have been alternate hypotheses about endometrial stem cells residing 
in the basal layer of the endometrium which are activated in response to certain 
signals and released at the time of menstruation or when injury occurs leading to a 
regenerated functionalis layer with a new niche of eMSC’s(Gargett et al., 2009).   
Endometrial stem cell therapy has already proven to be an exciting venture. For 
example, Bone marrow derived eMSC’s have been used to treat Asherman’s 
syndrome in mice studies. Asherman’s syndrome was mimicked in a mouse model 
and a Y+ bone marrow transplant was performed. Not only were Y+ cells detected 
at the endometrium but conception rates also improved (Alawadhi et al., 2014). This 
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study suggested that after endometrial injury, bone marrow derived stem cells not 
only migrate to the endometrium but also improve fertility. In humans, bone-marrow 
derived stem cells have been directly injected into the uterine artery leading to 
successful pregnancies (Santamaria et al., 2016). However, isolating mesenchymal 
stem cells of sufficient quality to give back to humans is costly and time consuming 
and injecting the uterine artery is invasive and could lead to serious complications.  
Hence, we attempted to increase the natural trafficking of stem cells. We 
investigated a DPP4 inhibitor, that reduces the degradation of CXCL12. Tissue 
injury derived CXCL12 enhances trafficking of stem cells expressing CXCR4 the 
CXCL2 receptor to the site of injury. 
 
10.3 THE SIMPLANT STUDY – SET UP 
 
This feasibility study was the first ever randomised study performed to attempt to 
improve the natural trafficking of bone marrow derived mesenchymal stem cells to 
human endometrium using medication. 
As this was a completely novel concept, the set-up of the study underwent 
extensive scrutiny by the hospital research governance team and sponsor before 
applications could be made to the national REC and MHRA. This was 
understandably necessary to ensure the safety and wellbeing of patients who would 
take part in the trial.  
Also, this was the first time UHCW sponsored an early phase clinical trial of an 
investigational medicinal product (CTIMP).  This meant that the set-up of this study 
was a steep learning curve for the whole team. The study pathway was carefully 
reviewed and we did extensive research into the safety of Sitagliptin in healthy, 
non-diabetic individuals who were at risk of pregnancy while taking medication. We 
had many TMG meeting to finalise plans for robust blinding and randomisation 
methods. These methods were successful because at no point in the study were 
these matters compromised.  
I had to learn about the production and supply of investigational medicinal products 
(IMP) before approaching manufacturers. I learnt that for the manufacture, 
packaging and labelling for any IMP, a Manufacturer/Importer Authorisation (MIA) 
	 172	
license is needed. I contacted many companies about meeting the requirements of 
the study in a specific time frame and at a reasonable cost. The trial pharmacist 
was invaluable in helping to review quotes and agreements to ensure there were no 
hidden costs or concerning features which would not be so obvious to me. 
Sharp Clinical Services provided a good service with timely supply of the IMP and a 
continued point of contact within the company. 
Patient and public involvement was vital for the set-up of the trial. I needed to be 
confident that the trial pathway would be acceptable to the cohort of patients that 
would be approached for the study.  
The trial pathway, the format and content of patient specific documents were 
reviewed by patients and their unreserved critique enabled me to make changes to 
address patient concerns but at the same time encompass GCP requirements.  
As a result, when the trial opened for recruitment I was confident the trial would be 
acceptable to patients with RPL and the documents were comprehensive to patient 
needs. 
 
10.4 THE SIMPLANT STUDY - RECRUITMENT 
 
Patients who see Professor Quenby in the recurrent miscarriage clinic are often at a 
state of despair having been tested for known causes of miscarriage, had 
cytogenetic testing on products of conception and feel disillusioned about where to 
go next.   
Original research had shown that the higher the number of first trimester 
miscarriages the lower the eMSC count. The SIMPLANT study was therefore 
offered to patients with high order first trimester miscarriages as this severe 
phenotype would be likely to have low eMSC’s and therefore potentially benefit 
more if the treatment worked. This is reflected in the average number of 
miscarriages over the whole patient group being 6.5 (sd = 3.16, range 2-12). 
Entering this trial was a big commitment for any patient. They had to effectively 
consent to having two endometrial biopsies, take a capsule every day, attend the 
hospital for regular follow up and avoid pregnancy for three months.  
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Recruitment however, was generally not a problem and the trial was popular with 
couples with severe phenotype despite the multiple clinic visits needed.  We 
managed to recruit all participants within one year, despite the trial being 
suspended for two months.  
Some patients understandably found the prospect of losing three opportunities to 
become pregnant at the cost of taking medication which could be placebo too much 
to accept and therefore declined taking part.   
 
10.5 THE SIMPLANT STUDY: TRIAL MANAGEMENT 
I was supported very well by the chief investigator who was involved with the day to 
day running of the trial. The trial manager was always available to help, to liaise 
with any issues which needed to be addressed with the sponsor and to help with 
daily governance issues. 
10.6 SIMPLANT: RESULTS 
 
Among the 30 participants who completed the study we had equal randomisation to 
each treatment group.  
The five withdrawals all occurred within the first month and no patient was 
withdrawn due to difficulties with tolerating the medication or difficulties accepting 
the study pathway. We did not do an intention to treat analysis as the outcome 
measure was dependant on the participants having a second biopsy and it was not 
appropriate for any of the five withdrawan patients to return for the second biopsy. 
This issue was discussed at the joint DMC/TSC and agreed. 
94% of the endometrial biopsies were taken by myself and 100% were analysed by 
Dr Emma Lucas allowing standardisation in methods of collection and analysis. 
The participants in each group were matched for age, baseline eMSC count, 
number of miscarriages and BMI.  
The results of this feasibility study have shown no significant difference in the 
eMSC count between the intervention group and the placebo group after 3 months 
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of treatment (p=0.660). There are various confounding factors which are discussed 
later in this chapter. 
 
10.7 CHANGE IN eMSC COUNT IN THE INITIAL AND 
FINAL BIOPSY 
In Group 0 there is a non-significant change in the eMSC count between the 
baseline and the final biopsy (p = 0.37). In Group 1 there was a significant increase 
in the eMSC count between the baseline and the final biopsy result.  
The small change in eMSC count seen in Group 0 between the baseline and final 
biopsy may be because the mean eMSC count at baseline in this group was 
actually higher.  
The adjusted Poisson regression model showed that the difference in the eMSC 
count between the two groups at baseline was 0.72 colonies. This was not 
statistically significant but the p value was small (0.071) and there is a difference of 
nearly one colony between the two groups at baseline in a small sample size. 
This imbalance in the overall mean at baseline between the two groups may have 
been because of experimental error or, more likely, because of the small sample 
size and the wide eligibility criteria for inclusion to the study in terms of patient 
demographics. A larger sample size with tighter inclusion and exclusion criteria 
would be needed to confirm or refute this.  The difference in the mean eMSC count 
between the baseline and final biopsy in group 1 is 0.61 colonies which is ten times 
higher than the change in the eMSC count in group 0 (0.06 colonies).  
The difference in group 1 is highly statistically significant (p = <0.001) and the 
confidence interval is narrow. This has demonstrated that in some patients we can 
increase the eMSC count at the endometrium. This finding and the significance of 
this needs further investigation. 
 
 
 
10.8 OTHER REULTS 
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The research conducted at Warwick Medical School that this work was based 
research  which had demonstrated that not only do RPL patients have a deficiency 
in endometrial stem cells but also that the stem cell-ness of the endometrium 
decreases with an increase in the numbers of miscarriages (Lucas et al., 2016b). 
This original research was however conducted via a retrospective analysis of 
endometrial biopsies and the reproductive history was known when performing the 
analysis. Retrospective analyses are subject to type 1 error with the risk of reporting 
outcomes which may be due to chance. 
Analysis of 29 endometrial biopsies in the SIMPLANT study has shown no 
relationship between the eMSC count with the number of previous first trimester 
miscarriages. As this was a prospective randomised study we can be more 
confident that there is actually no relationship in the eMSC count with the number of 
previous miscarriages. A larger sample size would be needed to confirm this. 	
 
10.9 ADVERSE EVENTS AND STUDY ACCEPTABILITY 
 
The only reported adverse event which occurred more than once in more than one 
participant was a headache. Headaches are a common side effect of Sitagliptin 
(>5% of patients) but there was not a statistically significant difference in the 
headaches reported between the two groups (p = 0.245). Given these results we 
can be confident that the headaches were unlikely to be related to the study 
medication. 
Questionnaires were completed by participants to assess the acceptability of the 
trial. 97% of participants returned the questionnaire. 93% found taking part in the 
study worthwhile and would recommend taking part to others. This gives me 
confidence that the trial was acceptable to participants and if we performed a larger 
pragmatic trial recruitment and compliance would not be an issue. 
We did not have any concerns with patient compliance to trial medication and there 
were no participants who withdrew because of difficulties taking the medication or 
side effects.  All participants who continued in the study attended for their final 
endometrial biopsy. This tells me that none of them found the biopsy too difficult to 
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tolerate at the baseline visit discouraging them or stopping them attending for the 
second biopsy.  
	
10.10 LIMITATIONS 
 
There are some promising results and findings from this study which could 
potentially be translated into a clinical outcome. Limitations of this study must be 
addressed before further work can be conducted.  
The sample size for this study was calculated using the results of clonogenic 
assays done at the Warwick Clinical Sciences Research Laboratory in 2014 which 
was the original work demonstrating that those with RPL had eMSC deficiency.  
This analysis was derived from dividing results obtained into those patients without 
RPL (those with less than 3 miscarriages) and those patients with RPL (3 or more 
miscarriages). Those patients with less than 3 miscarriages were those who had 
booked into the clinic for investigations after having up to 3 miscarriages, or, 
actually had primary or secondary unexplained subfertility with recurrent 
implantation failure 
These original stem cell assay results were therefore from patients of two different 
spectra of reproductive failure. There may have been a smaller difference in the 
average eMSC count between those with successful pregnancies when compared 
to those with RPL rather than comparing patients with implantation failure with 
patients with RPL. 
We do not have any stem cell assay results for patients without a history of 
miscarriage or implantation failure and had successful pregnancies. Although this 
would give us more of an idea of the stem cell count associated with successful 
pregnancy, these biopsies and assays are not possible to obtain.  
The significant difference in the eMSC count found in those with or without RPL in 
the patient cohort used may have actually resulted in an over-estimation in the 
expected effect size.  
Also, there was large interpatient variation in the baseline eMSC count between all 
participants. The baseline eMSC count among all participants varied from 1 to 145 
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colonies. The eMSC count did not seem to be related to age, the number of 
previous miscarriages or BMI.  
We may have seen this large variation in the stem cell count as our small sample 
size was small. This variation may have been more narrow if we had a larger 
sample size. This variation may even be due to cyclical variation of eMSC’s within 
the same patient.  
The variation in the baseline eMSC count is more likely because of the large 
variation in patient demographics. When setting up this study we needed to 
consider how to optimise trial recruitment but also needed to ensure the eligibility 
criteria ensured patient safety. Patients with an age of 18-42 and patients with any 
BMI could be included. This was because the safety of Sitagliptin had been proven 
in those above 18 and also because the pharmacokinetics of Sitagliptin are not 
altered by BMI.  
These criteria were perhaps too wide leading to a high variation in baseline eMSC 
counts amongst the participant cohort. We had young patients with a high BMI and 
older patients with a low BMI all with different reproductive histories which may 
have led to a wide variation in the results obtained. 
Our required sample size was 30 participants. Despite five withdrawals after 
randomisation we had 30 participants complete the study. The overall number of 
clonogenic assay results however, were affected by yeast contamination. This 
made it impossible to accurately assess the eMSC at the final biopsy in one of the 
participants. This feasibility study demonstrated that should a similar outcome 
measure be used for a further trial; the sample size needs to account for this 
possible hindrance. 
94% of the endometrial biopsies were taken by myself. The same method to scrape 
four walls of the uterus using the Endocell Wallach Catheter was used for every 
participant to maintain standardisation in the methods used to collect the 
endometrial biopsies. This catheter creates a suction effect to collect an 
endometrial biopsy. The superior wall of the uterus would always be scraped first 
which meant that the majority of the biopsy obtained was from the superior wall of 
the uterus in every participant. It must be appreciated however that there may have 
been a variation in the stem cell count in different parts of the endometrium for each 
participant. This possibility is impossible to overcome as there is no way of 
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predicting where there would be a higher or lower concentration of stem cells in 
different parts of the endometrium in different participants.  
The CFU assay takes 10 days to complete. It is expensive, time consuming and 
requires advanced laboratory skills. This study was possible to conduct with this 
small sample size but this assay would not be practical in a large sample setting.  
 
 
10.11 FUTURE WORK 
 
Although our primary outcome measure showed no difference in the final eMSC 
between the two treatment groups, once we have been unblinded to study 
treatment we will be able to establish in which group there was an increase in the 
eMSC count from baseline.  
The fact that there was no difference in the final eMSC count between the two 
treatment groups may reflect a ceiling of maximal stem cell-ness of the 
endometrium rather than a non-significant result. This needs to be explored. 
The significant increase in eMSC in one group may mean that we can increase 
trafficking of eMSC to the endometrium in certain patients. This is an area for 
further work as it may provide a therapeutic target.  
We firstly need to develop a new method of analysing the stem cell-ness of the 
endometrium using markers which are more practical, cheaper and less time 
consuming to conduct than the clonogenic assay which takes two weeks for each 
sample, so that we can conduct research with a bigger sample size. 
Once we have developed a new method of assessing the stem cell-ness of the 
endometrium we can look at the eMSC count in a larger group of patients. We can 
establish what patient factors are associated with a lower eMSC count, establish 
more accurately if there is a certain reference range of stem cell-ness within the 
endometrium and if there is an overall maximum eMSC count.  
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It would also be useful to look at cycle-cycle variation within the same patient which 
would be possible to do as patients now attend the Implantation Clinic in two cycles 
and have two endometrial biopsies performed.  
Future work would also involve looking at pregnancy outcomes and see if they 
relate to eMSC counts or the change in eMSC counts over 3 months. Ultimately, 
would want to design a project to look into whether the eMSC count can predict 
pregnancy outcomes.  
This study had a scientific primary outcome. We eventually need to conduct this an 
study with a clinical outcome such as live birth rate.  
	
10.12 CONCLUSIONS 
 
Patients with RPL have a deficiency of eMSC’s which contributes to abnormal 
patterns of decidualisation. Improving this deficiency is potential therapeutic target. 
If we are able to improve decidualisation of the endometrium there will be improved 
signalling between the embryo and the endometrium leading to improved 
endometrial selection of the appropriate embryo rather than repeatedly investing in 
pregnancies which lead to miscarriage.  
There was no significant difference in the eMSC after 3 months in the two treatment 
groups but participants in Group 1 had statistically significant increase in the eMSC 
count after 3 months when compared to baseline. The study was also acceptable to 
participants with few side effects. This feasibility study has provided us with a 
foundation from which to perform further work.  
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KEY	DATES	
	
Protocol	and	supporting	documents*	 	 	 	 November	2015	–	March	
2016	 		
Tommy’s	Grant	Approval	Letter:		 	 	 	 08/02/2016	 	 	
Ethics	Application		 	 	 	 	 	 08/04/2016	
Research	Ethics	Committee	(REC)	Meeting	 	 	 27/04/2016	
Response	from	REC	 	 	 	 	 	 10/05/2016	
Amendments	sent	 	 	 	 	 	 18/05/2016	
Favourable	opinion	from	REC	 	 	 	 	 14/06/2016	
MHRA	approval	
Site	initiation	visit	and	training	 	 	 	 	 23/08/2016	 	
Sponsor	greenlight	 	 	 	 	 	 14/09/2016	
Recruitment	commencement	date	 	 	 	 14/09/2016	
Trial	Suspension	 	 	 	 	 	 21/10/2016	
Internal	Monitoring	 	 	 	 	 	 14/11/2016	
Major	Amendment	1.0	approval		 	 	 	 9/11/2016	from	REC	
	 	 	 	 	 	 	 	 18/11/2016	from	MHRA	
Major	Amendment	2.0	approval		 	 	 	 06/12/2016	from	REC	
	 	 	 	 	 	 	 	 07/12/2016	from	MHRA	
Lift	of	suspension	&	trial	restart	 	 	 	 	 15/12/2016	
External	Audit:	 	 	 	 	 	 	 08/02/2017	
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Major	Amendment	3.0	approval		 	 	 	 2/05/2017	
Trial	Steering	Committee	Meetings	 		 	 	 	 	 	
	 	 	 	 	 	 	 	
	 10/06/2016,08/02/2017,31/05/2017	
Trial	management	Group	Meetings	 	
02/02/2016,	 22/02/2016,	 31/03/2016,	 19/05/2016,	 23/07/2016,	
23/08/2016,	30/01/2017,	08/05/2017	
	
	
	
*This included development of trial design, sample size calculations, contact with 
pharmaceutical companies, agreement of costs, manufacture and supply of IMP 
and placebo, method of randomisation, methods for un-blinding procedures, safety 
measures, peer review, statistician review, R&D review, sponsorship and funding 
agreements 
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Invitation to join the SIMPLANT study 
You are being invited to take part in a pilot research study called SIMPLANT. This study is for those 
women who are suffering with recurrent miscarriages.  
It is important for you to read this leaflet to understand why the research is being done and what it 
involves. This leaflet explains why we are doing the study and outlines the benefits and risks of taking 
part.  The results of this study will form part of a doctorate which will be supervised by Professor 
Siobhan Quenby. Please take some time to read the following information carefully and discuss it with 
friends, relatives and your GP if you wish. If you have any questions, please ask the Research Team who 
will be happy to help. 
 
What is the purpose of this study? 
Research has shown that women with recurrent miscarriage have low numbers of stem cells in the lining 
of the womb (endometrium). Sitagliptin, a medication, which is routinely used in treating patients with 
diabetes, has been shown to be successful in increasing the number of stem cells in other areas of the 
body where wound healing is taking place. This study will test whether giving Sitagliptin to women with 
recurrent miscarriage, increases the number of stem cells in the lining of the womb after an endometrial 
scratch (biopsy). If Sitagliptin is successful in increasing the number of stem cells, this in turn may help to 
improve the chance of a successful pregnancy by improving the environment for implantation. 
Where is this study being carried out? 
The study is being carried out at the Biomedical Research Unit at University Hospitals Coventry and 
Warwickshire NHS Trust.  
Why have you been chosen to take part? 
You have been invited to be part of this study because you have experienced 3 or more miscarriages and 
your health care team has not been able to find a cause. 
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Summary of what is involved 
1. We will check you are eligible to take part in the study. 
2. We will ask you to sign a consent form signed for the study  
3. Your GP will be informed by writing of your inclusion into trial with your consent 
4. You will be asked to attend for an endometrial biopsy 7-10 days after ovulation. We will ask you to 
sign a consent form for an endometrial biopsy  - this is then performed the same day 
5. You will be assigned at random to either Sitagliptin or Placebo (dummy) tablet. Each pack will 
contain 32 tablets.  
6. One tablet needs to be taken every day for a total of 3 months up until the day of the second 
endometrial biopsy.  
7. We will ask you to visit the research unit for general health check every 4 weeks +/- 4 days. We will 
give you a simple symptom diary to fill in so that we can monitor any problems closely. 
8. At each monthly visit we will give you the following months’ supply of tablets as long as you and we 
are happy to carry on. 
9. An endometrial biopsy will be performed again at the end of the 3-month period   
During the study we will ask you to do a pregnancy test at home every 2 weeks. Pregnancy test kits will be 
provided. It is important you do not get pregnant while participating in this trial as we do not clearly know 
of the safety of Sitagliptin in pregnancy 
Once you have had your second endometrial biopsy we will ask you to fill in a simple questionnaire related 
to your experience of being in a research trial. Your replies will be anonymous and will help to improve 
services in the future. 
Once results have been analysed you will be able to discuss your results in the context of the other 
participant’s results with the research team.  
 
What does taking part in this study involve? 
If you are happy to take part, we will check all the routine blood tests that you would have had to look for 
causes of your miscarriages to ensure you are eligible to take part in the study. We would also need to 
ensure you have regular periods with a 28 – 30 day cycle.  
 
If the blood tests are normal you will be asked to agree to take part in the study. This will involve being 
assigned at random to receive either Sitagliptin or placebo (dummy) tablets, which you will take for the 
duration of the study (3 months). You will have two endometrial biopsies: one just before treatment starts 
and one after 3 months of treatment. 
 
You will have an equal chance of receiving the Sitagliptin or the placebo treatment. Neither you nor the 
study team can influence which treatment you receive; a computer will make this decision. During the 
study, neither you nor the study team will know which treatment you are on, however it will be possible to 
access this information should it become necessary for your clinical care.  
 
You will be given a patient diary to keep a record of taking the tablets and any side effects you are 
experiencing. 
 
We will ask you to come to the Biomedical Research Unit every 4 weeks +/- 4 days to review this diary and 
make sure you are well.  
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What is an Endometrial Biopsy? 
An Endometrial Biopsy is a sample of the lining of the womb. A transvaginal (internal) ultrasound scan will 
be done to assess the thickness of the lining of the womb and to determine which way the womb is tilted so 
that we know how to take the biopsy. To take the biopsy a thin plastic straw will be passed through the 
cervix into the uterus. Gas and air (Entonox) is available if needed. The procedure usually takes a couple of 
minutes and will be done in clinic. Following the procedure the small sample of your womb lining will be 
frozen and stored in UHCW’s Tissue Bank for analysis of stem cells and genetic analysis. With your 
permission, any tissue left over after the analysis is complete will be stored anonymously in the Tissue Bank 
for use in future research studies. You do not have to give your consent for long term storage of your left 
over tissue samples if you do not wish.   
What are the possible risks of being in the study? 
Sitagliptin has been given to patients routinely for many years as part of their treatment for diabetes and is 
very safe. However, as with all medication, there are some side effects (affecting less than 1 in 10 people) 
associated with taking Sitagliptin that may or may not affect you. These include a sore throat, runny nose or 
a headache. Other less common side effects include change of bowel habit. There have also been some 
reports of skin conditions, muscle pain and allergic reactions in patients taking Sitagliptin. In extremely rare 
cases Sitagliptin may cause inflammation of the pancreas causing severe abdominal pain. We will monitor 
you closely throughout the study and you will be given a point of contact should you develop any worrying 
symptoms while in the study. 
 
The Endometrial Biopsy may cause some cramping abdominal pain at the time of the biopsy. Taking 
Paracetamol and Ibuprofen an hour before the biopsy can help with this. We also have gas and air available 
to use while having the biopsy. Some patients have also reported some spotting after the biopsy is taken, 
but this will resolve quickly on its own.  
 
What are the possible benefits of being in the study? 
We do not know if there is any benefit of taking Sitagliptin to the endometrium. It is possible that both the 
Sitagliptin and the placebo have no effect on the endometrium.  It is however important to have some 
patients on a placebo tablet so that we can accurately look at whether Sitagliptin increases the stem cell 
count. 
 
We know that taking an endometrial biopsy causes a wound healing response in the lining of the womb, 
which has been shown to improve pregnancy rates in women having IVF, so there may be some benefit to 
having an endometrial biopsy in recurrent miscarriage as well.    
What if I become pregnant during the study? 
It is very important that you do not try to become pregnant while you are taking part in the study. If you 
decide to take part in the study you will be asked to take a pregnancy test before you are enrolled on the 
study and then every 2 weeks for the duration of the study. Pregnancy test kits will be provided. You will 
also be provided with and required to use a reliable, non-hormonal contraceptive throughout your 
enrolment in the study. Once you have finished taking part in the study it is safe for you to try to get 
pregnant again straightaway if you wish.  
If you do become pregnant during the study, you should stop taking the study medication immediately and 
call the study team to arrange an appointment. 
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   SIMPLANT_PARTICIPANT INFORMATION SHEET V2.0  17/11/2016  IRAS196058 
  
 
Do I have to take part? 
Participation in the study is entirely voluntary. If you do not wish to take part you will not have to give a 
reason and your decision will not affect the care you receive. If you do decide to participate we would be 
most grateful if we could use any extra tissue from the endometrial biopsy for research purposes by our 
research team. The biopsy would not be used by any other team and the tissue sample would be frozen 
and stored in the Tissue Bank at UHCW anonymously. The sample would not be shared externally. 
If you would like to take part in the study but would not like your tissue to be used for other research 
purposes other than those for this study this will be respected and reflected on the consent form you sign. 
What if I wish to withdraw from the study?  
If you do decide to take part in the study you are free to withdraw yourself and your data from the study 
and stop taking the study medication at any time. You do not have to give a reason. If you decide to 
withdraw from the study we would ask you to let us know when you stopped taking the medication. 
Will the information you collect be kept private? 
All the information collected during the study will remain confidential like your medical records. With your 
consent we will inform your GP that you are taking part in the study. All information collected during the 
study will be recorded on a secure database, which will only be accessible to authorised people. You will 
have a personal ‘trial number’ which will be used to identify all of your information and test results. Once 
the results of the study are available they will be circulated to relevant medical staff and they will be 
published in medical journals, but there will be no details included that would allow identification of any 
patients involved. The personal information collected about you as part of this study e.g. your name and 
contact details, will be stored securely at UHCW for up to 3 years. Only authorized members of the study 
team will be allowed access to your personal information and it will not be shared with any third parties 
without your express permission. 
Who can I contact about any questions or problems? 
If you have any questions or concerns about any aspect of this study or would like to take part, please call 
the study office on 024 769 67528 and a member of the research team will be able to help.  
Prof. Siobhan Quenby is in charge of the study at this hospital, please see contact details below: 
PA to Prof. Quenby, Kerri Geraghty on 024 769 67528. 
Contact information for any complaints: 
If you experience any problems as a result of taking part in this study, or if you wish to make a formal 
complaint you can do so by writing to: 
Biomedical Research Unit, UHCW, Clifford Bridge Road, Coventry CV2 2DX or at simplant@uhcw.nhs.uk  
For independent advice on research, you can contact PALS (Patient Advice and Liaison Service) on 
freephone 0800 028 4203 or email: Feedback@uhcw.nhs.uk  
Who has reviewed the study? 
To protect your interests, all research in the NHS is looked at by a Research Ethics Committee.  This study 
has been reviewed and given favourable opinion by the HRA & South Central – Hampshire B Research 
Ethics Committee. 
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APPENDIX 3 – LETTER TO GENERAL PRACTITIONER 
SIMPLANT study consent form_v2.0 17/11/2016                        IRAS No 196058 
SIMPLANT   
 
 
 
CONSENT FORM           Screening Number:   - 
 
Study full title: Does the DPP4 inhibitor Sitagliptin increase endometrial mesenchymal cells 
in women with recurrent miscarriage? 
Short title: SIMPLANT study 
Principal Investigator: Professor Siobhan Quenby 
Version 2.0, 17/11/2016 
Please Initial  
 
……………………………..  ………………………     ……………………………... 
Name of participant     Date            Signature            
(BLOCK CAPITALS) 
……………………………..  ………………………     ……………………………... 
 
Name of person taking consent     Date             Signature 
(if different from researcher) 
 
……………………………..  ………………………     ……………………………... 
 
Name of researcher    Date     Signature 
1. I confirm that I have read and understood the information leaflet version 2.0, 
17/11/2016 for the above trial and consent to the procedures within the trial. I 
have had the opportunity to consider the information and ask questions. I 
have received satisfactory answers to all my questions.   
 
2. I understand that my participation is voluntary and that I am free to withdraw 
at any time without giving any reason and without my future medical care or 
legal rights being affected 
 
3. I understand that relevant sections of my medical records and/or data 
collected as part of the study may be looked at by responsible individuals 
from regulatory authorities or from the NHS Trust where it is relevant to my 
taking part in this study. I give my permission for these individuals to have 
access to these records. 
 
4. I understand that my information, and tissue samples collected as part of the 
study will be frozen and stored in the Tissue Bank at UHCW and analysed for 
stem cells and genetic analysis as part of this study. 
 
5. I agree for my tissue samples to be frozen and stored in the Tissue Bank at 
UHCW anonymously for use in future research by the research team. The 
sample would not be shared externally. Please initial in ONE of the two 
boxes. 
 
6. I agree for my G.P to be informed about my inclusion to this study.  
 
7. I understand that I must not try to get pregnant while I am taking 
part in this study and I agree to use reliable contraception for the duration of 
my involvement in the study 
 
8. I agree to take part in the study 
 
 
 
 
YES NO 
  
 
  
S 
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SIMPLANT study GP letter_v1.0_08.04.2016 
	
 
Patient name 	
DOB 	
Address 	
<G.P NAME> 
<PRACTICE NAME> 
<PRACTICE ADDRESS> 
<DATE> 
Dear <GP NAME> 
 
RE: SIMPLANT study 
Does the DPP4 Inhibitor (Sitagliptin)  Increase Endometrial Mesenchymal Stem Cells in Women 
with Recurrent Miscarriage? 
The Biomedical Research Unit at University Hospitals Coventry and Warwickshire NHS Trust are 
currently running the SIMPLANT study. This is a single centre pilot randomised double blind 
controlled trial looking at the effect of Sitagliptin in increasing the mesenchymal stem cell count at 
the endometrium.  
 
Your patient, <patient name>, agreed to take part in the trial when she attended hospital 
on <date of appointment> and was randomised to receive either:  
 
1. Intervention group:  100mg of Sitagliptin daily for 3 months  
2. Control group: oral placebo daily for 3 months 
 
As part of their involvement in the study your patient will also undergo two endometrial biopsies; 
one at the start and one at the end of the treatment period. It is therefore important they do not get 
pregnant during the trial. 
   
As this is a double blind study, neither the participant nor our study investigators know the 
treatment allocation of your patient. Your patient has the contact details of our research team in 
case of any difficulties. Patients in this study also carry a participant information card in case they 
are admitted as an emergency. This card can be given to the clinician looking after the patient and 
the research team can be contacted.  
 
Please find a copy of the information leaflet that was given to your patient enclosed for your 
information. If you would like any further details about the study, please feel free to contact our Trial 
Coordination team via simplantstudyoffice@uhcw.nhs.uk  or 024 7696 7528. 
 
Yours Sincerely,  			
Prof Siobhan Quenby 	
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Patient Initials:                     Screening ID:                   -   
 
                    Participant Trial ID:  
SIMPLANT_Participant Symptom Diary_V1.2_02/06/2016  IRAS No: 196058 
 
 
 
SIMPLANT 
Participant Symptom Diary 
 
Does the DPP4 Inhibitor (Sitagliptin) Increase Endometrial 
Mesenchymal Stem Cells in Women with Recurrent 
Miscarriage? 
 
Follow Up Appointment 
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Patient Initials:                     Screening ID:                   -   
 
                    Participant Trial ID:  
SIMPLANT_Participant Symptom Diary_V1.2_02/06/2016  IRAS No: 196058 
 
 
Date Symptom Duration Treatment 
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Patient Initials:                     Screening ID:                   -   
 
                    Participant Trial ID:  
SIMPLANT_Participant Symptom Diary_V1.2_02/06/2016  IRAS No: 196058 
 
If you have filled all the above boxes please contact the Research 
Unit to discuss your symptoms further 
 
Medication Compliance 
Day Time  
1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
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Patient Initials:                     Screening ID:                   -   
 
                    Participant Trial ID:  
SIMPLANT_Participant Symptom Diary_V1.2_02/06/2016  IRAS No: 196058 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
28  
29  
30  
31  
Menstrual Diary 
 
Length of period 
 
__________ days 
 
Heavy Days? 
 
Yes 
 
No 
If Yes 
Number of days 
_______________ 
Other Comments? 
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Patient Initials:                     Screening ID:                   -   
 
                    Participant Trial ID:  
SIMPLANT_Participant Symptom Diary_V1.2_02/06/2016  IRAS No: 196058 
 
 
Research Team contact details 
If you have any concerns or your pregnancy test  
is positive, Please contact us on 
simplant@uhcw.nhs.uk 
02476967528 (Kerri Geraghty – Secretary to Professor Quenby) 
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SIMPLANT_Participant questionnaire V1.2_02.06.2016                                    IRAS No196058 
 
Thank you for your participation in the SIMPLANT study. 
 
We would really value your opinion about your experience and would be grateful if you could 
complete this questionnaire. This will help us to ensure future research projects take your opinion 
on board.  
 
Please complete this after your cycle starts and post it back in the self-addressed envelope 
 
Thank you for your time. Your information is valuable to us. If you wish us to contact you to discuss 
feedback this can be arranged. Please ring Kerri Geraghty on 02476967528 
SIMPLANT 
PARTICIPANT QUESTIONNAIRE 
 
Does the DPP4 Inhibitor (Sitagliptin)  Increase Endometrial Mesenchymal 
Stem Cells in Women with Recurrent Miscarriage? 
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SIMPLANT  
PARTICIPANT QUESTIONNAIRE 
SIMPLANT_Participant questionnaire V1.2_02.06.2016                                    IRAS No196058 
 
. 
Scale: Please use the following scale to answer the following questions 
 
Strongly agree 5 
Agree 4 
Neither agree/disagree 3 
Disagree 2 
Strongly disagree 1 
 
I found taking part in the study a worthwhile 
experience 
5 4 3 2 1 
Given the choice, I would like to continue 
taking part in this study 
5 4 3 2 1 
I would recommend taking part in the study 
to others 
5 4 3 2 1 
I found taking part in the study supportive of 
my care 
5 4 3 2 1 
I would be open to taking part in other 
research studies 
5 4 3 2 1 
 
 
I found taking the study medication easy 5 4 3 2 1 
I found the side effects from the medication 
easy to manage 
5 4 3 2 1 
 
 
 
 
 
 
I forgot to take the study medication Often Sometimes Rarely Never 
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SIMPLANT  
PARTICIPANT QUESTIONNAIRE 
SIMPLANT_Participant questionnaire V1.2_02.06.2016                                    IRAS No196058 
 
1. Did the patient information leaflet describe the study clearly?  
Yes / No 
If No what do you think could be improved?............................................................. 
..................................................................................................................................... 
 
2. Did you any difficulties booking your appointment for your biopsy? 
a. Biopsy 1 – Yes / No 
b. Biopsy 2 – Yes / No 
If yes, please give details 
……………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………… 
 
3. Did you find it difficult to book the monthly hospital visits?  
Yes / No 
If yes, please give details 
……………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………… 
 
 
4. Did you find the hospital visits supportive to your care?   
Yes / No 
If No what do you think could be improved?............................................................ 
..................................................................................................................................... 
……………………………………………………………………………………………………………………………….. 
 
5. Were you able to contact the research team for support when 
needed? 
Yes / No 
If No, please give details 
……………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………… 
 
 
6. Do you have any suggestions as to how the whole experience could 
be improved? 
..................................................................................................................................... 
……………………………………………………………………………………………………………………………….. 
 
7. Any other comments? 
..................................................................................................................................... 
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SIMPLANT_Participant Information Card_v3.0_21.09.2016 IRAS ID: 196058 
 
 
 
SIMPLANT 
Participant Information Card 
 FOR INFORMATION ABOUT THE TRIAL OR 
INCASE OF EMERGENCY PLEASE CONTACT 
Telephone 02476 967528 during work hours (8am to 
4pm) or switchboard 02476 964000 outside working 
hours (ask for Dr Tewary or Prof Quenby)  
Participant: _____________________ 
FOR INFORMATION ABOUT THE TRIAL OR 
INCASE OF EMERGENCY PLEASE CONTACT 
Telephone 02476 967528 during work hours (8am to 
4pm) or switchboard 02476 964000 outside working 
hours (ask for Dr Tewary or Prof Quenby)                                                              
Participant: 
 
 
FOR INFORMATION ABOUT THE TRIAL OR 
INCASE OF EMERGENCY PLEASE CONTACT 
Telephone 02476 967528 during work hours (8am to 
4pm) or switchboard 02476 964000 outside working 
hours (ask for Dr Tewary or Prof Quenby)                                                              
Participant: 
 
 
 
SIMPLANT 
Participant Information Card 
 
SIMPLANT 
Participant Information Card 
 
SIMPLANT 
Participant Information Card 
 
SIMPLANT 
Participant Information Card 
 
SIMPLANT 
Participant Information Card 
 
SIMPLANT 
Participant Information Card 
 
SIMPLANT 
Participant Information Card 
 
SIMPLANT 
Participant Information Card 
 FOR INFORMATION ABOUT THE TRIAL OR 
INCASE OF EMERGENCY PLEASE CONTACT 
Telephone 02476 967528 during work hours (8am to 
4pm) or switchboard 02476 964000 outside working 
hours (ask for Dr Tewary or Prof Quenby)                                                              
Participant: 
 
 
TREATMENT: 100mg Sitagliptin or Placebo 
FOR INFORMATION ABOUT THE TRIAL OR 
INCASE OF EMERGENCY PLEASE CONTACT 
Telephone 02476 967528 during work hours (8am to 
4pm) or switchboard 02476 964000 outside working 
hours (ask for Dr Tewary or Prof Quenby)                                                              
Participant:        
 
 
FOR INFORMATION ABOUT THE TRIAL OR 
INCASE OF EMERGENCY PLEASE CONTACT 
Telephone 02476 967528 during work hours (8am to 
4pm) or switchboard 02476 964000 outside working 
hours (ask for Dr Tewary or Prof Quenby)                                                              
Participant: 
 
 
FOR INFORMATION ABOUT THE TRIAL OR 
INCASE OF EMERGENCY PLEASE CONTACT 
Telephone 02476 967528 during work hours (8am to 
4pm) or switchboard 02476 964000 outside working 
hours (ask for Dr Tewary or Prof Quenby)                                                              
Participant: 
 
 
FOR INFORMATION ABOUT THE TRIAL OR 
INCASE OF EMERGENCY PLEASE CONTACT 
Telephone 02476 967528 during work hours (8am to 
4pm) or switchboard 02476 964000 outside working 
hours (ask for Dr Tewary or Prof Quenby)                                                             
Participant:  
 
 
FOR INFORMATION ABOUT THE TRIAL OR 
INCASE OF EMERGENCY PLEASE CONTACT 
Telephone 02476 967528 during work hours (8am to 
4pm) or switchboard 02476 964000 outside working 
hours (ask for Dr Tewary or Prof Quenby)                                    
Participant: 
                                                 
            
Participant: 
 
 
TREATMENT: 100mg Sitagliptin or Placebo 
TREATMENT: 100mg Sitagliptin or Placebo TREATMENT: 100mg Sitagliptin or Placebo 
TREATMENT: 100mg Sitagliptin or Placebo 
TREATMENT: 100mg Sitagliptin or Placebo 
TREATMENT: 100mg Sitagliptin or Placebo 
TREATMENT: 100mg Sitagliptin or Placebo TREATMENT: 100mg Sitagliptin or Placebo 
TREATMENT: 100mg Sitagliptin or Placebo 
SIMPLANT 
Participant Information Card 
 FOR INFORMATION ABOUT THE TRIAL OR 
INCASE OF EMERGENCY PLEASE CONTACT 
Telephone 02476 967528 during work hours (8am to 
4pm) or switchboard 02476 964000 outside working 
hours (ask for Dr Tewary or Prof Quenby)                                                              
Participant: 
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APPENDIX 7 – PEER REVIEW FROM DR NIGEL 
SIMPSON 
	
  
 
Version 1.0 February 2016  
 
 
UHCW NHS Trust R,D & I 
Independent Peer Review Form 
 
 
 
 
5.  INDEPENDENT PEER REVIEW:  Please comment on the following areas: 
Area Reviewed Comments 
a) The originality of the research This is innovative and translational work, following earlier scientific 
studies and designed to optimise effective implantation in women 
with recurrent pregnancy loss 
b) The study design A prospective double-blinded RCT into the ability of a (in this 
context) novel therapy of a DPP4 inhibitor to effectively assist 
endometrial MSC numbers, sufficiently-powered, with secondary 
outcomes that include successful implantation 
c) The research methods - appropriateness 
and achievability of the chosen methods 
and outcome measures in meeting the 
objectives of the study 
Satisfactory 
d) Sampling – the appropriateness of the 
sampling methods and the 
inclusion/exclusion criteria  
Satisfactory 
1. Full Project Title:  (The project protocol should be attached to this form) 
Does the DPP4 Inhibitor (Sitagliptin)  Increase Endometrial Mesenchymal Stem Cells in Women with 
Recurrent Miscarriage? 
2. Short Title: 
  SIMPLANT - Sitagliptin for IMPLANTation 
3. Investigators  Name  Department 
(a)   Chief Investigator (For UHCW NHS Trust 
sponsored studies 
Professor	Siobhan	Quenby		
 
 
(b)   Principal Investigator (For External 
Sponsors) 
  
4. Application Details  
Funding Body  Tommys (NB needs substituting for ‘i4i’ on p34 para 19.1) 
Sponsor (if External)  
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Peer	review	–	Internal	–	SIMPLANT	–	Paul	O’Hare	–	27/02/2016	
	
	
REVIEW	OF	SIMPLANT	PILOT	RCT	–	S	TEWARY	AND	SIOBHAN	
QUENBY	
27/02/2016	
	
	
RESEARCH	IDEA/CONCEPT	
This	is	highly	innovative	and	has	potential	of	producing	a	game	changing	approach	to	the	treatment	
of	some	infertile	woman	using	a	drug	that	has	over	10	years	has	established	a	strong	safety	record	in	
the	treatment	of	type	2	diabetes	and	its	safety	has	been	extensively	scrutinised	in	very	large	scale	
clinical	trials	
	
SUGGESTIONS	
This	appears	to	be	a	well	designed	pilot	study	where	clearly	this	proof	of	concept	is	the	first	step	
necessary	before	data	would	be	available	to	define	subsequent	larger	studies.	30	seems	a	practical	
number	to	look	at.	
Investigators	seem	to	have	addressed	the	ethical	scrutiny	whether	there	is	enough	animal	data	or	
models	that	could	be	done	before	moving	on	to	patients.		The	answer	lies	in	interspecies	differences	
that	would	make	animal	models	of	little	value.	
Investigators	need	to	mention	on	safety	the	recent	2015	Tecnos	study	(Nejm)	that	represents	the	
long	term	use	of	sitagliptin	and	the	relatively	clean	results	putting	to	rest	concerns	about	possible	
pancreatitis,	heart	disease	or	cancer	over	the	many	years	of	study	in	thousands	of	subjects.	
Indemnity	issues	will	no	doubt	be	raised	and	the	sponsors	Univ/UHCW	have	insurance	cover	for	this	
unless	there	has	been	a	recent	change.	Clearly		if	these	sort	of	innovations	by	our	academics	are	to	
be	fostered	and	insurers	reassured	that	the	intervention	with	sitagliptin	will	not	carry	serious	risk	to	
these	volunteers	and	the	potential	benefits	for	infertile	women	could	be	substantial.	
This	class	of	drugs	the	gliptins	do	not	require	patients	with	diabetes	to	carry	out	blood	sugar	
monitoring	and	the	absence	of	hypoglycaemia	is	a	major	reason	for	their	current	use	in	diabetes.	
	
CONCLUSION	
Extremely	important	research	that	should	constitute	minimal	risk	to	participants	and	if	successful	
could	lead	on	to	groundbreaking	treatments	for	infertility	and	much	patient	benefit	from	a	relatively	
cheap	drug	on	a	worldwide	scale.There	appears	little	risk	to	the	sponsor	and	a	potential	for	
considerable	gain	and	considerable	impact	from	the	innovation.	
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APPENDIX 10 – INITIAL RECOMMENDATION 
RESPONSE FROM THE REC 
	
 
  
South Central - Hampshire B Research Ethics Committee 
Level 3  Block B 
Whitefriars 
Lewins Mead 
Bristol 
BS1 2NT 
 
Telephone: 0207 104 8052 
10 May 2016 
 
Professor Siobhan Quenby 
University Hospital Coventry and Warwickshire 
Clifford Bridge Road 
Coventry 
CV22DX 
 
Dear Professor Quenby  
 
Study Title: Does the DPP4 Inhibitor (Sitagliptin)  Increase 
Endometrial Mesenchymal Stem Cells in Women with 
Recurrent Miscarriage? 
REC reference: 16/SC/0229 
Protocol number: SQ167015 
EudraCT number: 2016-001120-54 
IRAS project ID: 196058 
 
The Research Ethics Committee reviewed the above application at the meeting held on 27 April 
2016. Thank you for attending to discuss the application. 
 
Provisional opinion 
 
The Committee was unable to give a favourable opinion based on the information and 
documentation received so far.  
 
The Committee requested the following information before confirming its final opinion: 
Participant Information Sheet 
1. Please amend the Participant Information Sheet to state that women would have to  
have regular periods for inclusion in the study and to advise whether they would be given 
a 28 or 35 day cycle of Sitagliptin. It should also be made clear in the PIS that they need to 
continue using the treatment up until the time of the second biopsy.  
2. Please amend the Participant Information Sheet to include information about te storage 
and subsequent use of participants’ samples, and that they would only be used by this 
research team. 
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3. Please indicate in the Participant Information Sheet that pregnancy test kits would be 
provided. 
 
4. Please amend the Participant Information Sheet and Consent Form so as to  
inform participants that, with their consent, their samples would be subject to genetic 
analysis. 
5. Please amend the Participant Information Sheet to make it clear that this is a pilot 
study  
and would form part of a doctorate. 
6. Please amend the Participant Information Sheet to explain how post-treatment 
follow-up  
of any subsequent pregnancy would work. This should include whether the researcher 
would remain blinded at this stage and how treating clinicians might be made aware of any 
results relevant to clinical care.  
7. Please indicate in the Participant Information Sheet that participants will be asked to 
complete a questionnaire about their experience during the study. 
 
8. Please add to the “Summary of what is involved” items referring to keeping a symptom 
diary and completing an end of study questionnaire. These documents should be titled 
‘Participant Questionnaire’ and Participant Symptom Diary’. 
 
9. Please consider whether you would be able to offer participants reimbursement of 
travel  
expenses and if so then please update the Participant Information Sheet accordingly. 
The Committee delegated authority to confirm its final opinion on the application to the Chair 
and Sue Edwards. 
 
The Committee nominated Georgina Castledine to be the point of contact should further 
clarification be sought from the applicant upon receipt of the decision letter. 
The Committee nominated the Chair to be the point of contact for the REC Manager if further 
information was required. 
When submitting a response to the Committee, the requested information should be 
electronically submitted from IRAS.  A step-by-step guide on submitting your response to the 
REC provisional opinion is available on the HRA website using the following link: 
http://www.hra.nhs.uk/nhs-research-ethics-committee-rec-submitting-response-provisional-opini
on/  
 
Please submit revised documentation where appropriate underlining or otherwise highlighting 
the changes which have been made and giving revised version numbers and dates. You do not 
have to make any changes to the REC application form unless you have been specifically 
requested to do so by the REC. 
 
The Committee will confirm the final ethical opinion within a maximum of 60 days from the date 
of initial receipt of the application, excluding the time taken by you to respond fully to the above 
	 216	
	
	
	
 
points.  A response should be submitted by no later than 09 June 2016. 
 
Summary of the discussion at the meeting 
 
Other ethical issues were raised and resolved in preliminary discussion before your 
attendance at the meeting.  
Ethical issues raised by the Committee in private discussion, together with responses 
given by the researcher when invited into the meeting 
 
The Committee welcomed the researcher to the meeting. 
 
Recruitment arrangements and access to health information, and fair participant 
selection 
 
The Committee noted that there was a placebo group so as to eliminate any confounding effect 
of the biopsy, but asked whether this was really necessary.  
 
You said that the problem was that women who suffered from repeated miscarriages may react 
to the biopsy differently to other women, which is why the repeated miscarriage placebo group 
would be needed for comparison purposes. 
 
The Committee accepted this response. 
 
Favourable risk benefit ratio; anticipated benefit/risks for research participants (present 
and future) 
 
The Committee sought clarification as to whether you had asked the manufacturers of Sitagliptin 
for safety data in respect of use in pregnancy arising from its use in other studies. 
 
You said that there was not enough data to confirm that the drug was safe in the case of 
pregnancy but that it had been administered up to 12 times in animals and had not caused any 
problems with fertility or pregnancy. You said that if a participant became pregnant, you would 
stop the treatment straight away and hoped that the treatment would become a pre-conception 
treatment to revolutionise treatment for those who suffer miscarriage and to give them a good 
womb to enable them to get pregnant.  
 
The Committee accepted this response. 
 
The Committee asked whether there would be any way that the treatment would adversely 
impact on someone getting pregnant after the trial and asked whether it was possible that it 
could lower endometrial stem cell numbers.  
 
The Committee stated that it should be made clear in the Participant Information Sheet that 
participants should not try to get pregnant whilst taking part in the trial. 
 
You said that there was no risk that the treatment would make a woman’s chance of getting 
pregnant any worse but admitted that the drug might not help. You agreed to update the 
Participant Information Sheet. 
 
The Committee asked whether there had been any epidemiological study on Sitagliptin. 
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You said that no there had not been an epidemiological study as Sitagliptin was a new drug 
offered to those with Type 2 diabetes and those beyond reproductive life. 
 
The Committee accepted this response. 
 
Care and protection of research participants; respect for potential and enrolled 
participants’ welfare and dignity 
 
Prior to the researcher entering the meeting the Committee raised the following point; 
 
The Committee asked whether consideration could be taken to reimburse participants travel 
expenses and stated that this should be made clear in the Participant Information Sheet. 
 
The Committee asked how long stem cell numbers stayed in the women’s endometrium. 
 
You said that in previous studies stem cells had been placed directly in the women’s 
endometrium, but some had suffered problems from this surgical procedure, but the stem cells 
numbers were usually maintained for up to three months. Professor Quenby said that they were 
looking for a less invasive procedure for women who had previously had miscarriages. 
 
The Committee asked how women would be followed-up and whether they would come into the 
clinic for this. 
 
You said that the participants involved in the study would be local patients who were well known 
and that they would be followed-up in the clinic where they knew the team well and would feel 
comfortable.   
 
The Committee accepted this response. 
 
The Committee asked whether women would have to have regular periods for inclusion in the 
study and asked whether they would be given a 28 or 35 day cycle of Sitagliptin and stressed 
that participants should not run out of pills. The Committee stated that it was important to ensure 
that women were still using the treatment when they received the second biopsy. The 
Committee stated that the Participant Information Sheet should include this information. 
 
You said that the longest cycle would be 35 days and confirmed that participants would not run 
out of Sitagliptin and that they would still be receiving the treatment when they had their second 
biopsy. You agreed to revise the Participant Information Sheet to make this clear to participants. 
 
The Committee noted that there was mention of storage and future use of participant samples 
and asked whether they would be held exclusively for this research team’s use or whether they 
would be shared externally. 
 
You said that samples would only be used for this research team’s use and agreed to make this 
clear in the Participant Information Sheet. 
 
The Committee asked whether the pregnancy test kits would be provided at no expense to the 
participants and stated that if so the Participant Information Sheet should be updated. 
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You confirmed that pregnancy test kits would be provided and agreed to update the Participant 
Information Sheet. 
 
Informed consent process and the adequacy and completeness of participant 
information 
 
Prior to the researcher entering the meeting the Committee raised the following point; 
 
The Committee stated that the Participant Information Sheet and consent form needed updating 
to inform participants that their samples would be subject to genetic analysis. 
 
The Committee stated that the Participant Information Sheet should make it clear that this would 
be a pilot study and would form part of a doctorate. 
 
The Committee noted that the Participant Information Sheet did not mention the use of an end 
of study questionnaire, and that neither this questionnaire nor the symptom diary was 
mentioned in the Summary of what is involved. This should be rectified and the titles of both 
documents should be amended by replacing the word ‘Patient’ by ‘Participant’. 
 
The Committee stated that the Participant Information Sheet should explain how post-treatment 
follow-up of any subsequent pregnancy would work. This should include whether the researcher 
would remain blinded at this stage and how treating clinicians might be made aware of any 
results relevant to clinical care. 
 
The researcher left the meeting and the Committee discussed the application further. 
 
Documents reviewed 
 
The documents reviewed at the meeting were: 
 
Document   Version   Date   
Covering letter on headed paper [Covering Letter]  V1.0  08 April 2016  
GP/consultant information sheets or letters [GP letter]  v1.0  08 April 2016  
Investigator's brochure / IMP Dossier [Investigator's brochure]    12 April 2016  
Letter from sponsor [Letter from sponsor]    22 February 2016  
Letter from statistician [Letter from statistician]    18 March 2016  
Non-validated questionnaire [Patient questionnaire]  v1.0  08 April 2016  
Other [Participant emergency contact card]  v1.0  08 April 2016  
Other [PPI summary report]    01 April 2016  
Other [PPI - Letter from lay TSC member]    08 April 2016  
Other [Student CV]    12 April 2016  
Other [Letter from funder]    08 February 2016  
Participant consent form [Informed consent form]  v1.0  08 April 2016  
Participant information sheet (PIS) [PIS]  v1.0  08 April 2016  
REC Application Form [REC_Form_08042016]    08 April 2016  
Referee's report or other scientific critique report [Peer Review - Dr. 
Nigel Simpson]  
  01 February 2016  
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You confirmed that pregnancy test kits would be provided and agreed to update the Participant 
Information Sheet. 
 
Informed consent process and the adequacy and completeness of participant 
information 
 
Prior to the researcher entering the meeting the Committee raised the following point; 
 
The Committee stated that the Participant Information Sheet and consent form needed updating 
to inform participants that their samples would be subject to genetic analysis. 
 
The Committee stated that the Participant Information Sheet should make it clear that this would 
be a pilot study and would form part of a doctorate. 
 
The Committee noted that the Participant Information Sheet did not mention the use of an end 
of study questionnaire, and that neither this questionnaire nor the symptom diary was 
mentioned in the Summary of what is involved. This should be rectified and the titles of both 
documents should be amended by replacing the word ‘Patient’ by ‘Participant’. 
 
The Committee stated that the Participant Information Sheet should explain how post-treatment 
follow-up of any subsequent pregnancy would work. This should include whether the researcher 
would remain blinded at this stage and how treating clinicians might be made aware of any 
results relevant to clinical care. 
 
The researcher left the meeting and the Committee discussed the application further. 
 
Documents reviewed 
 
The documents reviewed at the meeting were: 
 
Document   Version   Date   
Covering letter on headed paper [Covering Letter]  V1.0  08 April 2016  
GP/consultant information sheets or letters [GP letter]  v1.0  08 April 2016  
Investigator's brochure / IMP Dossier [Investigator's brochure]    12 April 2016  
Letter from sponsor [Letter from sponsor]    22 February 2016  
Letter from statistician [Letter from statistician]    18 March 2016  
Non-validated questionnaire [Patient questionnaire]  v1.0  08 April 2016  
Other [Participant emergency contact card]  v1.0  08 April 2016  
Other [PPI summary report]    01 April 2016  
Other [PPI - Letter from lay TSC member]    08 April 2016  
Other [Student CV]    12 April 2016  
Other [Letter from funder]    08 February 2016  
Participant consent form [Informed consent form]  v1.0  08 April 2016  
Participant information sheet (PIS) [PIS]  v1.0  08 April 2016  
REC Application Form [REC_Form_08042016]    08 April 2016  
Referee's report or other scientific critique report [Peer Review - Dr. 
Nigel Simpson]  
  01 February 2016  
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South Central - Hampshire B Research Ethics Committee 
Attendance at Committee meeting on 27 April 2016 
 
  
Committee Members:  
 
Name   Profession   Present    Notes   
Dr Diane Ackerley  Retired Doctor  Yes     
Mrs Lisa Armstrong  Senior Lecturer Social 
Work  
No     
Mrs Ravina Barrett  Pharmacist  Yes     
Mr Brian Birch (AVC)  Consultant Urological 
Surgeon  
Yes     
Mrs Janet Brember  Pharmacist  Yes     
Ms Julie Brinton  Speech and Language 
Therapist  
Yes     
Mr Mark Cassidy  Senior Lecturer in 
Radiography  
Yes     
Dr Alessandro di Nicola  Lecturer in Philosophy  Yes     
Ms Susan Edwards  Lead Contract Manager, 
NHS South West and 
Central Contract Support 
Unit  
Yes     
Mrs Angela Iveson  Acute Oncology Clinical 
Nurse Specialist  
Yes     
Professor Ron King (Chair)  Mathematician (Retired)   Yes     
Mr Geoff Lowndes  Chartered Engineer 
(Retired)  
Yes     
Miss Becci Petch   Clinical Trial Coordinator  Yes     
Dr Andrew Scott (Vice Chair)  Course Leader, M.Sc. 
Clinical Exercise Science  
No     
  
Also in attendance:  
 
Name   Position (or reason for attending)   
Miss Georgina Castledine  REC Manager  
Mrs Samantha  Trace  Research Assistant   
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University	Hospitals	Coventry	and	Warwickshire	NHS	Trust	
Clifford	Bridge	Road	
Walsgrave	
Coventry	
CV2	2DX	
	
Dear	Ms.	Edwards,		
	
RE:	SIMPLANT	study	(REC	ref:	16/SC/0229)	
Thank	you	for	your	provisional	response	with	the	changes	to	be	considered	for	the	SIMPLANT	study.	
We	have	closely	looked	at	the	information	requested	and	amended	the	documents	accordingly.		
Please	find	below	responses	to	all	queries.	All	updates	have	been	highlighted	in	yellow	on	the	
Participant	Information	Leaflet,	Participant	Questionnaire	and	Symptom	Diary.	
		
1.	Please	amend	the	Participant	Information	Sheet	to	state	that	women	would	have	to		
Have		regular	periods	for	inclusion	in	the	study	and	to	advise	whether	they	would	be	given	
a	28	or	35	day	cycle	of	Sitagliptin.	It	should	also	be	made	clear	in	the	PIS	that	they	need	to	
continue	using	the	treatment	up	until	the	time	of	the	second	biopsy.	
The	Participant	Information	Leaflet	has	now	been	amended	to	state	that	women	should	have	a	28-
30	day	cycle	for	inclusion	to	the	study.		This	is	because,	patients	with	a	cycle	length	that	is	consistent	
will	be	more	homogenous	and	thus	we	wish	to	minimise	confounding	factors.		
	The	Participant	Information	Leaflet	also	now	states	that	they	will	be	supplied	with	a	pack	of	32	
tablets	at	a	time.		After	giving	participants	the	first	pack	of	medication	we	will	see	them	for	a	review	
in	the	research	unit	at	4	weeks	+/-	4	days	(28+/-	4	days)	when	they	will	get	the	medication	for	the	
next	hospital	visit.	
It	also	states	that	‘one	tablet	needs	to	be	taken	every	day	for	a	total	of	3	months	up	until	the	day	of	
the	second	endometrial	biopsy.’		
	
2.	Please	amend	the	Participant	Information	Sheet	to	include	information	about	the	
storage	and	subsequent	use	of	participants’	samples,	and	that	they	would	only	be	used	by	
this	research	team.		
The	Participant	Information	Leaflet	now	states	
‘Following	the	procedure	the	small	sample	of	your	womb	lining	will	be	frozen	and	stored	in	UHCW’s	
Tissue	Bank	for	analysis	of	stem	cells	and	genetic	analysis.	With	your	permission,	any	tissue	left	over	
after	 the	 analysis	 is	 complete	 will	 be	 stored	 anonymously	 in	 the	 Tissue	 Bank	 for	 use	 in	 future	
research	studies.	You	do	not	have	to	give	your	consent	for	long	term	storage	of	your	left	over	tissue	
samples	if	you	do	not	wish.’	
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In	another	section	of	the	Participant	Information	Leaflet	it	also	states:	
‘If	you	do	decide	to	participate	we	would	be	most	grateful	if	we	could	use	any	extra	tissue	from	the	
endometrial	biopsy	for	research	purposes	by	our	research	team.	The	biopsy	would	not	be	used	by	
any	other	team	and	the	tissue	sample	would	be	frozen	and	stored	in	the	Tissue	Bank	at	UHCW	
anonymously.	The	sample	would	not	be	shared	externally.’	
	
3.	Please	indicate	in	the	Participant	Information	Sheet	that	pregnancy	test	kits	would	be	
provided	
The	Participant	Information	Leaflet	now	states:	
‘During	the	study	we	will	ask	you	to	do	a	pregnancy	test	at	home	every	2	weeks.	Pregnancy	test	kits	
will	be	provided.	It	is	important	you	do	not	get	pregnant	while	participating	in	this	trial	as	we	do	not	
clearly	know	of	the	safety	of	Sitagliptin	in	pregnancy.	
	
4. Please	amend	the	Participant	Information	Sheet	and	Consent	Form	so	as	to	inform	
participants	that,	with	their	consent,	their	samples	would	be	subject	to	genetic	
analysis.		
The	Participant	Information	Leaflet	now	states	that		
‘Following	the	procedure	the	small	sample	of	your	womb	lining	will	be	frozen	and	stored	in	UHCW’s	
Tissue	Bank	for	analysis	of	stem	cells	and	genetic	analysis.	With	your	permission,	any	tissue	left	over	
after	 the	 analysis	 is	 complete	 will	 be	 stored	 anonymously	 in	 the	 Tissue	 Bank	 for	 use	 in	 future	
research	studies.	You	do	not	have	to	give	your	consent	for	long	term	storage	of	your	left	over	tissue	
samples	if	you	do	not	wish.’	
The	consent	form	has	been	amended	to	clarify	that	the	participant’s	 left	over	tissue	will	be	stored	
anonymously	in	UHCW’s	Tissue	Bank	for	future	research	by	the	research	team	and	will	not	be	shared	
externally.	This	element	of	the	study	is	optional.			
	
5. Please	amend	the	Participant	Information	Sheet	to	make	it	clear	that	this	is	a	pilot	
studyand	would	form	part	of	a	doctorate		
	
It	is	now	stated	in	the	Participant	Information	Leaflet	that	this	is	a	pilot	study	and	would	form	part	of	
a	doctorate	supervised	by	Professor	Siobhan	Quenby.	(please	see	highlighted	in	yellow)	
	
	
6. Please	amend	the	Participant	Information	Sheet	to	explain	how	post-treatment	
follow-upof	any	subsequent	pregnancy	would	work.	This	should	include	whether	the	
researcher	would	remain	blinded	at	this	stage	and	how	treating	clinicians	might	be	
made	aware	of	any	results	relevant	to	clinical	care.		
It	was	originally	stated	in	the	Protocol	V1.0	section	20.2	that	the	definition	of	the	end	of	the	trial	will	
be	when	the	last	patient	has	had	their	second	endometrial	biopsy.	The	secondary	outcome	
measures	and	objectives	have	now	been	amended	not	to	include	pregnancy	outcomes.	Follow	up	
after	the	second	biopsy	is	part	of	standard	clinical	care	and	not	part	of	the	study.		
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This	trial	is	designed	to	examine	the	effect	of	Sitagliptin	on	the	endometrium	and	not	to	assess	the	
effect	of	Sitagliptin	on	pregnancy	outcome	as	this	would	require	a	larger	study.	The	results	of	the	
project	are	novel	and	will	not	be	given	to	treating	clinicians	as	their	relevance	is	not	known	and	they	
are	thus	uninterruptable	clinically	and	therefore	not	relevant.		For	example,	if	a	patient	has	a	low	
number	of	endometrial	stem	cells	we	do	not	know	at	present	what	effect	this	would	have	on	her	
pregnancy,	nor	do	we	have	any	preventative	action	to	take.	Thus	in	this	instance	such	information	is	
not	helpful.				
Furthermore,	any	pregnancy	will	occur	after	the	trial	has	finished	and	occur	after	the	endometrium	
has	renewed	following	menstruation.	We	have	no	idea	at	present	whether	Sitagliptin	will	affect	the	
endometrium	so	the	treatment	allocation	is	of	no	relevance	to	the	clinician	looking	after	the	patient	
in	pregnancy.		
However,	women	who	participated	in	the	research	project	will	be	offered	standard	recurrent	
miscarriage	clinic	care	which	includes	fortnightly	scans	in	the	first	trimester	and	high	risk	antenatal	
care	as	is	standard	practise.		
	
7.	Please	indicate	in	the	Participant	Information	Sheet	that	participants	will	be	asked	to	
complete	a	questionnaire	about	their	experience	during	the	study.		
This	has	now	been	included	in	the	Participant	Information	Leaflet	as:	
‘Once	you	have	had	your	second	endometrial	biopsy	we	will	ask	you	to	fill	in	a	simple	questionnaire	
related	to	your	experience	of	being	in	a	research	trial.	Your	replies	will	be	anonymous	and	will	help	
to	improve	services	in	the	future.’	
	
8. Please	add	to	the	“Summary	of	what	is	involved”	items	referring	to	keeping	a	
symptom	diary	and	completing	an	end	of	study	questionnaire.	These	documents	
should	be	titled	‘Participant	Questionnaire’	and	Participant	Symptom	Diary’.		
The	Participant	Information	Leaflet	now	states	
‘We	will	ask	you	to	visit	the	research	unit	for	general	health	check	every	4	weeks	+/-	4	days.	We	will	
give	you	a	simple	symptom	diary	to	fill	in	so	that	we	can	monitor	any	problems	closely’	
We	have	changed	the	titles	of	the	two	documents	and	resubmitted	the	new	versions.	
	
9. Please	consider	whether	you	would	be	able	to	offer	participants	reimbursement	of	
travel	expenses	and	if	so	then	please	update	the	Participant	Information	Sheet	
accordingly.		
	
We	would	not	be	able	to	offer	participants	reimbursement	of	travel	expenses.	Participants	who	have	
been	involved	in	the	PPI	group	are	aware	of	this	but	do	not	have	concerns.	
	
 
10. The	Committee	stated	that	it	should	be	made	clear	in	the	Participant	Information	
Sheet	that	participants	should	not	try	to	get	pregnant	whilst	taking	part	in	the	trial.		
	 224	
	
	
	
	
The	Participant	Information	Leaflet	now	states		
‘During	the	study	we	will	ask	you	to	do	a	pregnancy	test	at	home	every	2	weeks.	Pregnancy	test	kits	
will	be	provided.	It	is	important	you	do	not	get	pregnant	while	participating	in	this	trial	as	we	do	not	
clearly	know	of	the	safety	of	Sitagliptin	in	pregnancy.’	
It	also	states	
‘It	is	very	important	that	you	do	not	try	to	become	pregnant	while	you	are	taking	part	in	the	study.	If	
you	decide	to	take	part	in	the	study	you	will	be	asked	to	take	a	pregnancy	test	before	you	are	
enrolled	on	the	study	and	then	every	2	weeks	for	the	duration	of	the	study.	Pregnancy	test	kits	will	
be	provided.’	
	
11. You	said	that	there	was	no	risk	that	the	treatment	would	make	a	woman’s	chance	of	
getting	pregnant	any	worse	but	admitted	that	the	drug	might	not	help.	You	agreed	to	
update	the	Participant	Information	Sheet.		
	
This	has	been	included	in	the	original	Patient	Information	Leaflet	as:	
‘We	do	not	know	if	there	is	any	benefit	to	taking	Sitagliptin	to	the	endometrium.	It	is	possible	that	
both	the	Sitagliptin	and	the	placebo	have	no	effect	on	the	endometrium”.			
Other	issues	raised:	
As	per	requests	from	the	HRA	we	have	added	in	more	details	about	the	side	effect	profile	on	the	
Participant	Information	Leaflet	of	Sitagliptin	to	allow	full	disclosure	to	participants.	
	
Since	the	meeting	on	the	27th	April	we	have	had	a	meeting	with	Professor	Arvanitis	who	is	the	Head	
of	Research	at	the	Institute	of	Digital	Healthcare	who	has	been	approached	about	database	creation	
for	the	trial.	He	has	now	been	included	in	the	list	of	study	contacts.	
	
In	light	of	responses	above	other	changes	made	to	the	protocol	which	include:	
	
1. In	section	4	this	has	been	corrected	to	say	that	the	study	will	be	funded	for	24	months	and	
open	to	recruitment	for	12	months.	This	was	an	oversight	in	the	original	protocol	and	has	
been	amended	to	be	in	line	with	the	original	study	summary	on	page	6	of	the	protocol.	
2. After	our	meeting	with	Professor	Arvanitis	the	protocol	has	been	corrected	to	make	it	clear	
that	the	data	in	the	database	will	be	link	anonymised	and	not	anonymous	as	has	been	stated	
in	the	IRAS	form.		
	
I	hope	these	amendments	help	us	to	reach	a	favourable	opinion.	
Thank	you	again	for	your	time.	
	
Yours	Sincerely,		
	
	
Professor	Siobhan	Quenby	
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Professor Siobhan Quenby 
University Hospital Coventry and Warwickshire 
Clifford Bridge Road 
Coventry 
CV22DX 
 
Email: hra.approval@nhs.net 
 
01 August 2016 
 
Dear Professor Quenby,    
 
 
Study title: Does the DPP4 Inhibitor (Sitagliptin) Increase Endometrial 
Mesenchymal Stem Cells in Women with Recurrent 
Miscarriage? 
IRAS project ID: 196058 
EudraCT number: 2016-001120-54  
Protocol number: SQ167015 
REC reference: 16/SC/0229   
Sponsor University Hospitals Coventry and Warwickshire NHS Trust 
 
I am pleased to confirm that HRA Approval has been given for the above referenced study, on the 
basis described in the application form, protocol, supporting documentation and any clarifications 
noted in this letter.  
 
Participation of NHS Organisations in England  
The sponsor should now provide a copy of this letter to all participating NHS organisations in England.  
 
Appendix B provides important information for sponsors and participating NHS organisations in 
England for arranging and confirming capacity and capability. Please read Appendix B carefully, in 
particular the following sections: 
x Participating NHS organisations in England – this clarifies the types of participating 
organisations in the study and whether or not all organisations will be undertaking the same 
activities 
x Confirmation of capacity and capability - this confirms whether or not each type of participating 
NHS organisation in England is expected to give formal confirmation of capacity and capability. 
Where formal confirmation is not expected, the section also provides details on the time limit 
given to participating organisations to opt out of the study, or request additional time, before 
their participation is assumed. 
x Allocation of responsibilities and rights are agreed and documented (4.1 of HRA assessment 
criteria) - this provides detail on the form of agreement to be used in the study to confirm 
capacity and capability, where applicable. 
Further information on funding, HR processes, and compliance with HRA criteria and standards is also 
provided. 
Letter of HRA Approval 
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IRAS project ID 196058 
 
Page 2 of 8 
 
 
It is critical that you involve both the research management function (e.g. R&D office) supporting each 
organisation and the local research team (where there is one) in setting up your study. Contact details 
and further information about working with the research management function for each organisation 
can be accessed from www.hra.nhs.uk/hra-approval.  
 
Appendices 
The HRA Approval letter contains the following appendices: 
x A – List of documents reviewed during HRA assessment 
x B – Summary of HRA assessment 
 
After HRA Approval 
 
The document “After Ethical Review – guidance for sponsors and investigators”, issued with your REC 
favourable opinion, gives detailed guidance on reporting expectations for studies, including:  
x Registration of research 
x Notifying amendments 
x Notifying the end of the study 
The HRA website also provides guidance on these topics, and is updated in the light of changes in 
reporting expectations or procedures. 
 
In addition to the guidance in the above, please note the following: 
x HRA Approval applies for the duration of your REC favourable opinion, unless otherwise 
notified in writing by the HRA. 
x Substantial amendments should be submitted directly to the Research Ethics Committee, as 
detailed in the After Ethical Review document. Non-substantial amendments should be 
submitted for review by the HRA using the form provided on the HRA website, and emailed to 
hra.amendments@nhs.net.  
x The HRA will categorise amendments (substantial and non-substantial) and issue confirmation 
of continued HRA Approval. Further details can be found on the HRA website. 
 
Scope  
HRA Approval provides an approval for research involving patients or staff in NHS organisations in 
England.  
 
If your study involves NHS organisations in other countries in the UK, please contact the relevant 
national coordinating functions for support and advice. Further information can be found at 
http://www.hra.nhs.uk/resources/applying-for-reviews/nhs-hsc-rd-review/. 
  
If there are participating non-NHS organisations, local agreement should be obtained in accordance 
with the procedures of the local participating non-NHS organisation. 
 
User Feedback 
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APPENDIX 13 – TRIAL MEDICATION LABEL 
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APPENDIX 14 – SCREENING LOG 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
 
SIMPLANT study 
 
Chief Investigator: Professor Siobhan Quenby   Site name:  University Hospitals Coventry and Warwickshire 
 
REC no.: 16/SC/0229 
Sponsor No: SQ167015 
  *Enter the participant’s unique trial ID SIMPLANT_screening log_v3.0_06.04.2017 
SCREENING LOG  
 
 
 
Screening 
No. 
Subject 
initials 
Date of birth 
(dd/mm/yyyy) 
Date of 
screening 
(dd/mm/yyyy) 
Eligible? 
(Y/N) 
Enrolled? 
(Y/N) 
Date of consent 
(dd/mm/yyyy) If YES, Trial ID* 
If No, reason for refusal or 
ineligibility 
 
S052 
 
 
 
 
   
 
  
S053 
 
 
 
 
   
 
  
S054 
 
 
 
 
   
 
  
S055 
 
 
 
 
   
 
  
S056 
 
 
 
 
   
 
  
S057 
 
 
 
 
   
 
  
S058 
 
 
 
 
   
 
  
S059 
 
 
 
 
   
 
  
S060 
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APPENDIX 15 – RECRUITMENT LOG 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
1                                                                                                                                                                            SIMPLANT Recruitment Log_V3.0_02.05.2017 
SIMPLANT study 
 
Chief Investigator: Professor Siobhan Quenby    Site name:  University Hospitals Coventry and Warwickshire 
REC no: 16/SC/0229 
 
 
Trial 
ID Participant’s Name 
Participant’s 
Hospital 
Number 
 
Date of 
birth 
(dd/mm/y
yyy) 
Date of 
Consent 
(dd/mm/yy) 
Screeni
ng no.   
 
Date of 
Randomisation 
(dd/mm/yy) 
Did 
participant 
complete 
study? 
(Y/N) 
If participant did not complete 
study, give reason 
R24 
 
 
 
  
  
  
 
R25 
 
 
 
  
  
  
 
R26 
 
 
 
  
  
  
 
R27 
 
 
 
  
  
  
 
R28 
 
 
 
  
  
  
 
R29 
 
 
 
  
  
  
 
R30 
 
 
 
  
  
  
 
R31 
 
 
 
  
  
  
 
RECRUITMENT LOG 
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APPENDIX 16 – PHARMACY IMP ACCOUNTABILITY LOG 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
 
Pharmacy IMP Accountability Log Document Version 1 Date: 03/05/2016 Page: ___ 
Sponsor:  University Hospitals Coventry & Warwickshire NHS Trust 
EudraCT:  2016-001120-54 
Pharmacy IMP Accountability Log 
 
For use by Sponsor/Sponsor Representative only 
Initial delivery of IMP to site 
 
All IMP is delivered at the start of the study and entered into quarantine. 
IMP checked and received by 
Print name:    Sign:   Date: 
IMP is undamaged, labelled correctly and fit for use. 
IMP released from quarantine and available for use at site. 
Print name:    Sign:   Date: 
 
 
Principal Investigator: __________________     Hospital Site: University Hospital Coventry Manufacturer: Sharp Clinical Services 
 
Pack 
Number 
Participant 
Trial ID 
Patient 
Initials 
Batch 
Number 
Expiry Completed by Quantity 
Returned 
& 
destroyed 
Completed by Monitor Check 
Initials 
(Disp/Chk) 
Date Initials 
(Disp/Chk) 
Date Initials Date 
      /    /    
      /    /    
      /    /    
      /    /    
      /    /    
      /    /    
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APPENDIX 17 – SAMPLE OF CRF PACK – BASELINE 
VISIT 
	
 
 
 
 
CASE REPORT FORM 
BOOKLET 
SIMPLANT 
 
 
 
 
  
 
 
Patient Initials           
 
 
 Screening ID:                                        -     T                    To be used until randomisation  
 
 
 Participant Trial ID:             Used from randomisation 
 
 
 
 
 
 
 
 
 
 
 
  
Chief Investigator   Professor Siobhan Quenby 
Sponsor Number:   SQ167015 
 
EudraCT Number  
 
 2016 – 001120 - 54 
Name of site   University Hospital Coventry and Warwickshire NHS Trust 
CRF Version Number  V 2.0, 16.12.2016  
S 
R 
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CRF Completion Guidelines 
General 
Complete the CRF using a black ballpoint pen and ensure that all entries are complete and legible. Avoid the 
use of abbreviations and acronyms. The CRF should be completed as soon as possible after the scheduled 
visit. Do not use participant identifiers anywhere on the CRF, such as name, hospital number etc., in order to 
maintain the confidentiality of the participant. Ensure that the header information (i.e. participant’s initials and 
ID number) is completed consistently throughout the CRF.  Missing initials should be recorded with a dash (i.e. 
D-L). 
 
Each CRF page should be signed and dated by the person completing the form. 
The ‘completed by’ Name in the footer of each page must be legible and CRFs should only be completed by 
individuals delegated to complete CRFs on the Site Delegation log (and signed by the PI). 
 
Ensure that all fields are completed on each page:  
x If a test or investigation was Not Done record ND in the relevant box(es) 
x Where information is Not Known write NK in relevant box(es) 
x Where information is not applicable write NA in the relevant box(es) 
 
Corrections to entries 
If an error is made, draw a single line through the item, then write the correct entry on an appropriate blank 
space near the original data point on the CRF and initial and date the change. 
Do NOT 
x Obscure the original entry by scribbling it out 
x Try to correct/ modify the original entry 
x Use Tippex or correction fluid 
Medications taken by the participant during the trial should be recorded on the “Concomitant Medications Log” 
using the generic name whenever possible, except combination products which will be recorded using the 
established trade name.   
 
Verbatim Adverse Event terms (initial medical term) should be recorded as the final diagnosis whenever 
possible. 
 
Complete all dates as day, month, year i.e. 13/NOV/2016. Partial dates should be recorded as NK/NOV/2016. 
 
Source documents such as lab reports, biopsy results etc. should be filed separately from the CRF (if not in 
the medical notes) for each participant and be signed and dated by a delegated Investigator as proof of review 
of the assessment during the trial.  Questionnaires should be considered as the CRF appendices (except 
standard approved questionnaire e.g. EQ-5D)   
 
If a participant prematurely withdraws from the trial a single line must be drawn across each uncompleted 
page to correspond with the last visit of the participant as mentioned on the “End of Study” page. 
 
The protocol deviation log should be used to record comments relating to each CRF visit that cannot be 
captured on the page itself. This includes reason for delayed or missed protocol visits or trial assessments, 
unscheduled visits etc.   
 
If additional pages are required of the Concomitant Medications or Adverse Event Forms please print the 
continuation page and mark the page as ‘a’, ‘b’ etc as required.   
 
The Chief Investigator (for lead site)/Principal Investigator is responsible for the accuracy of the data reported 
on the CRF.  The CI/PI must sign and date the Principal Investigator’s Sign Off page to certify accuracy, 
completeness and legibility of the data reported in the CRF. 
 
Serious Adverse Events (SAEs)  
SAEs should be scanned and emailed within 24 hours of the site being aware of the event using the trial 
specific SAE report form to RD&Isponsorship@uhcw.nhs.uk.  
 
Storage 
 
CRF documents should be stored in a locked, secure area when not in use where confidentiality can be 
maintained.  Ensure that they are stored separately to any other documents that might reveal the identity of 
the participant.
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Completed by: ____________________   ______________________  Date:  ____/ _____ __/__________ 
                        Name                                 Sign                (DD / MMM / YYYY) 
 
 Page 3 of 30 
 
Pt Screening No: 
: 
Initials: S 
 
SIMPLANT 
SIMPLANT CRF v2.0, 16.12.2016 
 
 
 
Date of Baseline Visit:    
 
 
PARTICIPANT ELIGIBILITY CRITERIA 
The following criteria must be ‘YES’ to be recruited to the trial 
 
YES NO 
Provision of written informed consent   
History of recurrent miscarriage - 3 or more miscarriages   
Regular menstrual cycle, up to 30 days in length   
Age 18 – 42 years at consent   
Willing to consent to give consent for the study and endometrial biopsy   
Ability to fully understand requirements of protocol   
 
 
ELIGIBILITY REVIEW 
 
PARTICIPANT EXCLUSION CRITERIA: 
The following criteria must be 'NO' to be recruited to the trial: 
 
YES NO 
Type I Diabetes   
Type II Diabetes   
Pregnancy   
Breastfeeding   
Known sensitivity to Sitagliptin   
Taking any medications with potential to react with IMP (Digoxin or Enalapril)   
Previous diagnosis of pancreatitis   
Renal impairment with *eGFR <50 ml/min or AKI ≥1    
Hepatic impairment, defined as Alanine Transferase (ALT) >38 U/L, ALP>105 U/L Bilirubin 
(BR) >20 umol    
Inclusion in another interventional trial   
Unwilling to use effective contraception for duration of trial (from consent)   
Allergy/sensitivity to excipients of the IMP/placebo   
BASELINE VISIT  
   D        D          M      M       M           Y       Y       Y      Y 
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Completed by: ____________________   ______________________  Date:  ____/ _____ __/__________ 
                        Name                                 Sign                (DD / MMM / YYYY) 
 
 Page 4 of 30 
 
Pt Screening No: 
: 
Initials: S 
 
SIMPLANT 
SIMPLANT CRF v2.0, 16.12.2016 
*eGFR will be calculated using the Cockroft Gault Equation: 
eGFR (ml/min) =   (140 – Age) x Weight (Kg) x 1.04 
                              Serum Creatinine (umol/L) 
 
 
Informed Consent 
Date of signed written Informed consent: 
 
 
Version no and date of consent form: 
Version No:           
Date:  
 
Name of individual taking informed consent: 
 
 
 
 
 
 
 
 
Variables Values 
Age              yrs         
Weight              kg 
Serum Creatinine              umol/L              
eGFR              ml/min 
AKI               (or)   tick here if not reported  
Participant Eligibility Investigator Sign-Off  
Is the participant eligible to participate in the trial? 
 
Investigator Name:_________________________ 
 
Investigator Sign:__________________________ 
Date:   
 
  Yes       
  
  No, complete below 
Reason(s) for failure: 1. 
2. 
3. 
   D        D          M      M       M           Y       Y       Y      Y 
 
   D        D          M      M       M           Y       Y       Y      Y 
 
   D        D          M      M       M           Y       Y       Y      Y 
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Completed by: ____________________   ______________________  Date:  ____/ _____ __/__________ 
                        Name                                 Sign                (DD / MMM / YYYY) 
 
 Page 5 of 30 
 
Pt Screening No: 
: 
Initials: S 
 
SIMPLANT 
SIMPLANT CRF v2.0, 16.12.2016 
Demographic Data (collected retrospectively from 1st miscarriage clinic) 
 
Date of 1st miscarriage clinic appt:   
Date of Birth  
Ethnicity Complete below 
White White British  White Irish  White Other   
Mixed race 
White & Black 
Caribbean  
 
 
White & 
Black African 
 
 
White & Asian  
Other mixed 
background 
 
 
Asian or Asian British Indian  Bangladeshi  Pakistani  
Other Asian 
background 
 
 
Black or Black British Caribbean  African  Black Other    
Chinese or other 
ethnicity Chinese 
 Other    
 
Clinical Assessments 
Height cm 
Weight kg 
BMI 
 
 
 
Medical History 
Has the Patient had any relevant medical 
history? 
  No      Yes, complete below 
Condition / illness / procedure Start date (DD/MMM/YYYY) 
Stop Date 
(DD/MMM/YYYY) 
Or tick if 
ongoing 
at visit? 
 
_____/_____/_____ _____/_____/_____ 
 
 
 
_____/_____/_____ _____/_____/_____ 
 
 
 
_____/_____/_____ _____/_____/_____ 
 
 
 
_____/_____/_____ _____/_____/_____ 
 
 
 
_____/_____/_____ _____/_____/_____ 
 
 
   D        D          M      M       M           Y       Y       Y      Y 
 
   D        D          M      M       M           Y       Y       Y      Y 
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Completed by: ____________________   ______________________  Date:  ____/ _____ __/__________ 
                        Name                                 Sign                (DD / MMM / YYYY) 
 
 Page 6 of 30 
 
Pt Screening No: 
: 
Initials: S 
 
SIMPLANT 
SIMPLANT CRF v2.0, 16.12.2016 
 
_____/_____/_____ _____/_____/_____ 
 
 
 
_____/_____/_____ _____/_____/_____ 
 
 
 
_____/_____/_____ _____/_____/_____ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lifestyle 
Alcohol   Drinker    Non-drinker 
 
Average no of units / week 
 
Smoking Has participant ever smoked?     No         Yes, complete below 
 
        Current smoker     
        Ex smoker, ceased smoking _____/_____/_____ 
 
      Smoked for ____  years / months (delete as appropriate) 
      Avg daily no of cigarettes/cigars/pipes ______ 
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Completed by: ____________________   ______________________  Date:  ____/ _____ __/__________ 
                        Name                                 Sign                (DD / MMM / YYYY) 
 
 Page 7 of 30 
 
Pt Screening No: 
: 
Initials: S 
 
SIMPLANT 
SIMPLANT CRF v2.0, 16.12.2016 
 
 
 
 
 
 
 
 
 
Pregnancy history - Detail all previous pregnancies, use codes below for fields marked by *  
 
Year 
Gestation 
(weeks) Outcome* 
Type of 
Management* 
Sex of baby       
( M / F ) 
Mode of 
delivery* 
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
Outcome 1 - Live birth 2 - Still birth 3 - Early misc <14/40 4 -Late misc 14- <24/40 
5 - Ectopic pregnancy 6 - Molar pregnancy 7 - Resolved PUL 8 - Termination 
Type of management 1- Expectant 2 - Medical 3 - Surgical  
Mode of Delivery 1 - Normal vaginal delivery 2 - Instrumental delivery 3 - Elective C/S 4 - Emergency C/S 
 5 - Vaginal breech 6 - N/A   
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Completed by: ____________________   ______________________  Date:  ____/ _____ __/__________ 
                        Name                                 Sign                (DD / MMM / YYYY) 
 
 Page 8 of 30 
 
Pt Screening No: 
: 
Initials: S 
 
SIMPLANT 
SIMPLANT CRF v2.0, 16.12.2016 
 
BIOCHEMISTRY 
Laboratory Parameter 
Value Unit  If parameter indicated as out of 
normal range on report, please check 
if clinically significant IF CS consider 
if it is an AE and add to log (if 
appropriate):: 
SODIUM  mmol/L  No         Yes 
POTASSIUM  mmol/L  No         Yes 
UREA  mmol/L  No         Yes 
CREATININE  umol/L  No         Yes 
TOTAL PROTEIN  g/L  No         Yes 
TOTAL BILIRUBIN  mmol/L  No         Yes 
ALBUMIN  g/L  No         Yes 
ALK PHOS (ALP)  U/L  No         Yes 
ALT  U/L  No         Yes 
AKI (eGFR)  If Yes – 1, 2, 3 
(Please circle) 
 No         Yes 
  
 
 
 
 
 
 
 
 
 
 
Biochemistry  
Clinical Biochemistry Laboratory tests 
performed? 
 No (Comment Below)   Yes, Complete below 
Comment*:_____________________________ 
Date of Sample (collected at 1st miscarriage 
clinic) :    
   D        D          M      M       M           Y       Y       Y      Y 
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Completed by: ____________________   ______________________  Date:  ____/ _____ __/__________ 
                        Name                                 Sign                (DD / MMM / YYYY) 
 
 Page 9 of 30 
 
Pt Screening No: 
: 
Initials: S 
 
SIMPLANT 
SIMPLANT CRF v2.0, 16.12.2016 
 
 
 
  
 
Menstrual Cycles 
 
Length of cycle (bleed days / cycle length) 
  
                             / 
 
Heavy 
 
 
  Yes      No 
 
Previous history (ensure documented on medical 
history) 
                               Yes      No 
Fibroids 
Endometriosis 
Uterine anomaly 
End of Baseline Visit –Checklist 1: 
 Yes No 
1. Does the participant satisfy the inclusion and exclusion criteria to date?   
3. Have the Medical History and Concomitant Medication pages been completed?   
4. Is the participant still willing to proceed in the trial?   
5. Has the participant signed a consent form for the study   
6 Ovulation Kits supplied   
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APPENDIX 18 – ADVERSE EVENT REPORTING FORM 
	
	
	
	
	
	
	
	
	
	
	
	
 
 
 
 
 
 
Completed by: ____________________   ______________________  Date:  ____/ _____ __/__________ 
                        Name                                 Sign                (DD / MMM / YYYY) 
 
SIMPLANT CRF v2.0, 16.12.2016 
 Page 26 of 30 
 
Patient Trial ID: Initials: R 
 
SIMPLANT 
 
ADVERSE EVENTS PAGE 
 
AE No 
Event Name  
(Please give Diagnosis if 
known) 
Start date 
(DD/MMM/YYYY) 
Stop date 
(DD/MMM/YYYY) 
Serious? 
If serious, 
please 
complete 
SIMPLANT 
SAE form 
Con-
comitant 
Medication 
given 
Severity 
0 - Mild 
1- Mode-
rate 
2 - Severe 
Study Drug 
Action 
0 - None 
1 - Temporarily 
Interrupted 
2 - permanently 
withdrawn 
Outcome 
0 - Resolved 
1- Resolved 
with sequelea 
2 - Not resolved 
Relationship to  
Study Drug  
0 - Definitely  
1 - Probably  
2 - Possibly 
3 - Unlikely 
4 - Not related 
5 - Not assessable 
 
1 
 
____/____/____ 
 
 
____/_____/____ 
 No 
 Yes 
 No 
 Yes     
 
2 
 
____/_____/____ ____/_____/____ 
 No 
 Yes 
 No 
 Yes     
 
3 
 
____/_____/____ ____/_____/____ 
 No 
 Yes 
 No 
 Yes     
 
4 
 
____/_____/____ ____/_____/____ 
 No 
 Yes 
 No 
 Yes     
 
5 
 
____/_____/____ ____/_____/____ 
 No 
 Yes 
 No 
 Yes     
6 
 
____/_____/____ ____/_____/____ 
 No 
 Yes 
 No 
 Yes     
I have reviewed the AEs on this page and have assessed them for seriousness, causality, severity and outcome and confirm that, to the best of my knowledge, it accurately 
reflects the study information obtained for this participant  
 PI signature _______________________________ _________________ Date:_________________________      Please check box if this is the last page used 
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APPENDIX 19 – SERIOUS ADVERSE EVENT 
REPORTING FORM 
	
SIMPLANT	SAE	Report	Form,	Version	2.0;	03.11.2016	
  Page	1	of	4	
  
 
SERIOUS	ADVERSE	EVENT	REPORT	FORM		
FOR	UHCW	SPONSORED		CLINICAL	TRIALS	OF	INVESTIGATIONAL	MEDICINAL	PRODUCTS		
	
Sponsor	Reference	
Number	
	
	
Study	Title:	 	
	
Patient	Study	Number	and		Initials			 	
Centre:	 	
	
This	form	is	to	be	completed	within	24	hours	of	becoming	aware	of	the	Serious	Adverse	Event	
	
1.	Type	of	Report		 										Initial	 						 Follow	Up				 	 Final																					Initial	&	Final	
(Tick	relevant	box)	
	
Date	of	Report	 	 	 	 	 	
	
Serious	Adverse	Event:		______________________________________________________	
	
Date	of	Onset	 	 	 	 	 	 	 	
	
Date	of	Study	
Team	Aware	 	 	 	 	
	 	 		
NB	If	the	event	is	a	pregnancy	it	should	be	reported	on	a	UHCW	Pregnancy	Notification	Form		
	
2.	Serious	Criteria:				
	
	 Resulted	in	death	
	 Life	threatening		
	 In-patient	hospitalisation	or	prolongation	of	existing	hospitalisation		
	 Persistent	or	significant	disability/incapacity	
	 Congenital	anomaly/birth	defect		
	 Other		
3.	Narrative	-Briefly	describe	the	event	(attach	supporting	documentation	if	applicable)	
	
Admission	Date		 	 	 	 	 Discharge	Date			 	
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SIMPLANT	SAE	Report	Form,	Version	2.0;	03.11.2016	
  Page	2	of	4	
This section is to be completed by the Chief/Principal Investigator or other 
medically qualified Investigator as agreed by the Sponsor 
 
 
Both the Causality & Expectedness MUST be completed by the Chief/Principal 
Investigator or other medically qualified Investigator as agreed by the 
Sponsor for all IMP studies 
 
	
	
	
	
	
	
4a.	Cau ality	and	Expectedness			
	
Evaluation	of	causal	relationship	with	study	drug	1	
	
Related-	If	the	casual	relationship	between	the	IMP	and	the	SAE	is	at	least	a	reasonable	possibility	
	
Un	Related-	If	there	is	no	causal	relationship		between	the	IMP	and	the	SAE	
	
	
(Name	of	drug)		............................................................................................................	
	
	
Related		 	 	 	 	 Unrelated	 	 	
	
	
4b.	
	
The	assessment	of	expectedness	must	be	based	on	the	information	contained	in	the	Investigator	
Brochure	and/or	the	Summary	of	Product	Characteristics	
		
Expected	 	 	 	 	 Unexpected	 	 	
	
If	the	event	is	related	and	unexpected	it	is	a	Suspected	Unexpected	Serious	Adverse	Reaction	(SUSAR)	and	
requires	expedited	reporting.	Inform	the	Sponsor	immediately	
											Telephone	number:		02476	966907/966195			Email:	RD&Isponsorship@uhcw.nhs.uk.		
_______________________________________________________________________	
	
Evaluation	of	causal	relationship	with	study	drug	2		
	
(Name	of	drug)	............................................................................................................	
	
	
Related		 	 	 	 	 Unrelated	 	 	
	
	
	
If	causal	relationship	is	‘related’	was	the	event	‘expected’	
	
The	assessment	of	expectedness	must	be	based	on	the	reference	safety	information	contained	in	the	
Investigator	Brochure	and/or	the	Summary	of	Product	Characteristics	
		
Expected	 	 	 	 	 Unexpected	 	 	
	
If	the	event	is	related	and	unexpected	it	is	a	Suspected	Unexpected	Serious	Adverse	Reaction	(SUSAR)	and	
requires	expedited	reporting.	Inform	the	Sponsor	immediately.	
Telephone	number:		02476	966907/966195			Email:	RD&Isponsorship@uhcw.nhs.uk.		
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SIMPLANT	SAE	Report	Form,	Version	2.0;	03.11.2016	
  Page	3	of	4	
	
5.	Is	the	Study		
Investigational	Medicinal	Product	Blinded	or	Unblinded?	
	
Blinded		 	 Unblinded 	
	
6.	Was	the	event	related	to	a	protocol	violation?	
				
		Yes	 	 No	 	 	 	 	
	
7.		Study	Medication	Information:	
	
Participant	has	been	
Administered	Study	
Drug?	
	Yes	(Provide	details	in	box	below)	 	
	No	(Give	reason	i.e.	screening)	.……………………………………………………………………...	
Name	of	Medication	 Indication(s)	for	Use	 Dose	(units)	
Route	of	
Administration	
Date	of	First	
Administration	
Date	of	Last	
Administration	
	 	 	 	 	 	
	 	 	 	 	 	
	 	 	 	 	 	
	 	 	 	 	 	
	 	 	 	 	 	
	
8.	Action	taken	with	investigational	product	due	to	event:	
	 Dose	not	changed		
	 Temporarily	discontinued	 Date:		 	 	 	 	 	 	
	 Permanently	discontinued	Date:		 	 	 	 	 	 	
	 Dose	reduced		-	provide	details_________________________________________________	
	 Other	–	provide	details________________________________________________________		
	 Not	applicable			
	
9.	Was	the	patient	withdrawn	from	the	study	as	a	result	of	this	event?			Yes 	 	 No 	 	 	
	
10.		Outcome	of	the	Event				
	 Resolved		 Date	of	Resolution:	
	 Resolved	with	Sequelae	 	
	 Ongoing	 	
	 Unknown	at	present					
	 Fatal				 	 Date	of	Death:		 	 	 	 	 	
Cause	of	Death	...................................................................................................................................	
Cause	of	death	obtained	from	(tick	one)	
Working	Diagnosis	 	 	 Coroners	Inquest	 	 Death	Certificate	
Supporting	documentation	to	be	supplied	with	SAE	
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SIMPLANT	SAE	Report	Form,	Version	2.0;	03.11.2016	
  Page	4	of	4	
	
Reporting	Person:			
	
Principal	Investigator/Delegated	medically	qualified	
individual	as	agreed	by	the	sponsor:	
Name:		 Name	:	
Role:	 Role:	
Signature:	 Signature:	
Date:	 Date:		
Contact	No:	 Contact	No:	
	
Please	return	the	completed	form	and	copies	of	any	additional	documents	to	the	Research	Governance	
Office,	by	email	to	isabella.petrie@uhcw.nhs.uk		
	
Reporting	of	SUSARs	to	the	Research	Ethics	Committee	and	Regulatory	Authority	for	UHCW	sponsored	
studies	will	be	undertaken	in	accordance	with	SOP	17	–	Safety	Reporting	(CTIMPs)	
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APPENDIX – 20 FINAL TMG MEETING SUMMARY 
	
	
Final CTIMP TMG Meeting Summary 
Short title: SIMPLANT 
RD&I Number:  SQ167015 
EudraCT Number: 2016-001120-54 
Chief Investigator: Prof Siobhan Quenby 
Trial Manager:  Becky Haley (Acting)  
 
 
Date of Meeting 23/08/2016 
Location of Meeting: Cancer Seminar Room, 3rd Floor opposite Ward 34 
Attendees:  
Prof Siobhan Quenby, Chief Investigator (SQ) 
Dr Shreeya Tewary, Trial Manager (ST) 
Becky Haley, (Acting) Trial Manager (BH) 
Mojid Khan, Sponsor Pharmacy Lead (MK) 
Emma Lucas (EL) 
 
Apologies: Isabella Petrie, Research Governance Manager (IP) Peter Kimani, Trial Statistician (PK) 
Item  (Any item marked “No” requires a comment)  Yes  No  N/A  Comment  
1.0  TRIAL TEAM  
1.1  Coordinating Team     
Indrani Manoharan, the new Trial Manager starts 
on September 5th and will lead on SIMPLANT.  BH 
has acted as interim Trial Manager following Katie 
Bruce’s maternity leave.  Shivam Joshi will 
provide study support e.g. data management and 
recruitment uploads. 
IP sends her apologies due to impending HTA 
inspection.  She will review minutes and TMF/ 
final document set prior to Sponsor approval.   
1.2 Supporting Departments    
Emma Lucas attended the meeting to discuss 
arrangements for analysis of the endometrial 
biopsies.   
Item  (Any item marked “No” requires a comment)  Yes  No  N/A  Comment  
2.0  STUDY DETAILS   
2.1  Protocol      
Protocol v1.2, 18.05.16 approved by CI, Sponsor 
and Statistician, signed copy retained in TMF. 
2.2 Study procedures discussed, specify:    
There are four study specific procedures, listed in 
appendix 1.   
Emma Lucas attended the meeting to discuss the 
analysis of the biopsies. The procedure was 
outlined as per the study specific procedure: 
colony forming assay.   
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2.3 Study specific SOPs, please list:    
Randomisation and unblinding - The TMG were 
satisfied with outlined process and PK has 
reviewed this outside of the meeting.  MK to 
review prior to finalising and sending to PK to 
complete randomisation. PK has received the 
treatment pack allocation list from Sharp so is 
ready to proceed with randomisation once 
document finalised.  
Key documents will be reviewed and signed off by 
appropriate personnel.  
2.4 Randomisation procedures in place    
The participant hospital number should be 
included in the ‘confirmation of randomisation’ 
email to support correct patient identification prior 
to discharge.  BC to action.   
A copy of the randomisation confirmation email 
should be kept with the code break envelopes in 
the event of the patient not knowing the pack IDs.  
BC to add to study specific procedure.  
Admin support within the core team will be 
requested to help create the envelopes.  BC to 
request.   
RD&I governance and grants team (independent 
of the trial team) will perform be the randomisation 
handlers.  Staff to receive training to undertake 
role.  BC to action.   
2.5 Code break procedures     
Details reviewed as per study specific procedure: 
Randomisation and Unblinding.  Patients issued 
with emergency contact cards with BRU and 
Switchboard detailed but this also needs to state 
to ask for Dr Tewary or Prof Quenby.   
Amendment to be submitted to Sponsor inbox for 
review. BC to action.   
2.6 
Study emergency Out of 
Hours contact and 
unblinding in place and 
tested? (Documented 
evidence in TMF) 
   
24-hour code break - Switchboard have agreed to 
facilitate and forward any calls to ST or SQ whose 
details have been added to their system.  ST and 
BC to formalise arrangements with Switchboard 
Manager. ST and SQ coordinate leave to ensure 
that at least one investigator is always available. 
MK has Pharmacy SOP for code break which 
could be used to test the 24-hour code break 
procedure.  MK to forward to BC for review.   
Code break testing to be undertaken once 
unblinding envelopes have been delivered to site. 
BC / MK to action.  
MK advised that Annex 13 requirements provide 
the option for the label to include emergency 
contact details.  MK noted that the label already 
states that patients will carry an emergency 
contact card providing such details. 
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2.7 
Confirmation of 
recruitment target and 
timelines 
   
Planned start date is early September 2016.  
Recruitment of 34 patients is expected to take 9 
months and therefore expected closure to 
recruitment by end May 2017.  LPLV will therefore 
be end August 2017. See Appendix 2. 
The expiry date of the IMP/placebo is February 
2018 so this allows for a little slippage in 
recruitment (last patient must be recruited by 
November 2016).    
Item  (Any item marked “No” requires a comment)  Yes  No  N/A  Comment  
3.0  DATA COLLECTION   
3.1  Case Report Form reviewed and finalised    
The primary outcome data in the CRF currently 
includes the percentage but is to include the 
number of endometrial colonies.  ST/EL to review 
the primary outcome data and provide data points 
ahead of finalising CRF – PK to review prior to 
finalising.   
Statistician (PK) to analyse primary outcome and 
AE/SAE and process evaluation secondary 
outcomes only.  Other secondary outcome data 
will not be included within the CRF as data set too 
large – RNA sequencing, methylation status and 
immunohistochemistry. EL to confirm locations of 
each source document. 
Specific changes –  
• eGRF should be listed under biochemistry 
but is referred to as AKI (Acute Kidney 
Injury) – ST to provide updated CRF 
datapoint, eligibility criteria to be updated 
accordingly to include both terms – BC to 
action 
• ST to find out how eGRF is calculated as 
this can vary. 
BH to ask Indrani Manaharan to create a source 
document locations list once in post.   
3.2 
Case Report Form sign off 
- by CI, Sponsor and 
Statistician? 
   
SQ approved current content and changes 
outlined in meeting.  CRF Review/Approval form 
to be completed once finalised. ST to action 
3.3 Database and validation    
Once the CRF is finalised the database 
programming can begin.  MedSciNet is to be used 
for data capture with data transposed once 
implemented.  Design and build takes c. 6-8 
weeks. Indrani will lead on this once in post. 
3.4 Data entry and query resolution    
Data queries will be sent from Coordinating team 
back to site for resolution.  Data query form to be 
created.  BC/Indrani Manoharan to action once in 
post.   
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Item  (Any item marked “No” requires a comment)  Yes  No  N/A  Comment  
5.0  REGULATORY AND ETHICAL APPROVALS   
5.1 Ethics Committee    
Received 14 June 2016. HRA Approval received 1 
August 2016 
5.2 MHRA    Received 25 July 2017.   
5.3 Process for Sponsor Green Light     
Documents to be reviewed by IP / Governance 
team prior to Sponsor Green Light.  Actions from 
this meeting needed ahead of this will need to be 
completed. 
5.4 Site activation checklist and SIV    
To be completed as part of Sponsor Green Light 
process.  BC/IP to complete checklist.   
Item  (Any item marked “No” requires a comment)  Yes  No  N/A  Comment  
6.0  
TRIAL 
DOCUMENTATION AND 
TMF   
6.1 TMF/ISF complete    
As this is a single-centre, single sponsor study the 
TMF and ISF will be combined.  The TMF will be 
held in RD&I with file notes specifying documents 
to be held in a folder within the BRU. 
6.2 Amendments    
To be submitted to 
RD&Isponsorship@uhcw.nhs.uk for sponsor 
review ahead of ethical and regulatory approvals 
(as required). 
6.3 Non-compliance    
A protocol deviation log will need to be completed 
for any protocol non-compliances. BC/Indrani to 
create and include within TMF.   
Item  (Any item marked “No” requires a comment)  Yes  No  N/A  Comment  
7.0  MONITORING & COMMITTEES   
7.1 
Monitoring plan finalised 
and signed by CI and 
Sponsor 
   
Monitoring arrangements reviewed at and 
approved at DMEC/TSC.  Monitoring Plan to be 
finalised with IP following meeting ahead of trial 
initiation. 
7.2 Monitoring and audit arrangements    
Monitoring to be conducted as per monitoring 
plan.  Study will be audited by Independent 
Auditor at next annual review – anticipated prior to 
end of 2016. 
7.3 Trial Committee scheduled as per monitoring plan    
First meeting has taken place.  Next meeting to be 
scheduled in December 2016 (six monthly). 
7.4 Members all signed DMEC/TSC Charter    
DMEC/TSC Charters received from all but Aurelio 
Tobias and Nicola Haddon.  ST/BC to chase.   
7.5 
Calendar updated with 
reminders of committee 
dates 
   New Trial Manager to add all key trial dates to diary once in post.   
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Item  (Any item marked “No” requires a comment)  Yes  No  N/A  Comment  
8.0  DELEGATION   
8.1 Sponsor to CI delegation reviewed    CI responsibilities form completed and in TMF.   
8.2 
Requirement to comply 
with UHCW SOPs - read 
and sign 
   BC to outline SOPs that will need to be read by the trial team prior to trial initiation.   
8.3 Staff training and SIV    
Dr Tewary will lead SIV visits.  SIV to be 
conducted twice to ensure all staff are able to 
attend.  Pharmacy invited to attend.   
Attendance register to be completed, including 
SIV slides version number.  BC to add version 
number and send attendance log to ST. CV and 
GCP certificates to be collected from all staff and 
stored in TMF.  ST to action.   
Emma Lucas to complete GCP training.  Details 
for eLearning course to be sent.  BC to send.  
8.4 
Signed copy of delegation 
log received and sent to 
Pharmacy 
   
Coordinating centre delegation log started, to be 
completed.  BC to action.   
Site delegation log to be completed at SIV and 
forwarded to Pharmacy once complete.   
Item  (Any item marked “No” requires a comment)  Yes  No  N/A  Comment  
9.0  FUNDING & CONTRACTS  
9.1 Contracts checklist completed and signed?    
Warwick University contract signed, awaiting sub-
contract with UHCW to be signed.   
9.2 Funding arrangements    
Study funding part of programme funding from 
Tommy’s Charity. As contracts had not been 
signed a letter from the Sponsor confirmed that 
the study costs would be underwritten in full.   
Item  (Any item marked “No” requires a comment)  Yes  No  N/A  Comment  
10.0  PHARMACOVIGILENCE  
10.1 
Pharmacovigilence 
arrangements discussed 
and agreed 
   
Reporting, management and monitoring to be 
performed as per Study specific procedure: Safety 
reporting v1.0, 28.06.16. 
10.2 AE recording    
Recorded in CRF and reviewed as part of ongoing 
monitoring. Forms reviewed and approved by 
TMG. 
10.3 SAE and SUSAR reporting    SAE form to be completed by site team and sent to Sponsor within 24-hours.  
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Summary of actions: 
No Section Action Delegated 
individual 
1 2.3 To review Randomisation and Unblinding study specific 
procedure prior to finalising.   
MK  
2 2.4 Hospital number to be added to ‘Confirmation of 
randomisation’ email 
BC 
3 2.4 Clarify randomisation and unblinding study specific 
procedure to include requirement to keep copy of 
randomisation confirmation email with code break envelopes 
BC 
10.4 24-hour unblinding    Refer to 1.6 
Item  (Any item marked “No” requires a comment)  Yes  No  N/A  Comment  
11.0  LABORATORY AND EQUIPMENT  
11.1 Details of laboratories and analysis    
Blood samples to be analysed as per Trust 
standard practice (collected as part of standard 
care).  Emma Lucas to lead on analysis of biopsy 
as per Colony Forming Assay study specific 
procedure.   
11.2 Normal laboratory ranges    
Lab ranges documented in the eligibility criteria in 
the protocol are stated according to Trust normal 
ranges.  ST to provide confirmation of normal 
ranges e.g. Pathology handbook to include within 
TMF.   
11.2 Destruction of samples    
The cells cultured from the endometrial biopsy do 
not fall under the HTA.  Samples to be destroyed 
according to Trust policy (incineration). 
11.3 Patient supplies    
Patient to be supplied with pregnancy and 
ovulation tests from NHS stock.  Patient diaries to 
be printed ready to be issued to patients.  BC to 
request RD&I admin support to prepare. 
11.4 Calibration of equipment    
Conducted and documentation by Vinci.  Stored 
centrally. 
Z:\Equipment - Clinical and Non Clinical\Medical 
Equiptment Certificates\2nd Floor\PRI Suite Opp 
Ward 24   
Item  (Any item marked “No” requires a comment)  Yes  No  N/A  Comment  
12.0  ANNUAL REPORTS  
12.1 Calendar updated with reminders?    
Date of First APR:14 June 2017 
Date of First DSUR: 25 July 2017 
 
Dates to be added to calendar of Trial Manager 
once in post.   
12.2 Anticipated closure date    Expected last patient recruitment by end May 2017, LPLV therefore end August 2017. 
	 252	
	
	
	
4 2.4 Complete training for undertaking randomisation call 
handlers 
BC 
5 2.4 Request RD&I admin support to create code break 
envelopes (and CRF packs). Packs to be created. 
BC 
6 2.5 Amendment to emergency contact cards to include specific 
names to contact, submit to Sponsor for review 
BC 
7 2.6 Meet with Switchboard Manager to formalise code break 
arrangements 
ST/BC 
8 2.6 Provide copy of pharmacy code break procedure for testing 
and documenting 24-hour code-break 
MK 
9 2.6 Test and document outcome of 24-hour code break once 
envelopes delivered 
MK / BC 
10 3.1 Review the primary outcome data and provide data points 
ahead of finalising CRF 
ST/EL 
11 3.1 Provide details of source document locations for laboratory 
analysis 
EL/ST 
12 3.1 eGRF to be updated in CRF to AKI (as appears on lab 
reports), eligibility criteria to be updated for clarity 
ST / BC 
13 3.1 Determine how eGFR/AKI calculated as this can differ ST 
14 3.1 Request Indrani to create source document location list once 
in post 
BC 
15 3.1 CRF review/approval form to be completed once finalised ST/SQ 
16 3.4 Data query form to be created  BC/IM 
17 4.2 Complete Shipment Request Form and return to Sharpe MK 
18 4.6 Send all RSI documents to SQ and ST MK 
19 4.6 Add file note to TMF to outline RSI documents BC 
20 4.7 SPC log to be updated to review every 3 months BC 
21 5.4 Complete sponsor green light checklist  BC/IP 
22 6.3 Protocol deviation log to be completed BC/IP 
23 7.1 Monitoring plan to be finalised IP 
24 7.4 Outstanding TSC/DMEC charters to be chased BC/ST 
25 7.5 Add all key trial dates to calendar BC/I 
26 8.2 Provide list of SOPs to read and review to site team BC 
27 8.3 SIV to be completed including attendance register and 
collection of CV/GCP certificates for all staff 
ST 
28 8.3 EL to complete GCP training EL 
    
Actions highlighted in blue must be completed prior to Sponsor Green Light.  
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APPENDIX 22 – LETTER TO REC AND MHRA WITH 
PROPOSED CHANGES 
	
 
1 
 
Professor Siobhan Quenby  
Professor / Honorary Consultant 
 University of Warwick and  
University Hospitals Coventry & Warwickshire NHS Trust 
Division of Reproductive Health, 
Clinical Sciences Research Institute 
Warwick Medical School 
Clifford Bridge Road 
Coventry CV2 2DX  
Tel:  0121 42 43723 
Fax:  0121 42 43167 
Email:  s.quenby@warwick.ac.uk  
 
Dear Sir/Madam,   
 
Ref: Major Amendment 2.0 dated 15/11/2016  
 
Study title: Does the DPP4 Inhibitor (Sitagliptin) 
Increase Endometrial Mesenchymal Stem 
Cells in Women with Recurrent 
Miscarriage? 
IRAS project ID: 196058 
EudraCT number: 2016-001120-54 
Sponsor reference: SQ167015 
Protocol version V1.2 dated 18th May 16 
REC reference: 16/SC/0229 
MHRA serious breach reference number 13268/0003/001-0002 
Sponsor University Hospitals Coventry and 
Warwickshire NHS Trust 
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Part 1: Amendment to request the restart of the trial 
 
We write this letter based on the RD&I investigational report and CAPA (dated 28/10/2016) as 
agreed by the Sponsor along with the Governance and Trial Team, we request restart of the trial.  
 
Please find the final report attached with this submission for further details. Please note that we have 
received favourable ethical opinion from South Central - Hampshire B Research Ethics Committee on 
09/11/2016 for Notice of Substantial Amendment 1.0 (suspension of trial by Sponsor). 
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Part 2: Amendment to trial protocol 
 
Section 1: Trial Flowchart and Schedule of Events 
 
Current protocol (version 1.2 dated 11th May 16): 
 
Trial flowchart  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Limitations with current protocol: 
After patients have had their initial and follow up consultations in the recurrent miscarriage clinic they 
attend for a new appointment after each miscarriage. In the case of >5 miscarriages this can mean 
>5 ‘new appointments’ for the same patient along with the follow up visits that come with it.  
 
The trial flow chart has been revised to take away the GP referral as this does not occur for every 
new appointment for the same patient in standard practice. Also, the new trial flow chart takes away 
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the ‘4 week follow up appointment’ as sometimes patients are brought back for follow up sooner than 
this.  
The schedule of events has also been changed to reflect the new trial flow chart.  
 
Other changes made to the schedule of events only clarifies details within the original protocol. This 
includes 
1. Inclusion of statement to say that ‘If no positive ovulation test in first cycle then biopsy 
arranged 1 week prior to next period due’. 
2. Process Evaluation questionnaire will be returned by the participant within 4 weeks of  second 
endometrial biopsy visit 
3. The baseline visit for the trial remains the same 
 
Amended protocol (1.4, dated: 15/11/2016): 
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Section 2: Participant Entry  
 
Current protocol (version 1.2 dated 11th May 16): 
 
Patients invited to participate in this trial will be identified from the recurrent miscarriage clinic. There 
is a recurrent miscarriage clinic every week at UHCW lead by Professor Quenby, a world renowned 
Professor in the area of recurrent miscarriage. Professor Quenby or Professor Brosens will first 
approach any of the patients who will be recruited to this study. 
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Limitations with current protocol: 
The current protocol did not mention approaching patients in The Implantation Clinic at UHCW where 
patients with recurrent miscarriage also attend.  
 
Amended protocol (v1.4, dated: 15/11/2016): 
Patients invited to participate in this trial will be identified from the recurrent miscarriage clinic or the 
implantation clinic There is a recurrent miscarriage clinic every week at UHCW lead by Professor 
Quenby, a world renowned Professor in the area of recurrent miscarriage.  There are two 
implantation clinics every week at UHCW lead by Professor Quenby and Professor Brosens who will 
first approach any of the patients who will be recruited to this study. 
 
 
Section 3: Inclusion/exclusion criteria regarding renal function 
 
Current protocol (version 1.2 dated 11th May 16): 
• Inclusion criteria: Adequate renal function, defined as Urea 2.5 – 7.8mmol/L, Creatinine 50 -
90umol/L, potassium 3.5 – 5.3mmol/L, Sodium 133 -146mmol/L 
• Exclusion criteria: Renal impairment with eGFR/AKI<50 mL/min 
 
 
Limitations with current protocol: 
We are confirming normal renal function prior to potentially starting patients on Sitagliptin. This is 
because the SmPC (last updated: 14-Mar 16) states: 
 
‘When considering the use of sitagliptin, its conditions for use in patients with renal impairment 
should be checked.  
For patients with mild renal impairment (creatinine clearance [CrCl ≥ 50mL/min], no dose adjustment 
is required. 
For patients with moderate renal impairment [CrC; ≥30 to < 50mL/min], the dose of Januvia is 50 mg 
once daily.’ 
 
There have been patients who have normal renal function and this is reflected with a normal 
CrCl/eGFR (creatinine clearance/estimated glomerular filtration rate). However, with the current 
inclusion criteria they are rendered ineligible for the trial but because one of the parameters of the 
renal function tests falls out of reference range. For example, patients with a urea <2.4 mmol/L 
(range 2.5 – 7.8mmol/L,) or Creatinine <50umol/ with otherwise normal blood tests are currently not 
eligible for the trial. These results are of no clinical significance and actually only express normality 
for this population of young fit and healthy women.  
 
We would like to use eGFR exclusion criteria as this is a more important and accurate way of 
assessing renal functions. This also takes away the possibility of results being affected by the 
patients hydration status. eGFR will be calculated using the Cockfroft Gault Equation as per the 
standard practice of measuring eGFR. 
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Dr Paul O’Hare who is a consultant physician and our endocrinology advisor and Mr Mojid Khan, the 
clinical trials pharmacist at UHCW have been informed of the problem and have agreed that eGFR 
will be a more accurate way of measuring renal function but at the same time will ensure that fit and 
healthy patients are not rendered ineligible. Please find statement from Dr. O’Hare attached with this 
submission. 
 
Amended protocol (v1.4, dated: 15/11/2016): 
• Inclusion criteria: No longer includes renal function – in exclusion criteria  
• Exclusion criteria: Renal impairment (eGFR 50mL/min/AKI >1*) 
 
Note: eGFR will be calculated using The Cockcroft Gault Equation (1.09 x (190 – Age) x 
weight / Creatinine  
 
 
Section 4: Inclusion/exclusion criteria regarding hepatic function 
 
Current protocol (version 1.2 dated 11th May 16): 
• Inclusion criteria: Adequate hepatic function, defined as total protein 60 – 80g/L, Albumin 35-
50g/L, Bilirubin 4-20umol/L, Alkaline Phosphatase (ALP) 35-105U/L, Alanine Transferase 
(ALT) 5-38 U/L 
Exclusion criteria: Liver impairment, defined as any value out of normal range (total protein 60 
– 80g/L, Albumin 35-50g/L, Bilirubin 4-20umol/L, Alkaline Phosphatase (ALP) 35-105U/L, 
Alanine Transferase (ALT) 5-38 U/L) 
 
Limitations with current protocol: 
Patients with a bilirubin <2 umol/L (range 4-20umol/L) or ALP 34 U/L (range 35-105U/L) with 
otherwise normal blood tests are currently not eligible for the trial. These results are of no clinical 
significance and actually only express a normality for this population of young fit and healthy women.  
 
These results are out of the reference ranges but clinically insignificant and so currently fit and 
healthy individuals cannot be included with these current reference ranges stated in the exclusion 
criteria. 
 
Also, the SmPC for Sitagliptin and hepatic impairment states:  
  
‘No dose adjustment is necessary for patients with mild to moderate hepatic impairment. Sitagliptin 
has not been studied in patients with severe hepatic impairment and care should be exercised’ 
 
ALT, ALP and bilirubin are sufficient markers of hepatic function to exclude any hepatic impairment.’ 
 
Amended protocol (v1.4, dated: 15/11/2016): 
• Inclusion Criteria: No longer includes hepatic function 
• Exclusion Criteria: Liver impairment, (defined as any value out of normal range Alanine 
Transferase (ALT) >38 U/L, ALP >105U/L, Bilirubin (BR ) >20umol*) 
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Section 5: Pre-randomisation, Evaluation and Screening 
 
Current protocol (version 1.2 dated 11th May 16): 
‘In the recurrent miscarriage clinic patients routinely have their initial consultation and a range of 
blood tests looking for causes of recurrent miscarriage performed on the day of the consultation. 
They are then followed up four weeks later in clinic to discuss results of these investigations.  
 
To recruit participants to SIMPLANT we will give information leaflets to those eligible for the study at 
their initial appointment at the recurrent miscarriage clinic. The blood tests looking for causes of 
recurrent miscarriage will already include the pre-randomisation blood tests that are needed prior to 
initiating Sitagliptin. This will not involve taking any extra blood. 
 
Limitations with current protocol: 
 
The protocol has been amended to clarify the sequence of events for recruiting patients to the trial.  
1. We have clarified when the participant information leaflet will be given to patients to 
coincide with the schedule of events 
2. We have changed ‘four weeks’ to a ‘few weeks’ as patients can be called back to clinic 
sooner than this.  
3. We have clarified what we would do about recruiting patients who have been investigated 
in the last 3 months or been seen in other hospitals 
4. The protocol now also clarifies that we may email or post the participant information leaflet 
to patients. 
 
 
Amended protocol (v1.4, dated: 15/11/2016): 
In the recurrent miscarriage clinic patients routinely have their consultation and a range of blood tests 
looking for causes of recurrent miscarriage performed on the day of the consultation. They will be 
given the information leaflet for the trial at this visit. They are then followed up a few weeks later in 
clinic to discuss results of these investigations.  
 
The blood tests looking for causes of recurrent miscarriage will already include the pre-randomisation 
blood tests that are needed prior to initiating Sitagliptin. This will not involve taking any extra blood. 
 
Patients who have already been investigated in the last 3 months or seen in other hospitals may 
show interest in the trial in which case we may also telephone patients and provide the participant 
information leaflet by email or post before the patient is brought back to clinic.  
 
Patients identified from the implantation clinic will be referred to the recurrent miscarriage clinic to 
have routine blood tests to ensure there is no cause for their miscarriages before being recruited to 
SIMPLANT.  
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Section 6: Enrolment procedure 
 
We would like to obtain informed consent at a time convenient for the patient. Also patients are 
sometimes brought back for follow up of investigations sooner than 4 weeks.  
 
Current protocol (version 1.2 dated 11th May 16): 
‘The consent will be taken at the follow up visit in the recurrent miscarriage clinic. By this time the 
patients will have had 4 weeks to think about participation and will have had an opportunity to ask 
questions at two clinic visits. We will make sure the patient has read and understood the patient 
information leaflet, been given the opportunity to ask questions and encouraged to discuss their 
involvement with their GP family and friends.’ 
 
Amended protocol (v1.4, dated: 15/11/2016): 
Consent will be taken at a time that suits the patient after they have had sufficient time to read the 
patient information leaflet and eligibility has been confirmed.  
 
 
 
Section 7: Pharmacovigilence and Safety monitoring 
This section has been edited to reflect correct reporting procedures to the Sponsor and regulatory 
authorities. Please find changes in the tracked version of the protocol. 
 
 
Section 8: Unblinding 
 
Originally, Sharpe Clinical Services were going to make the master unblinding list and provide the 
code break envelopes however this was done by an independent statistician.  
The location of the code break envelopes and the unblinding procedures remain the same.  
 
 
 
 
 
Yours Sincerely, 
 
Prof. Siobhan Quenby 
15/11/2016 
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RESTART 
	
 
A Research Ethics Committee established by the Health Research Authority 
South Central - Hampshire B Research Ethics Committee 
Level 3  Block B 
Whitefriars 
Lewins Mead 
Bristol 
BS1 2NT 
 
Tel: 02071048052 
 
 
 
 
 
 
 
 
07 December 2016 
 
Mrs Ceri Jones 
University Hospital Coventry and Warwickshire 
Clifford Bridge Road 
Coventry 
CV2 2DX 
 
 
Dear Mrs Jones 
 
Study title: Does the DPP4 Inhibitor (Sitagliptin)  Increase Endometrial 
Mesenchymal Stem Cells in Women with Recurrent 
Miscarriage? 
REC reference: 16/SC/0229 
Protocol number: SQ167015 
EudraCT number: 2016-001120-54  
Amendment number: 2 
Amendment date: 18 November 2016 
IRAS project ID: 196058 
 
The above amendment was reviewed by the Sub-Committee in correspondence.  
 
Ethical opinion 
 
The members of the Committee taking part in the review gave a favourable ethical opinion 
of the amendment on the basis described in the notice of amendment form and supporting 
documentation. 
 
Approved documents 
 
The documents reviewed and approved at the meeting were: 
 
Document   Version   Date   
Covering letter on headed paper    17 November 2016  
Notice of Substantial Amendment (CTIMP)  2  18 November 2016  
Other [ internal investigation report]    04 November 2016  
Other [Supporting Statement from Dr O'Hare,]    21 October 2016  
Please note: This is the favourable 
opinion of the REC only and does not 
allow the amendment to be implemented   
at NHS sites in England until the 
outcome of the HRA assessment has 
been confirmed.  
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